

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056815 A1

(51) International Patent Classification⁷: C07D 413/14,
417/14, 409/14, 401/14, 401/12, A61K 31/4155, A61P
7/02

1, 97657 Sandberg (DE). WILL, David, William; Kirch-
strasse 21, 65830 Kriftel (DE). MATTER, Hans; Feldber-
gring 37, 63505 Langenselbold (DE).

(21) International Application Number:
PCT/EP2003/013979

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
10 December 2003 (10.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
02028915.3 23 December 2002 (23.12.2002) EP
03011308.8 19 May 2003 (19.05.2003) EP


(71) Applicant: AVENTIS PHARMA DEUTSCHLAND
GMBH [DE/DE]; Brüningstrasse 50, 95929 Frankfurt
(DE).

Published:
— with international search report

(72) Inventors: NAZARÉ, Marc; Felix-Lahnstein-Str. 4b,
65510 Idstein (DE). WEHNER, Volkmar; Lindenstrasse

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS



(57) Abstract: The present invention relates to compounds of the formula (I), in which R⁰, R¹, R², R³, R⁴, Q, V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure

or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.


WO 2004/056815 A1

B20

Description

Pyrazole-derivatives as factor Xa inhibitors

5 The present invention relates to compounds of the formula I,



in which R⁰ ; R¹ ; R² ; R³ ; R⁴ ; Q ; V, G and M have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of

10 cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of

15 the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Normal haemeostasis is the result of a complex balance between the processes of clot initiation, formation and clot dissolution. The complex interactions between blood cells,

20 specific plasma proteins and the vascular surface, maintain the fluidity of blood unless injury and blood loss occurs (EP-A-987274). Many significant disease states are related to abnormal haemeostasis. For example, local thrombus formation due to rupture of atherosclerotic plaque is a major cause of acute myocardial infarction and unstable angina. Treatment of an occlusive coronary thrombus by either thrombolytic therapy or percutaneous angioplasty may be

25 accompanied by acute thrombolytic reclosure of the affected vessel.

There continues to be a need for safe and effective therapeutic anticoagulants to limit or prevent thrombus formation. It is most desirable to develop agents that inhibit coagulation without directly inhibiting thrombin but by inhibiting other steps in the coagulation cascade

like factor Xa and/or factor VIIa activity. It is now believed that inhibitors of factor Xa carry a lower bleeding risk than thrombin inhibitors (A. E. P. Adang & J. B. M. Rewinkel, *Drugs of the Future* 2000, 25, 369-383).

Low molecular weight, factor Xa-specific blood clotting inhibitors that are effective but do not
5 cause unwanted side effects have been described, for example, in WO-A-95/29189.

However, besides being an effective factor Xa-specific blood clotting inhibitor, it is desirable that such inhibitors also have further advantageous properties, for instance stability in plasma and liver and selectivity versus other serine proteases whose inhibition is not intended, such as thrombin. There is an ongoing need for further low molecular weight factor Xa specific blood
10 clotting inhibitors, which are effective and have the above advantages as well.


Specific inhibition of the factor VIIa/tissue factor catalytic complex using monoclonal antibodies (WO-A-92/06711) or a protein such as chloromethyl ketone inactivated factor VIIa (WO-A-96/12800, WO-A-97/47651) is an extremely effective means of controlling thrombus
15 formation caused by acute arterial injury or the thrombotic complications related to bacterial septicemia. There is also experimental evidence suggesting that inhibition of factor VIIa/tissue factor activity inhibits restenosis following balloon angioplasty. Bleeding studies have been conducted in baboons and indicate that inhibition of the factor VIIa/tissue factor complex has the widest safety window with respect to therapeutic effectiveness and bleeding risk of any
20 anticoagulant approach tested including thrombin, platelet and factor Xa inhibition. Certain inhibitors of factor VIIa have already been described. EP-A-987274, for example discloses compounds containing a tripeptide unit, which inhibit factor VIIa. However, the property profile of these compounds is still not ideal, and there is an ongoing need for further low molecular weight factor VIIa inhibitory blood clotting inhibitors.

25

The present invention satisfies the above needs by providing novel compounds of the formula I, which exhibit better factor Xa and/or factor VIIa inhibitory activity and are favorable agents with high bioavailability.

30

Thus, the present invention relates to compounds of the formula I,



wherein

R^0 is 1) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen,

5 wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R_8 , and which is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R_8 ,

10 2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R_8 , or

15 3) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R_8 ,

20 R_8 is 1) halogen,
2) $-NO_2$,
3) $-CN$,
4) $-C(O)-NH_2$,
5) $-OH$,
6) $-NH_2$,
7) $-O-CF_3$

25

8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by halogen or $-O-(C_1-C_8)\text{-alkyl}$,

9) $-(C_1-C_8)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 , $-OH$ or a methoxy residue,

5 10) $-O-(C_1-C_8)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 , $-OH$ or a methoxy residue,

11) $-SO_2-CH_3$ or

12) $-SO_2-CF_3$,

provided that R_8 is at least one halogen, $-C(O)-NH_2$ or $-O-(C_1-C_8)\text{-alkyl}$ residue, if R^0 is a
10 monocyclic or bicyclic 6- to 14-membered aryl,

15 R^{10} is a direct bond, $-(C_0-C_2)\text{-alkylene-C(O)-NR}^{10}$, $-NR^{10}-C(O)-NR^{10}$, $-NR^{10}-C(O)-$, $-SO_2$, $-(C_1-C_6)\text{-alkylene}$, $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-S-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-CH(OH)-(CH_2)_n$, $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n$, $-(C_2-C_3)\text{-alkylene-O-(C}_0\text{-C}_3\text{)-alkylene}$, $-(C_2-C_3)\text{-alkylene-S(O)}$, $-(C_2-C_3)\text{-alkylene-S(O)}_2$, $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n$, $-(C_2-C_3)\text{-alkylene-S(O)}_2-NH-(R^{10})$, $-(C_2-C_3)\text{-alkylene-N(R}^{10})$ or $-(C_0-C_3)\text{-alkylene-C(O)-O}$;

20 wherein R^{10} is as defined below, and wherein n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by $-(CH_2)_m$ - or $-(CH_2)_n$ - are unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-NH_2$ or $-OH$; or $-(C_3-C_6)\text{-cycloalkylene}$, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-NH_2$ or $-OH$;

25

R^{11} is a hydrogen atom, $-(C_1-C_4)\text{-alkyl}$, wherein alkyl is unsubstituted or substituted one to three times by R_{13} ; $-(C_1-C_3)\text{-alkylene-C(O)-NH-R}^0$, $-(C_1-C_3)\text{-alkylene-C(O)-O-R}^{10}$, a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or

trisubstituted independently of one another by R₈, wherein R₈ is as defined above; a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen; -(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-S(O)-(C₁-C₄)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl, 5 -(C₁-C₃)-alkylene-S(O)₂-N(R^{4'})-R^{5'}, -(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl, -(C₀-C₃)-alkylene-(C₃-C₈)-cycloalkyl, or -(C₀-C₃)-alkylene-het, wherein het is a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₄,

10 R^{4'} and R^{5'} are independent of one another are identical or different and are hydrogen atom or -(C₁-C₄)-alkyl,

R² is a direct bond or -(C₁-C₄)-alkylene, or

15 R¹ and R³ together with the atoms to which they are bonded can form a 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₄, or

20 R¹-N-R²-V can form a 4- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₄,

25 R₁₄ is halogen, -OH, =O, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -NO₂, -(C₀-C₄)-alkyl-C(O)-O-R¹⁸, -CN, -(C₀-C₄)-alkyl-N(R¹⁸)-R²¹, -(C₀-C₄)-alkyl-O-R¹⁸, -(C₀-C₄)-alkyl-het, -(C₀-C₈)-alkyl-SO₂, -SO₂-(C₁-C₄)-alkyl, -SO₂-N(R¹⁸)-R²¹, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -NR¹⁸-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R¹⁸ and R²¹ are independently from each other hydrogen atom, -(C₁-C₃)-perfluoroalkyl or -(C₁-C₆)-alkyl,

- Y is
- 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
 - 2) ~~a 6- to 14-membered aryl~~, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
 - 3) ~~a monocyclic or bicyclic 4- to 15-membered heterocyclyl~~, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

10

- G is a direct bond, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-CH(OH)-(CH_2)_n-$,
 $-(CH_2)_m-$, $-(CH_2)_m-O-(CH_2)_n-$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)-SO_2-(CH_2)_n-$,
 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n-$, $-(CH_2)_m-C(O)-(CH_2)_n-$,
 $-(CH_2)-S-(CH_2)_n-$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n-$,
 $-(CH_2)_m-NR^{10}-$, $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n-$ or $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n-$,

15

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6,

- W is
- 1) ~~a hydrogen atom~~,

20

- 2) $-(C_1-C_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

- 3) $-C(O)-N(R^{11})-R^{12}$,

- 4) $-(CH_2)_m-NR^{10}$,

25

- 5) a 6- to 14-membered aryl; wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

- 6) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

30

- 7) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or


- 8) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, wherein R¹⁴ is defined above,

5

R³ and R⁴ are independent of one another are identical or different and are

- 1) hydrogen atom,
- 2) halogen,
- 3) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 10 4) -(C₁-C₃)-perfluoroalkyl,
- 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 6) -(C₀-C₄)-alkylene-O-R¹⁹, wherein R¹⁹ is
 - 15 a) hydrogen atom,
 - b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or
 - c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 - 20 d) -CF₃, or
 - e) -CHF₂,
- 7) -NO₂,
- 8) -CN,
- 9) -SO_s-R¹¹, wherein s is 1 or 2,
- 25 10) -SO_t-N(R¹¹)-R¹³, wherein t is 1 or 2,
- 11) -(C₀-C₄)-alkylene-C(O)-R¹¹,
- 12) -(C₀-C₄)-alkylene-C(O)-O-R¹¹,
- 13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹³,
- 14) -(C₀-C₄)-alkylene-N(R¹¹)-R¹³,

- 15) $-NR^{10}-SO_2-R^{10}$,
 16) $-S-R^{10}$,
 17) $-(C_0-C_2)\text{alkylene}-C(O)-O-(C_2-C_4)\text{alkylene}-O-C(O)-(C_1-C_4)\text{alkyl}$,
 18) $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-R^{17}$,
 5 19) $-(C_0-C_2)\text{alkylene}-C(O)-O-(C_2-C_4)\text{alkylene}-O-C(O)-O-(C_1-C_6)\text{alkyl}$,
 20) $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-O-R^{17}$,
 21) $-(C_0-C_4)\text{alkylene}-(C_6-C_{14})\text{aryl}$, wherein aryl is mono-, di- or trisubstituted independently of one another by R^{13} ,
 22) $-(C_0-C_4)\text{alkylene}-(C_4-C_{15})\text{heterocyclyl}$, wherein heterocyclyl is unsubstituted or
 10 mono-, di- or trisubstituted independently of one another by R^{13}
 23) $-(C_0-C_4)\text{alkylene}-(C_3-C_8)\text{cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
 24) $-(C_0-C_4)\text{alkylene}-\text{het}$, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
 15 25) $-(C_0-C_4)\text{alkylene}-O-CH_2-(C_1-C_3)\text{-perfluoroalkylene}-CH_2-O-(C_0-C_4)\text{alkyl}$,
 26) a residue from the following list



wherein Me is methyl, or

if two -OR19 residues are attached to adjacent atoms they can form together with the atoms which they are attached to a 5- or 6- membered ring, which is unsubstituted or substituted one, two, three or four times by R13,

5 R11 and R12 are independently of one another identical or different and are


- 1) hydrogen atom,
- 2) -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) -(C₀-C₆)-alkyl-(C₃-C₈)-cycloalkyl,
- 10 4) -SO_t-R¹⁰, wherein t is 1 or 2,
- 5) -(C₀-C₆)-alkyl-(C₆-C₁₄)-aryl, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13,
- 6) -(C₁-C₃)-perfluoroalkyl,
- 7) -O-R¹⁷, or
- 15 8) -(C₀-C₆)-alkyl-(C₄-C₁₅)-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded can form a 4- to 8-
20 membered monocyclic heterocyclic ring which in addition to the nitrogen atom can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

R13 is hydrogen atom, halogen, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-
25 R²⁰, -N(R¹⁰)-R²⁰, -(C₃-C₈)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃,
-N(R¹⁰)-S(O)_u-R¹⁰,

wherein u is 1 or 2, -S-R¹⁰, -SO_r-R¹⁰, wherein r is 1 or 2, -S(O)_v-N(R¹⁰)-R²⁰,
wherein v is 1 or 2, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy,
-O-CF₃, -(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, -(C₁-C₄)-alkoxy-phenyl,
30 -(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, -(C₁-C₃)-perfluoroalkyl,

-O-R₁₅, -NH-C(O)-NH-R¹⁰, -NH-C(O)-O-R¹⁰, or a residue from the following list



5

R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₆)-alkyl, -(C₃-C₄)-alkyl-OH, -(C₃-C₄)-alkyl-O-(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl,

R₁₅ and R₁₆ are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together with the carbon atom to which they are bonded they can form a 3- to 6 membered

10

carbocyclic ring which is unsubstituted or substituted one to three times by R¹⁰, and

R₁₇ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl,

-(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl,

wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by

15

-OH,

-O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

20

2) The present invention also relates to compounds of the formula I,

wherein

- R⁰ is:
- 1) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R₈,
 - 2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl out of the group
5 benzothiophen, indazolyl, indolyl, isoindolyl, isoquinolyl, phenylpyridyl, phthalazinyl, pyridyl, pyridinyl, pyrimidinyl, quinazolinyl and quinolyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈, or
 - 3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen,
10 wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈, and which is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen,
wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted
15 independently of one another by R₈,

- R₈ is:
- 1) halogen,
 - 2) -NO₂,
 - 3) -CN,
 - 20 4) -C(O)-NH₂,
 - 5) -OH,
 - 6) -NH₂,
 - 7) -O-CF₃
 - 8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by halogen or -O-(C₁-C₈)-alkyl,
 - 25 9) -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue, or
 - 10) -O-(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue,
 - 30 11) -SO₂-CH₃ or
 - 12) -SO₂-CF₃,

provided that R⁸ is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue, if R⁰ is a monocyclic or bicyclic 6- to 14-membered aryl,

Q is a direct bond, -(C₀-C₂)-alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -(C₁-C₆)-alkylene, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-, -(CH₂)_m-S-(CH₂)_n-, -(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-CH(OH)-(CH₂)_n-, -(CH₂)_m-O-C(O)-NR¹⁰-(CH₂)_n-, -(C₂-C₃)-alkylene-O-(C₀-C₃)-alkylene-, -(C₂-C₃)-alkylene-S(O)-, -(C₂-C₃)-alkylene-S(O)₂-, -(CH₂)_m-NR¹⁰-C(O)-O-(CH₂)_n-, -(C₂-C₃)-alkylene-S(O)₂-NH-(R¹⁰)-, -(C₂-C₃)-alkylene-N(R¹⁰)-, or -

10 -(C₀-C₃)-alkylene-C(O)-O-,

wherein R¹⁰ is as defined below, and wherein n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by -(CH₂)_m- or -(CH₂)_n- are unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH; or -(C₃-C₆)-cycloalkylene, wherein

15 cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH;

R¹ is a hydrogen atom, -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R¹³; -(C₁-C₃)-alkylene-C(O)-NH-R⁰, -(C₁-C₃)-alkylene-C(O)-O-R¹⁵, a

20 monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R⁸, wherein R⁸ is as defined above; a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen; -(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-S(O)-(C₁-C₄)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl,

25 -(C₁-C₃)-alkylene-S(O)₂-N(R^{4'})-R^{5'}, -(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl, -(C₀-C₃)-alkylene-(C₃-C₈)-cycloalkyl, or -(C₀-C₃)-alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R^{4'} and R^{5'} are independent of one another are identical or different and are hydrogen atom or -(C₁-C₄)-alkyl,

R² is a direct bond or -(C₁-C₄)-alkylene, or

R¹ and R³ together with the atoms to which they are bonded can form a 6- to 8-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

R¹-N-R²-V can form a 4- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
R¹⁴ is halogen, -OH, =O, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -NO₂, -(C₀-C₄)-alkyl-C(O)-O-R¹⁸,
-CN, -(C₀-C₄)-alkyl-N(R¹⁸)-R²¹, -(C₀-C₄)-alkyl-O-R¹⁸, -(C₀-C₄)-alkyl-het, -(C₀-C₈)-alkyl-SO₂,
-SO₂-(C₁-C₄)-alkyl, -SO₂-N(R¹⁸)-R²¹, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂,
-NR¹⁸-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C₁-C₈)-alkyl]₂,
wherein R¹⁸ and R²¹ are independently from each other hydrogen atom, -(C₁-C₃)-perfluoroalkyl or -(C₁-C₆)-alkyl,

V is

- 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
- 2) a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
- 3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

G is a direct bond, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-CH(OH)-(CH_2)_n$,
 $-(CH_2)_m$, $-(CH_2)_m-O-(CH_2)_n$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)-SO_2-(CH_2)_n$,
 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$,
 $(CH_2)-S-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,
 5 $-(CH_2)_m-NR^{10}$, $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n$ or $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n$,

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6,

- 10 M is
- 1) a hydrogen atom,
 - 2) $-(C_1-C_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
 - 3) $-C(O)-N(R^{11})-R^{12}$,
 - 4) $-(CH_2)_m-NR^{10}$,
 - 15 5) $-(C_6-C_{14})$ -aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
 - 6) $-(C_4-C_{15})$ -heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
 - 7) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or
 - 20 trisubstituted independently of one another by R14, or
 - 8) a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, wherein R14 is defined above,


25

R^3 and R^4 are independent of one another are identical or different and are

- 1) hydrogen atom,
- 2) halogen,
- 3) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted
- 30 independently of one another by R13,

- 4) $-(C_1-C_3)$ -perfluoroalkyl,
- 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6) $-(C_0-C_4)$ -alkylene-O-R19, wherein R19 is
 - 5 a) hydrogen atom,
 - b) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
 - c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - 10 d) $-CF_3$,
 - e) $-CHF_2$,
- 7) $-NO_2$,
- 8) $-CN$,
- 9) $-SO_s-R^{11}$, wherein s is 1 or 2,
- 15 10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
- 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
- 12) $-(C_0-C_4)$ -alkylene-C(O)-O-R¹¹,
- 13) $-(C_0-C_4)$ -alkylene-C(O)-N(R¹¹)-R¹²,
- 14) $-(C_0-C_4)$ -alkylene-N(R¹¹)-R¹²,
- 20 15) $-NR^{10}-SO_2-R^{10}$,
- 16) $-S-R^{10}$,
- 17) $-(C_0-C_2)$ alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,
- 18) $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-R^{17}$,
- 19) $-(C_0-C_2)$ alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl,
- 25 20) $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-O-R^{17}$,
- 21) $-(C_0-C_4)$ -alkylene-(C₆-C₁₄)-aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R13,
- 22) $-(C_0-C_4)$ -alkylene-(C₄-C₁₅)-heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13

- 23) $-(C_0-C_4)\text{-alkylene-(C}_3\text{-C}_8\text{)-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 24) $-(C_0-C_4)\text{-alkylene-het}$, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 5 25) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-(C}_1\text{-C}_3\text{)-perfluoroalkylene-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$, or
- 26) a residue from the following list



wherein Me is methyl, or

if two -OR19 residues are attached to adjacent atoms they can form together with the atoms which they are attached to a 5- or 6- membered ring, which is unsubstituted or substituted one, two, three or four times by R13,


R11 and R12 are independently of one another identical or different and are

- 1) hydrogen atom,
- 2) $-(C_1-C_6)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)\text{-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$,
- 4) $-\text{SO}_t\text{-R}^{10}$, wherein t is 1 or 2,


- 5) $-(C_0-C_6)\text{-alkyl-(}C_6-C_{14}\text{)-aryl}$, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13,
- 6) $-(C_1-C_3)\text{-perfluoroalkyl}$,
- 7) $-O-R^{17}$, or
- 8) $-(C_0-C_6)\text{-alkyl-(}C_4-C_{15}\text{)-heterocyclyl}$, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded can form a 4- to 8-membered monocyclic heterocyclic ring which in addition to the nitrogen atom can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

R13 is halogen, $-NO_2$, $-CN$, $=O$, $-OH$, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_3-C_8)\text{-cycloalkyl}$, $-(C_0-C_3)\text{-alkylene-O-R}^{10}$, $-\text{Si}(\text{CH}_3)_3$, $-N(R^{10})-\text{S(O)}_u-R^{10}$, wherein u is 1 or 2, $-\text{S-R}^{10}$, $-\text{SO}_r-R^{10}$, wherein r is 1 or 2, $-\text{S(O)}_v-N(R^{10})-R^{20}$, wherein v is 1 or 2, $-C(O)-R^{10}$, $-(C_1-C_8)\text{-alkyl}$, $-(C_1-C_8)\text{-alkoxy}$, phenyl, phenyloxy, $-O-CF_3$, $-(C_0-C_4)\text{-alkyl-C(O)-O-C(R}^{15}, R^{16})\text{-O-C(O)-R}^{17}$, $-(C_1-C_4)\text{-alkoxy-phenyl}$, $-(C_0-C_4)\text{-alkyl-C(O)-O-C(R}^{15}, R^{16})\text{-O-C(O)-O-R}^{17}$, $-(C_1-C_3)\text{-perfluoroalkyl}$, $-O-R^{15}$, $-\text{NH-C(O)-NH-R}^{10}$, $-\text{NH-C(O)-O-R}^{10}$, or a residue from the following list



18



R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₆)-alkyl or -(C₁-C₃)-perfluoroalkyl,

5 R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together with the carbon atom to which they are bonded they can form a 3- to 6 membered carbocyclic ring which is unsubstituted or substituted one to three times by R¹⁰, and

R¹⁷ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl,

10 -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH, -O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically

15 tolerable salts.

3) Thus, the present invention relates to compounds of the formula I, wherein

R⁰ is 1) a monocyclic or bicyclic 6- to 14-membered aryl out of the group phenyl,

20 naphthyl, biphenyl, anthryl or fluorenyl, wherein aryl is mono-, di- or trisubstituted independently of one another by R⁸,

2) a heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl,

25 indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, wherein said

heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

3) a heterocyclyl, wherein heterocyclyl is selected out of the group acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidiny, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl,

wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and which is additionally substituted by a heterocyclyl selected out of the group acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidiny, aziridinyl, benzimidazolyl,

benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl,
 benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-
 carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-
 dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-
 5 dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl,
 imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl,
 isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl,
 isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-
 isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl,
 10 oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-
 oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl,
 phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl,
 phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
 15 pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl,
 pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-
 pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidinyl,
 tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 1,4,5,6-tetrahydro-
 pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-
 20 thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,
 thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl,
 thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl,
 thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl,
 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-
 25 triazolyl, 1,3,4-triazolyl and xanthenyl,

wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of
 one another by R8,

R8 is 1) halogen,

30 2) -NO₂,

3) -CN,

4) -C(O)-NH₂,

- 5) -OH,
- 6) -NH₂,
- 7) -O-CF₃,
- 8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is as defined above and wherein aryl is mono-, di- or trisubstituted independently of one another by halogen or -O-(C₁-C₈)-alkyl,
- 9) -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue, or
- 10) -O-(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue,
- 11) -SO₂-CH₃ or
- 12) -SO₂-CF₃,

provided that R₈ is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue, if R⁰ is a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is as defined above,

Q is a direct bond, -(C₀-C₂)-alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -(C₁-C₆)-alkylene, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-, -(CH₂)_m-S-(CH₂)_n-, -(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-CH(OH)-(CH₂)_n-, -(CH₂)_m-O-C(O)-NR¹⁰-(CH₂)_n-, -(C₂-C₃)-alkylene-O-(C₀-C₃)-alkylene-, -(C₂-C₃)-alkylene-S(O)-, -(C₂-C₃)-alkylene-S(O)₂-, -(CH₂)_m-NR¹⁰-C(O)-O-(CH₂)_n-, -(C₂-C₃)-alkylene-S(O)₂-NH-(R¹⁰)-, -(C₂-C₃)-alkylene-N(R¹⁰)- or -(C₀-C₃)-alkylene-C(O)-O-,

wherein R¹⁰ is as defined below, and wherein n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by -(CH₂)_m- or -(CH₂)_n- are unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH; or -(C₃-C₆)-cycloalkylen, wherein cycloalkylen is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH;

R^1 is a hydrogen atom, $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted one to three times by R_{13} ; $-(C_1-C_3)$ -alkylene- $C(O)-NH-R^0$, $-(C_1-C_3)$ -alkylene- $C(O)-O-R_{15}$, an aryl out of the group phenyl, naphthyl, biphenyl, anthryl or fluorenyl, wherein aryl is mono-, di- or trisubstituted independently of one another by R_8 , wherein R_8 is as defined above;

a monocyclic or bicyclic 4- to 15-membered heterocycl, which is as defined above;

$-(C_1-C_3)$ -perfluoroalkylene, $-(C_1-C_3)$ -alkylene- $S(O)-(C_1-C_4)$ -alkyl,

$-(C_1-C_3)$ -alkylene- $S(O)_2-(C_1-C_3)$ -alkyl, $-(C_1-C_3)$ -alkylene- $S(O)_2-N(R^{4'})-R^{5'}$,

$-(C_1-C_3)$ -alkylene- $O-(C_1-C_4)$ -alkyl, $-(C_0-C_3)$ -alkylene- (C_3-C_8) -cycloalkyl, or

$-(C_0-C_3)$ -alkylene-het, wherein het is a residue selected out of the group azepine,

azetidine, aziridine, azirine, 1,4-diazapane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine,

diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan,

imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline,

isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-

oxazepane, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine,

oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole,

pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine,

pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine

thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine,

thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine,

1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein het is unsubstituted or mono-, di-

or trisubstituted independently of one another by R_{14} ,

$R^{4'}$ and $R^{5'}$ are independent of one another are identical or different and are hydrogen atom or $-(C_1-C_4)$ -alkyl,

R^2 is a direct bond or $-(C_1-C_4)$ -alkylene, or

R^1 and R_3 together with the atoms to which they are bonded can form a 6- to 8-membered cyclic residue selected out of the group azocane, azocane-2-one, 1,2-diazepine, 1,3-

diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, [oxocane, oxocan-2-one, piperazine, piperidine, pyran, pyrazine, pyridazine, pyrimidine or 5,6,7,8-tetrahydro-1H-azocin-2-one, wherein said cyclic group
 5 is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

R¹-N-R²-V can form a 4- to 8-membered cyclic group selected out of the group azepine, azetidine, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said
 10 cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, =O, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -NO₂, -(C₀-C₄)-alkyl-C(O)-O-R¹⁸, -CN, -(C₀-C₄)-alkyl-N(R¹⁸)-R²¹, -(C₀-C₄)-alkyl-O-R¹⁸, -(C₀-C₄)-alkyl-het, wherein het is a
 20 residue selected from azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or
 25 thiomorpholine,

-(C₀-C₈)-alkyl-SO₂, -SO₂-(C₁-C₄)-alkyl, -SO₂-N(R¹⁸)-R²¹, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -NR¹⁸-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C₁-C₈)-alkyl]₂,

wherein R¹⁸ and R²¹ are independently from each other hydrogen atom,
 30 -(C₁-C₃)-perfluoroalkyl or -(C₁-C₆)-alkyl,

- V is 1) a monocyclic or bicyclic 6- to 14-membered aryl out of the group phenyl, naphthyl, biphenyl, anthryl or fluorenyl, wherein aryl is mono-, di- or trisubstituted independently of one another by R¹⁴,
- 5 2) a heterocyclyl out of the group acridinyl, azaindole (1H-pyrrolopyridine), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidiny, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 1,4-diazepane, 4,5-dihydrooxazolyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 10 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, 15 isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, 20 phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinolinyl, 25 tetrahydrochinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, 30 thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

G is a direct bond, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-CH(OH)-(CH_2)_n$,
 $-(CH_2)_m$, $-(CH_2)_m-O-(CH_2)_n$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)-SO_2-(CH_2)_n$,
 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$, -
 5 $(CH_2)-S-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,
 $-(CH_2)_m-NR^{10}$, $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n$ or $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n$,

n and m are independently of one another identical or different and are the
 integers zero, 1, 2, 3, 4, 5 or 6,


- 10 M is
- 1) a hydrogen atom,
 - 2) $-(C_1-C_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted
 independently of one another by R14,
 - 3) $-C(O)-N(R^{11})-R^{12}$,
 - 15 4) $-(CH_2)_m-NR^{10}$,
 - 5) $-(C_6-C_{14})$ -aryl, wherein aryl is as defined above and wherein aryl is unsubstituted
 or mono-, di- or trisubstituted independently of one another by R14,
 - 6) $-(C_4-C_{15})$ -heterocyclyl, wherein heterocyclyl is as defined above and is
 unsubstituted or mono-, di- or trisubstituted independently of one another by
 20 R14, or
 - 7) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or
 trisubstituted independently of one another by R14,

R³ and R⁴ are independent of one another are identical or different and are

- 1) hydrogen atom,
- 25 2) halogen,
- 3) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted
 independently of one another by R13,
- 4) $-(C_1-C_3)$ -perfluoroalkyl,
- 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted
 30 independently of one another by R13,

- 6) $-(C_0-C_4)\text{-alkylene-O-R19}$, wherein R19 is
- a) hydrogen atom,
 - b) $-(C_1-C_4)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
 - 5 c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - d) $-\text{CF}_3$,
 - e) $-\text{CHF}_2$,
- 7) $-\text{NO}_2$,
- 10 8) $-\text{CN}$,
- 9) $-\text{SO}_s\text{-R}^{11}$, wherein s is 1 or 2,
- 10) $-\text{SO}_t\text{-N(R}^{11})\text{-R}^{12}$, wherein t is 1 or 2,
- 11) $-(C_0-C_4)\text{-alkylene-C(O)-R}^{11}$,
- 12) $-(C_0-C_4)\text{-alkylene-C(O)-O-R}^{11}$,
- 15 13) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-R}^{12}$,
- 14) $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-R}^{12}$,
- 15) $-\text{NR}^{10}\text{-SO}_2\text{-R}^{10}$,
- 16) $-\text{S-R}^{10}$,
- 17) $-(C_0-C_2)\text{alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-(C}_1\text{-C}_4\text{)-alkyl}$,
- 20 18) $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-R}^{17}$,
- 19) $-(C_0-C_2)\text{alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-O-(C}_1\text{-C}_6\text{)-alkyl}$,
- 20) $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-O-R}^{17}$,
- 21) $-(C_0-C_4)\text{-alkylene-(C}_6\text{-C}_{14})\text{-aryl}$, wherein aryl is mono-, di- or trisubstituted independently of one another by R13,
- 25 22) $-(C_0-C_4)\text{-alkylene-(C}_4\text{-C}_{15})\text{-heterocyclyl}$, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13
- 23) $-(C_0-C_4)\text{-alkylene-(C}_3\text{-C}_8\text{)-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

- 24) $-(C_0-C_4)\text{-alkylene-het}$, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 25) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-(C}_1\text{-C}_3\text{)-perfluoroalkylene-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$, or
- 26) a residue from the following list



wherein Me is methyl, or

- 10 if two -OR19 residues are attached to adjacent atoms they can form together with the atoms
which they are attached to a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring,
which is substituted one, two, three or four times by R13,

R11 and R12 are independently of one another identical or different and are


- 15
- 1) hydrogen atom,
 - 2) $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 - 3) $-(C_0-C_6)$ -alkyl- (C_3-C_8) -cycloalkyl,
 - 4) $-SO_t-R^{10}$, wherein t is 1 or 2,
- 20
- 5) $-(C_0-C_6)$ -alkyl- (C_6-C_{14}) -aryl, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³,
 - 6) $-(C_1-C_3)$ -perfluoroalkyl,


7) -O-R¹⁷, or

8) -(C₀-C₆)-alkyl-(C₄-C₁₅)-heterocyclyl, wherein alkyl and heterocyclyl are as defined above and are independently from one another unsubstituted or mono-, di- or trisubstituted by R¹³, or

R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a heterocyclic ring out of the group azepine, azetidine, dioxazole, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, 1,4-oxazepinyl, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

R¹³ is halogen, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₃-C₈)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)_u-R¹⁰, wherein u is 1 or 2, -S-R¹⁰, -SO_r-R¹⁰, wherein r is 1 or 2, -S(O)_v-N(R¹⁰)-R²⁰, wherein v is 1 or 2, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy, -O-CF₃, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷, -(C₁-C₃)-perfluoroalkyl, -O-R¹⁵, -NH-C(O)-NH-R¹⁰, -NH-C(O)-O-R¹⁰, or a residue from the following list





R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₆)-alkyl, -(C₀-C₄)-alkyl-OH, -(C₀-C₄)-alkyl-O-(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl,

R15 and R16 are independently of one another hydrogen, -(C₁-C₆)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰, and

R17 is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl,

wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by
-OH,
-O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

4) The present invention also relates to the compounds of the formula I, wherein

20. R⁰ is

- 1) a monocyclic or bicyclic 6- to 14-membered aryl out of the group phenyl, naphthyl, biphenyl, anthryl or fluorenyl, wherein aryl is mono-, di- or trisubstituted independently of one another by R⁸,
- 2) a heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl,

indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one
5 another by R8, or

3) a heterocyclyl out of the group azabenzimidazolyl, benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnolinyl, 2-furyl, 3-furyl; imidazolyl, indolyl, indazolyl, isochromanyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl,
10 pyridopyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrrolyl; 2-pyrrolyl, 3-pyrrolyl, quinolinyl, quinazolinyl, quinoxalinyl, tetrazolyl, thiazolyl, 2-thienyl or 3-thienyl,

which is additionally substituted by a heterocyclyl selected out of the group acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolanyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl,
25 octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinolinyl, tetrahydrochinolinyl, 1,4,5,6-

tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl,

wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,

- R8 is
1. fluorine, chlorine or bromine,
 2. -NO₂,
 3. -CN,
 4. -C(O)-NH₂,
 5. -OH,
 6. -NH₂,
 7. -OCF₃
 8. a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is as defined above and is mono-, di- or trisubstituted independently of one another by halogen or -O-(C₁-C₈)-alkyl,
 9. -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue, or
 10. -O-(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue,
 11. -SO₂CH₃ or
 12. -SO₂CF₃,

provided that R8 is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue, if R0 is a aryl or a heterocyclyl, which are as defined above,

Q is a direct bond, $-(C_0-C_2)$ -alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-,
-(C₁-C₆)-alkylene,

R¹ is a hydrogen atom, $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted one to
5 three times by R¹³; $-(C_1-C_3)$ -alkylene-C(O)-NH-R⁰, $-(C_1-C_3)$ -alkylene-C(O)-O-R¹⁵,
-(C₁-C₃)-perfluoroalkylene, $-(C_1-C_3)$ -alkylene-S(O)-(C₁-C₄)-alkyl,
-(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl, $-(C_1-C_3)$ -alkylene-S(O)₂-N(R^{4'})-R^{5'},
-(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl, $-(C_0-C_3)$ -alkylene-(C₃-C₈)-cycloalkyl, or
-(C₀-C₃)-alkylene-het, wherein het is a residue selected out of the group azepine,
10 azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine,
diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan,
imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline,
isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-
oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine,
15 oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole,
pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine,
pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine
thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine,
thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine,
20 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein het is unsubstituted or mono-, di-
or trisubstituted independently of one another by R¹⁴,
R^{4'} and R^{5'} are independent of one another are identical or different and are
hydrogen atom or $-(C_1-C_4)$ -alkyl,

25 R² is a direct bond or $-(C_1-C_4)$ -alkylene, or

R¹-N-R²-V form a 4- to 8-membered cyclic group selected out of the group azepine, azetidine,
1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine,
imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline,
30 isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-

oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is fluorine, chlorine, bromine, iodine, -OH, =O, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -NO₂, -C(O)-OH, -CN, -NH₂, -C(O)-O-(C₁-C₄)-alkyl, -(C₁-C₈)-alkylsulfonyl, -SO₂-(R¹⁸)-R²¹, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -NR¹⁸-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R¹⁸ and R²¹ are independently from each other hydrogen atom, -(C₁-C₃)-perfluoroalkyl or -(C₁-C₆)-alkyl,

- V is
- 1) a het residue out of the group azaindole (1H-pyrrolopyridine), azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, which is as defined above and wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 - 2) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

G is a direct bond, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-CH(OH)-(CH_2)_n-$,
 $-(CH_2)_m-$, $-(CH_2)_m-O-(CH_2)_n-$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)-SO_2-(CH_2)_n-$,
 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n-$, $-(CH_2)_m-C(O)-(CH_2)_n-$,
 5 $-(CH_2)-S-(CH_2)_n-$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n-$,
 $-(CH_2)_m-NR^{10}-$, $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n-$ or $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n-$,


n and m are independently of one another identical or different and are the
 integers zero, 1, 2, 3, 4, 5 or 6,


10

- M is
- 1) a hydrogen atom,
 - 2) $-(C_1-C_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted
 independently of one another by R14,
 - 3) $-C(O)-N(R^{11})-R^{12}$,
 - 15 4) $-(CH_2)_m-NR^{10}$,
 - 5) phenyl or naphthyl, wherein phenyl or naphthyl are unsubstituted or mono-, di-
 or trisubstituted independently of one another by R14,
 - 6) heterocyclyl, wherein heterocyclyl is a residue out of the group which can be
 20 derived from azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine,
 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline,
 ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane,
 piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine,
 pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone,
 25 tetrahydropyran, 1,4,5,6-tetrahydro-pyridaziny, tetrazine, tetrazole, thiadiazole,
 thiazole, thiophene, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine,
 1,2,3-triazole or 1,2,4-triazole, wherein said heterocyclyl is unsubstituted or
 mono-, di- or trisubstituted independently of one another by R14, or
 - 7) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or
 30 trisubstituted independently of one another by R14,

R³ and R⁴ are independent of one another are identical or different and are

- 1) hydrogen atom,
- 2) -(C₀-C₃)-alkylene-O-CH₂-CHF₂,
- 3) -(C₀-C₃)-alkylene-O-CH₂-CF₃,
- 4) -(C₀-C₃)-alkylene-O-CH₂-CF₂-CH₂-O-(C₀-C₄)-alkyl,
- 5) -(C₀-C₃)-alkylene-O-CH₂-CF₂-CF₂-CH₂-O-(C₀-C₄)-alkyl,
- 6) -(C₀-C₃)-alkylene-O-CHF₂,
- 7) -(C₀-C₃)-alkylene-O-CH₂-CH₂-CH₂-O-(C₀-C₄)-alkyl,
- 8) -(C₀-C₃)-alkylene-O-CH₂-CH₂-O-(C₀-C₄)-alkyl,



- 9) -(C₀-C₃)-alkylene-C(O)-N-,
- 10) -(C₀-C₃)-alkylene-C(O)-N(R¹⁰)-CN,
- 11) -(C₀-C₃)-alkylene-C(O)-azetidinyI,
- 12) -(C₀-C₃)-alkylene-C(O)-azetidinyI, wherein azetidinyI is substituted by
-(C₀-C₃)-alkylene-O-(C₀-C₄)-alkyl,
- 13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-N-pyrrolidin-1-yl,
- 14) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-N-piperidin-1-yl,
- 15) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-(C₁-C₄)-alkyl-cyclopropyl, wherein -(C₁-C₄)-alkyl is
substituted by R¹³,
- 16) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-O-R¹⁷,
- 17) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-(C₁-C₄)-alkyl-heterocyclyl, wherein heterocyclyl is as
defined above and wherein alkyl and heterocyclyl are independently from one
another unsubstituted or mono-, di- or trisubstituted by R¹³,
- 18) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-(C₁-C₄)-alkylene-C(O)-O-(C₀-C₄)-alkyl,
- 19) -(C₀-C₄)-alkylene-C(O)-N(R²¹)-R²², wherein R²¹ and R²² are both
ethylene-C(O)-O-(C₀-C₄)-alkyl,
- 20) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-CH₂-CH₂-SO₂-methyl,

- 21) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-CH}_2\text{-CH}_2\text{-SO}_2\text{-CF}_3$,
- 22) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-CH}_2\text{-CH}_2\text{-SO}_2\text{-NH}_2$,
- 23) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-SO}_2\text{-CF}_3$,
- 24) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-SO}_2\text{-N(R}^{10})\text{-R}^{20}$,
- 5 25) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-SO}_2\text{-methyl}$,
- 26) $-(C_0-C_4)\text{-alkylene-SO}_2\text{-N(R}^{11})\text{-CN}$,
- 27) $-(C_0-C_4)\text{-alkylene-S-CF}_3$,
- 28) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-(C}_1\text{-C}_4\text{)-alkylene-Si-(CH}_3\text{)}_3$,
- 29) $-(C_0-C_4)\text{-alkylene-C(O)-O-(C}_1\text{-C}_4\text{)-alkylene-cyclopropyl}$,
- 10 30) $-(C_0-C_4)\text{-alkylene-C(O)-O-(C}_1\text{-C}_4\text{)-alkylene-C(O)-O-(C}_0\text{-C}_4\text{)-alkyl}$, or
- 31) $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-CN}$,

provided that one of R^3 or R^4 is not a hydrogen atom,

15 R^{11} and R^{12} are independently of one another identical or different and are

- 1) hydrogen atom,
- 2) $-(C_1-C_6)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 20 3) $-(C_0-C_6)\text{-alkyl-(C}_6\text{-C}_{14})\text{-aryl}$, wherein aryl is as defined above and wherein alkyl and aryl are independently from one another unsubstituted or mono-, di- or trisubstituted by R^{13} ,
- 4) $-O-R^{17}$, or
- 5) $-(C_0-C_6)\text{-alkyl-(C}_4\text{-C}_{15})\text{-heterocyclyl}$, wherein alkyl and heterocyclyl is as defined above and independently from one another are unsubstituted or
- 25 mono-, di- or trisubstituted by R^{13} , or

R^{11} and R^{12} together with the nitrogen atom to which they are bonded can form a ring selected out of the group azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline,


imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, 1,4-oxazepine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, which is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₃,

10 R₁₃ is


hydrogen atom, fluorine, chlorine, bromine, iodine, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)₂-R¹⁰, -S-R¹⁰, -SO₂-R¹⁰, -S(O)₂-N(R¹⁰)-R²⁰, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy-, -O-CF₃, -(C₁-C₃)-perfluoroalkyl, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷, -O-R¹⁵, -NH-C(O)-NH-R¹⁰, -NH-C(O)-O-R¹⁰, or a residue from the following list

20

25



38



R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₆)-alkyl, -(C₀-C₄)-alkyl-OH,
 5 -(C₀-C₄)-alkyl-O-(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl,

R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together form a
 ring out of the group cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein
 each ring is unsubstituted or substituted one to three times by R¹⁰, and

10 R¹⁷ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl,
 -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl,
 wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by
 -OH,

15 -O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically
 tolerable salts.

20 5) The present invention also relates to the compounds of the formula I, wherein

25 R⁰ is 1) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted
 independently of one another by R₈,

2) a heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈, or

3) a heterocyclyl out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈,

and in addition is substituted by a residue selected out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈

R₈ is 1. F, Cl, Br or I,

2. -C(O)-NH₂,

3. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or a methoxy residue, or

4. -O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or a methoxy residue,

provided that R₈ is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue, if R₀ is a aryl or a heterocyclyl, which are as defined above,

Q is a direct bond, -C(O)-; -SO₂- or -(C₁-C₆)-alkylene, -(C₀-C₂)-alkylene-C(O)-NR¹⁰-,

R¹ is hydrogen atom, -(C₁-C₂)-alkyl, -(C₁-C₃)-alkylene-C(O)-NH-R₀, -(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-C(O)-O-R¹⁵, -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl or

-(C₁-C₃)-alkylene-S(O)₂-N(R^{4'})-R^{5'}, wherein R^{4'} and R^{5'} are independent of one another are identical or different and are hydrogen atom or -(C₁-C₄)-alkyl,

R² is a direct bond or -(C₁-C₂)-alkylene,

R¹-N-R²-V can form a 4- to 7- membered cyclic group out of the group azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is fluorine, chlorine, -OH, =O, -(C₁-C₈)-alkyl, -C(O)-OH, -CN, -NH₂, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -C(O)-NH₂ or -N(R¹⁸)-R²¹, wherein R¹⁸ and R²¹ are independently from each other hydrogen atom, -(C₁-C₃)-perfluoroalkyl or -(C₁-C₄)-alkyl,

V is 1. a cyclic residue out of the group containing compounds which are derived from azaindole (1H-pyrrolopyridine), aziridine, azirine, azetidine, azetidinone, 1,4-diazepane, pyrrole, pyrrolidine, pyridonyl, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyrimidine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, tetrazine, tetrazole, azepine, diazirine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, pyridazine, piperidine, piperazine, pyrrolidinone, ketopiperazine, furan, pyran, dioxole, 1,4-oxazepane, oxazole, isoxazole, 2-isoxazoline, isoxazolidine, morpholine, oxirane, oxaziridine, 1,3-dioxolene, 1,3-dioxolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxaziridine, thiophene, thiopyran, thietan, thiazole, isothiazole, isothiazoline, isothiazolidine, 1,2-oxathiolan, thiodiazole, thiopyran, 1,2-thiazine, 1,3-thiazole, 1,3-thiazine, 1,4-thiazine, thiadiazine or thiomorpholine,

wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

2. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

G is a direct bond, -(CH₂)_m-, or -(CH₂)_m-NR¹⁰-,

m is the integers zero, 1, 2, 3 or 4,

M is 1. a hydrogen atom,

2. heterocyclyl, wherein heterocyclyl is a residue out of the group which can be
5 derived from azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline,

ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, piperazine,
piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine,
pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-
10 pyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene,
1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said
heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one
another by R14,

3. -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted
15 independently of one another by R14, or

4. (C₃-C₆)-cycloalkyl,

5. -C(O)-N(R¹¹)-R¹²,

R³ and R⁴ are independent of one another are identical or different and are

1) hydrogen atom,

20 2) halogen,

3) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted
independently of one another by R13,

4) -(C₁-C₃)-perfluoroalkyl,

5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted
25 independently of one another by R13,


6) -(C₀-C₄)-alkylene-O-R¹⁹, wherein R¹⁹ is

a) hydrogen atom,

b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or
trisubstituted independently of one another by R13, or

30 c) phenyl, wherein phenyl is unsubstituted or mono-, di- or
trisubstituted independently of one another by R13,

- d) $-\text{CF}_3$, or
e) CHF_2 ,
- 7) $-\text{CN}$,
8) $-\text{NR}^{10}-\text{SO}_2-\text{R}^{10}$,
5 9) $-\text{SO}_s-\text{R}^{11}$, wherein s is 1 or 2,
10) $-\text{SO}_t-\text{N}(\text{R}^{11})-\text{R}^{12}$, wherein t is 1 or 2,
11) $-(\text{C}_0-\text{C}_4)\text{-alkylene-C(O)-R}^{11}$,
12) $-(\text{C}_0-\text{C}_4)\text{-alkylene-C(O)-O-R}^{11}$,
13) $-(\text{C}_0-\text{C}_4)\text{-alkylene-C(O)-N(R}^{11})-\text{R}^{12}$,
10 14) $-(\text{C}_0-\text{C}_4)\text{-alkylene-N(R}^{11})-\text{R}^{12}$,
15) $-(\text{C}_0-\text{C}_2)\text{alkylene-C(O)-O-(C}_2-\text{C}_4)\text{-alkylene-O-C(O)-(C}_1-\text{C}_4)\text{-alkyl}$,
16) $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-R}^{17}$,
17) $-(\text{C}_0-\text{C}_2)\text{alkylene-C(O)-O-(C}_2-\text{C}_4)\text{-alkylene-O-C(O)-O-(C}_1-\text{C}_6)\text{-alkyl}$,
18) $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-O-R}^{17}$,
15 19) $-(\text{C}_0-\text{C}_4)\text{-alkylene-(C}_3-\text{C}_6)\text{-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
20) $-(\text{C}_0-\text{C}_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0-\text{C}_3)\text{-alkyl}$,
21) $-(\text{C}_0-\text{C}_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0-\text{C}_3)\text{-alkyl}$,
22) $-(\text{C}_0-\text{C}_3)\text{-alkylene-O-CH}_2\text{-(C}_1-\text{C}_3)\text{-perfluoroalkylene-CH}_2\text{-OH}$, or
20 23) a residue from the following list



wherein Me is methyl,

if two -OR19 residues are attached to adjacent atoms they can form together with the atoms which they are attached to a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, which is substituted one, two, three or four times by R13,


5 R11 and R12 are independently of one another identical or different and are

- 1) hydrogen atom,
- 2) $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)$ -alkyl- (C_6-C_{14}) -aryl, wherein aryl is as defined above and wherein
10 alkyl and aryl are independently from one another unsubstituted or mono-, di- or trisubstituted by R13,
- 4) $-O-R^{17}$, or
- 5) $-(C_0-C_6)$ -alkyl- (C_4-C_{15}) -heterocyclyl, wherein alkyl and heterocyclyl is as defined above and independently from one another are unsubstituted or
15 mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded can form a ring selected out of the group azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]-oxazepane, 1,4-oxazepine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

30 R13 is fluorine, chlorine, $-NO_2$, $-CN$, $=O$, $-OH$, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_0-C_3)$ -alkylene- $O-R^{10}$, $-Si-(CH_3)_3$, $-N(R^{10})-S(O)_2-R^{10}$, $-S-R^{10}$,

-SO₂-R¹⁰, -S(O)₂-N(R¹⁰)-R²⁰, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy-, -O-CF₃, -(C₁-C₃)-perfluoroalkyl, -NH-C(O)-NH-R¹⁰, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷, -O-R¹⁵, -NH-C(O)-O-R¹⁰, or a residue from the following list



wherein Me is methyl,

R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₆)-alkyl, -(C₀-C₄)-alkyl-OH,

10 -(C₀-C₄)-alkyl-O-(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl,

R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together form a ring out of the group cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰, and

R¹⁷ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl, 15 -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH, -O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

20

6) The present invention also relates to the compounds of the formula I, wherein

RO is a heterocyclyl out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, 25 pyridazinyl and pyrazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R⁸,

and in addition is substituted by a residue selected out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein said residue is

5 unsubstituted or mono-, di- or trisubstituted independently of one another by R8,

R8 is 1. is F, Cl, Br, I,

2. -C(O)-NH₂,

3. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or a methoxy residue, or

10 4. -O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or a methoxy residue,

provided that R8 is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue, if R0 is a aryl or a heterocyclyl, which are as defined above,

Q is a direct bond, -C(O)-; -SO₂- or -(C₁-C₆)-alkylen, -(C₀-C₂)-alkylen-C(O)-NR¹⁰-,

15 R¹ is hydrogen atom or -(C₁-C₂)-alkyl,

R² is a direct bond or -(C₁-C₂)-alkylen, or

R¹-N-R²-V can form a 4- to 7- membered cyclic group out of the group piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 20 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

R14 is fluoro, chlorine, -(C₁-C₄)-alkyl or -NH₂,

25 V is 1. a cyclic residue out of the group containing compounds, which are derived from azaindölyl (1H-pyrrolopyridyl), azetidine, azepine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diazirine, 1,3-dioxolane, dioxazole, furan, imidazole, isoquinoline, isothiazole, isothiazolidine, isothiazoline, isoxazole, 2-isoxazoline, isoxazolidine, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, 1,2-oxathiolan, piperidine, pyran, pyrazine, pyrazole, pyridazine, 30 piperazine, pyridine, pyridone, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, quinazoline, quinoline, tetrazine, tetrazole, thiadiazine, 1,2-thiazine, 1,3-thiazine, 1,4-

thiazine, 1,3-thiazole, thietan, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole,

wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

- 5 2. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

G is a direct bond, $-(CH_2)_m-$, or $-(CH_2)_m-NR^{10}-$,

m is the integers zero, 1, 2, 3 or 4,

M is 1. a hydrogen atom,

- 10 2. heterocyclyl, wherein heterocyclyl is a residue out of the group which can be derived from 1,4-diazepane, ketomorpholine, thiophene, pyridazone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, pyridonyl, imidazole, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, thiadiazole or thiomorpholine, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,


- 15 3. $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

4. (C_3-C_6) -cycloalkyl,

R³ and R⁴ are independent of one another are identical or different and are

- 1) hydrogen atom,
 2) halogen,
 25 3) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 4) $-(C_1-C_3)$ -perfluoroalkyl,
 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 30 6) $-(C_0-C_4)$ -alkylene-O-R19, wherein R19 is
 a) hydrogen atom,

- b) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
- c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 5 d) $-CF_3$, or
- e) $-CHF_2$,
- 7) $-CN$,
- 8) $-NR^{10}-SO_2-R^{10}$,
- 9) $-SO_s-R^{11}$, wherein s is 1 or 2,
- 10 10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
- 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
- 12) $-(C_0-C_4)$ -alkylene-C(O)-O-R¹¹,
- 13) $-(C_0-C_4)$ -alkylene-C(O)-N(R¹¹)-R¹²,
- 14) $-(C_0-C_4)$ -alkylene-N(R¹¹)-R¹²,
- 15 15) $-(C_0-C_2)$ alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,
- 16) $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-R^{17}$,
- 17) $-(C_0-C_2)$ alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl,
- 18) $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-O-R^{17}$,
- 19) $-(C_0-C_3)$ -alkylene-(C₃-C₆)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-
- 20 , di- or trisubstituted independently of one another by R13,
- 20) $-(C_0-C_4)$ -alkylene-(C₃-C₆)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-
- , di- or trisubstituted independently of one another by R13, or
- 21) $-(C_0-C_3)$ -alkylene-O-CH₂-CF₂-CH₂-O-(C₀-C₃)-alkyl,
- 22) $-(C_0-C_3)$ -alkylene-O-CH₂-CF₂-CF₂-CH₂-O-(C₀-C₃)-alkyl,
- 25 23) $-(C_0-C_3)$ -alkylene-O-CH₂-(C₁-C₃)-perfluoroalkylene-CH₂-OH, or
- 24) a residue from the following list



wherein Me is methyl,

5 R11 and R12 are independently of one another identical or different and are


- 1) hydrogen atom,
- 2) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)$ -alkyl- (C_3-C_6) -cycloalkyl,
- 4) $-O-R^{17}$, or
- 5) $-(C_0-C_6)$ -alkyl- (C_4-C_{15}) -heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein heterocyclyl is selected out of the group azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine, or

R11 and R12 together with the nitrogen atom to which they are bonded form a heterocyclic ring, which is selected out of the group azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, 1,4-oxazepine, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine,

R13 is fluorine, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰,

-(C₃-C₆)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -S-R¹⁰, -SO₂-R¹⁰,

-(C₁-C₃)-perfluoroalkyl, or a residue from the following list



wherein Me is methyl,

R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₄)-alkyl or

5 -(C₁-C₃)-perfluoroalkyl,

R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₄)-alkyl, or together form a ring out of the group cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰, and

R¹⁷ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl,

10 -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH, -O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

15

7) The present invention also relates to the compounds of the formula I, wherein

R⁰ is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R⁸,

and wherein R¹, R², R³, R⁴, R⁸, V, G, M and Q are as defined under 6).

20

8) The present invention also relates to the compounds of the formula I, wherein

R⁰ is a heterocyclyl selected out of the group indolyl, isoindolyl, benzofuranyl, benzothiophenyl, 1,3-benzodioxolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromanyl, isochromanyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridinyl, purinyl and pteridinyl,


25

wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈,
and wherein R₁, R₂, R₃, R₄, R₈, V, G, M and Q are as defined under 6).

- 5 9) The present invention also relates to the compounds of the formula I, wherein
- R₀ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R₈,
- R₈ is F, Cl, Br, -OCH₃, -C(O)-NH₂ or -O-CF₃,
- Q is a direct bond, -C(O)-; -SO₂-, -CH₂-C(O)-NH-, methylene or ethylene;
- 10 R¹ is hydrogen atom,
- R² is a direct bond or methylene,
- R¹-N-R²-V can form a 4- to 8-membered cyclic group out of the group azetidine, pyrrolidine, piperidine and piperazine,
- R₁₄ is fluorine, chlorine, methyl, ethyl or -NH₂,
- 15 V is 1. a residue out of the group containing compounds which is derived from azaindoyl (1H-pyrrolopyridyl), azetidine, 1,4-diazepane, isoxazole, isoquinoline, piperazine, piperidine, pyrazine, pyridazine, pyrimidine, pyrrolidine, quinazoline, quinoline or tetrahydropyrane, wherein said cyclic residue is unsubstituted or mono- or disubstituted independently of one another by R₁₄, or
- 20 2. phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R₁₄,
- G is a direct bond, -(CH₂)_m-, or -(CH₂)_m-NR¹⁰-,
- m is the integers zero, 1 or 2,
- 25 M is a hydrogen atom, (C₂-C₄)-alkyl, azepanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, ketomorpholinyl, morpholinyl, [1,4]Oxazepanyl, piperidinyl, piperidonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidyl, pyrrolidinyl, 1,4,5,6-tetrahydropyridazinyl, or tetrahydropyranyl, wherein the residues are unsubstituted or mono- or disubstituted independently of one another by R₁₄
- 30 R³ and R⁴ are independent of one another are identical or different and are
- 1) hydrogen atom,

- 2) fluorine, chlorine, bromine, iodine,
- 3) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4) $-(C_1-C_3)$ -perfluoroalkyl,
- 5 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6) $-(C_0-C_2)$ -alkylene-O-R19, wherein R19 is
 - a) hydrogen atom,
 - b) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
 - 10 c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - d) $-CF_3$, or
 - e) $-CHF_2$
- 15 7) $-CN$,
- 8) $-NR^{10}-SO_2-R^{10}$,
- 9) $-SO_s-R^{11}$, wherein s is 1 or 2,
- 10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
- 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
- 20 12) $-(C_0-C_4)$ -alkylene-C(O)-O-R¹¹,
- 13) $-(C_0-C_4)$ -alkylene-C(O)-N(R¹¹)-R¹²,
- 14) $-(C_0-C_4)$ -alkylene-N(R¹¹)-R¹²,
- 15) $-(C_0-C_2)$ alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,
- 16) $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-R^{17}$,
- 25 17) $-(C_0-C_2)$ alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl,
- 18) $-C(O)-O-C(R^{15}, R^{16})-O-C(O)-O-R^{17}$,
- 19) $-(C_0-C_3)$ -alkylene-(C₃-C₆)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

- 20) pyridinyl, wherein pyridinyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 21) thiazolyl, wherein thiazolyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 5 22) $-(C_0-C_4)\text{-alkylene-(C}_3\text{-C}_6\text{)-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 23) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$,
- 24) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$,
- 25) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-(C}_1\text{-C}_3\text{)-perfluoroalkylene-CH}_2\text{-OH}$, or
- 10 26) a residue from the following list



wherein Me is methyl,

15 R11 and R12 are independently of one another identical or different and are


- 1) hydrogen atom,
- 2) $-(C_1-C_4)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)\text{-alkyl-(C}_3\text{-C}_6\text{)-cycloalkyl}$,
- 20 4) $-O-R^{17}$, or
- 5) $-(C_0-C_6)\text{-alkyl-heterocyclyl}$, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein heterocyclyl is selected out of the group azetidine, imidazolidine, morpholine, (1,4)-oxazepane or pyrrolidine or

R11 and R12 together with the nitrogen atom to which they are bonded can form a ring, which is selected out of the group azetidine, imidazolidine, morpholine, (1,4)-oxazepane, 1,4-oxazepine, piperazine, piperidine, pyrrolidine or thiomorpholine,

R13 is fluorine, chlorine, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰,

5 - (C₃-C₆)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -S-R¹⁰, -SO₂-R¹⁰, -(C₁-C₄)-alkyl,

-(C₁-C₃)-perfluoroalkyl, or a residue from the following list



10 wherein Me is methyl,

R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₄)-alkyl or
-(C₁-C₃)-perfluoroalkyl,

R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₄)-alkyl, or together form
a ring out of the group cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each

15 ring is unsubstituted or substituted one to three times by R¹⁰, and

R¹⁷ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl,
-(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein
said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH,
-O-(C₁-C₄)-alkyl or R¹⁰,

20 in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically
tolerable salts.

10) The present invention also relates to the compounds of the formula I, wherein

25 R⁰ is pyridyl, wherein pyridyl is unsubstituted or mono- or disubstituted independently of
one another by R⁸,

and wherein R¹, R², R³, R⁴, R⁸, V, G, M and Q are as defined under 9).


11) The present invention also relates to the compounds of the formula I, wherein

R0 is a heterocyclyl out of the group thienyl, thiadiazolyl, isoxazolyl and thiazolyl, wherein said heterocyclyl is substituted by a residue selected out of the group thienyl, 2-thienyl

5 and 3-thienyl, wherein said residue is unsubstituted or mono- or disubstituted independently of one another by R8,


and wherein R1, R2, R3, R4, R8, V, G, M and Q are as defined under 9).

10 The present invention also relates to the compounds of the formula Ib,



wherein R⁰ ; R¹ ; R² ; R³ ; R⁴; Q; V, G and M have the meanings indicated in formula I.

15 The present invention also relates to the compounds of the formula Ic,



wherein R⁰ ; R¹ ; R² ; R³ ; R⁴; Q; V, G and M have the meanings indicated in formula I.

20 The present invention also relates to the compounds of the formula I, which are

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

25 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-(6-Chloro-benzothiazol-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5 5-(5-Chloro-thiophen-2-yl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
5-(5-Chloro-thiophen-2-yl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-(2,4-dichloro-phenyl)-2H-pyrazole-3-
- 10 carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-(2,4-dichloro-phenyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-propyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-propyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
5-tert-Butyl-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
5-tert-Butyl-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-
- 20 isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 25 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[2-(5-Chloro-thiophen-2-yl)-thiazol-4-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid
- 30 (1-isopropyl-piperidin-4-yl)-amide,
1-[2-(5-Chloro-thiophen-2-yl)-thiazol-4-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

- 2-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic
- 10 acid (1-isopropyl-piperidin-4-ylmethyl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-ylmethyl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-amide,
- 15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-amide,
2-(4-Chloro-benzyl)-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-(4-Chloro-benzyl)-4-cyano-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-
- 20 piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid methyl ester,
- 25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-
- 30 pyrazole-3-carboxylic acid ethyl ester,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid ethyl ester,

- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(morpholine-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(morpholine-4-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-dimethylamide 5-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-dimethylamide 3-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2-
10 hydroxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(2-hydroxy-ethyl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],
{[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid,
15 {[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-amino}-acetic acid,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl)-
20 1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
Sulfuric acid mono-(2-{[1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-ethyl) ester,
Sulfuric acid mono-(2-{[2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-amino}-ethyl) ester,
25 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-oxo-oxazolidine-3-carbonyl)-2H-
30 pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-oxo-oxazolidine-3-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-morpholin-4-yl-ethyl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-morpholin-4-yl-ethyl)-amide],
- 5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [bis-(2-methoxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [bis-(2-methoxy-ethyl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(4,5-
- 10 dihydro-oxazol-2-yl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(4,5-dihydro-oxazol-2-yl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[3-(2-hydroxy-ethyl)-2-oxo- imidazolidine-1-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)- amide,
- 15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[3-(2-hydroxy-ethyl)-2-oxo- imidazolidine-1-carbonyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)- amide,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxymethyl-pyrrolidine-1- carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxymethyl-pyrrolidine-1- carbonyl)-
- 20 1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- {[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4- ylcarbamoyl)-1H-pyrazole-3-carbonyl]-methyl-amino}-acetic acid,
- {[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4- ylcarbamoyl)-2H-pyrazole-3-carbonyl]-methyl-amino}-acetic acid,
- 25 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4- ylcarbamoyl)-1H-pyrazole-3-carbonyl]-piperidine-4-carboxylic acid ethyl ester,
- 1-[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4- ylcarbamoyl)-2H-pyrazole-3-carbonyl]-piperidine-4-carboxylic acid ethyl ester,
- 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4- ylcarbamoyl)-
- 30 1H-pyrazole-3-carbonyl]-azetidine-2-carboxylic acid,
- 1-[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4- ylcarbamoyl)-2H-pyrazole-3-carbonyl]-azetidine-2-carboxylic acid,

- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(thiomorpholine-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(thiomorpholine-4-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-pyrrolidine-2-carboxylic acid,
- 1-[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-pyrrolidine-2-carboxylic acid,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxy-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 10 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxy-piperidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-pyrrolidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 20 5-(2,5-Bis-methoxymethyl-pyrrolidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5-(2,5-Bis-methoxymethyl-pyrrolidine-1-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 25 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxymethyl-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxymethyl-piperidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5-(8-Aza-spiro[4.5]decane-8-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 30 5-(8-Aza-spiro[4.5]decane-8-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-methanesulfonyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-methanesulfonyl-pyrrolidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(1,1-dioxo-tetrahydro-1-thiophen-3-yl)-methyl-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide] ,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1,1-dioxo-tetrahydro-1-thiophen-3-yl)-methyl-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide] ,
 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-
- 10 1H-pyrazole-3-carbonyl]-azetidine-3-carboxylic acid,
 1-[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-azetidine-3-carboxylic acid,
 5-(Azetidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 15 5-(Azetidine-1-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-oxo-piperazine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-oxo-piperazine-1-carbonyl)-1H-pyrazole-
- 20 3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4,4-difluoro-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4,4-difluoro-piperidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 25 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[(1,4]oxazepane-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[(1,4]oxazepane-4-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-azetidine-1-carbonyl)-2H-
- 30 pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-azetidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-trifluoromethyl-pyrrolidine-1- carbonyl)-
2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-trifluoromethyl-pyrrolidine-1- carbonyl)-
1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
5 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-dimethyl-pyrrolidine-1- carbonyl)-2H-
pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-dimethyl-pyrrolidine-1- carbonyl)-1H-
pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-
10 isopropyl-piperidin-4-yl)-amide] 3-[(2-sulfamoyl-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(1-
isopropyl-piperidin-4-yl)-amide] 5-[(2-sulfamoyl-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
cyclopropylamide 5-[(1-isopropyl-piperidin-4-yl)-amide],
15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-
cyclopropylamide 3-[(1-isopropyl-piperidin-4-yl)-amide],
{[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4- ylcarbamoyl)-1H-
pyrazole-3-carbonyl]-amino}-methanesulfonic acid,
{[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4- ylcarbamoyl)-2H-
20 pyrazole-3-carbonyl]-amino}-methanesulfonic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
cyclobutylamide 5-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-
cyclobutylamide 3-[(1-isopropyl-piperidin-4-yl)-amide],
25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-
isopropyl-piperidin-4-yl)-amide] 3-[(2-methoxy-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(1-
isopropyl-piperidin-4-yl)-amide] 5-[(2-methoxy-ethyl)-amide],
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(pyrrolidine-1-carbonyl)-2H- pyrazole-3-
30 carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(pyrrolidine-1-carbonyl)-1H- pyrazole-3-
carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5 Phosphoric acid mono-(2-[[1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-ethyl) ester,
- Phosphoric acid mono-(2-[[2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-amino}-ethyl) ester,
- 1-[[5-Chloro-pyridin-2-ylcarbamoyl]-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester,
- 10 1-[[5-Chloro-pyridin-2-ylcarbamoyl]-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid,
- 1-[[5-Chloro-pyridin-2-ylcarbamoyl]-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3-cyclobutylamide 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid bis-[(1-isopropyl-piperidin-4-yl)-amide],
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 20 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 2-[[4-Chloro-phenylcarbamoyl]-methyl]-4-cyano-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 25 3-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-propionic acid,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-amide),
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-carbamoylmethyl-amide 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 30 [[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-acetic acid ethyl ester,

- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(3-hydroxy-propyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-(2S)-azetidine-2-carboxylic acid,
- 5 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2S,2-hydroxymethyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-2S-pyrrolidine-2-carboxylic acid,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2S,2-methoxymethyl-pyrrolidine-1-
- 10 carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5-(2R,5R,2,5-Bis-methoxymethyl-pyrrolidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(4,5-dihydro-oxazol-2-yl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 15 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-piperidine-4-carboxylic acid ethyl ester,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-morpholin-4-yl-ethyl)-amide],
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4,4-difluoro-piperidine-1-carbonyl)-2H-
- 20 pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-oxo-oxazolidine-3-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-(2-oxo-imidazolidin-1-yl)-ethyl)-amide],
- 25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[(2,2,2-trifluoro-ethyl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(1,1-dioxo-tetrahydro-1-thiophen-3-yl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-
- 30 isopropyl-piperidin-4-yl)-amide] 3-[(3-(2-oxo-pyrrolidin-1-yl)-propyl)-amide],
- 5-(Azetidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(thiazolidine-3-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 2-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-3,3,3-trifluoro-propionic acid,
- 5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-trimethylsilanylmethyl-amide,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[4-(2-oxo-pyrrolidin-1-yl)-piperidine-1-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methanesulfonylaminocarbonyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 10 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-azetidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 15 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid, *is it? no*
- 5-(Azetidine-1-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-sulfamoyl-ethyl)-amide],
- 20 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[bis-(2-hydroxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2-hydroxy-1,1-bis-hydroxymethyl-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 25 [[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-acetic acid isopropyl ester,
- 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester,
- [[1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-acetic acid isopropyl ester,
- 30 [[1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-acetic acid ethyl ester,

A₃
 ↑ EP
 1 432 788

er
 2,2,2-trifluoroethyl

} same as
 x above
 but ethyl.

- {1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid, X
- 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(3-hydroxy-azetidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, X
- 5 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid cyclopropylmethyl ester, X
- 2-[(1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino)-3-methyl-butyric acid ethyl ester, X
- 2-[(1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino)-3-methyl-butyric acid, X
- 10 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide, X
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide, X
- 15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, X
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxy-ethoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, X
- 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, X
- 20 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxy]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, X
- 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2,2-trifluoro-ethoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, X
- 25 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-methoxy-ethyl ester, X
- 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-hydroxy-ethyl ester, X
- 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[(1,4]oxazepane-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, X
- 30 5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1-(3-methoxy-benzyl)-1H-pyrazole-3-carboxylic acid, X
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-hydroxy-ethyl ester, X

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid carboxymethyl ester,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3-carboxylic acid ethyl ester

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3-carboxylic acid,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2-difluoro-ethoxy)-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2-difluoro-ethoxy)-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-hydroxymethyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-difluoromethoxymethyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2,2-trifluoro-ethoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-ethoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-3-hydroxy-propoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-3-methoxy-propoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(3-difluoromethoxy-2,2-difluoro-propoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(cyanamide),

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(N-cyano-methyl-amide),

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(N-cyano-methyl-amide),

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[N-cyano-(2,2,2-trifluoro-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[N-cyano-(2,2,2-trifluoro-ethyl)-amide],
5 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2,2-difluoro-ethyl)-N-cyano-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2,2-difluoro-ethyl)-N-cyano-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-amide),
10 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-methyl-amide),
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-methyl-amide),
15 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[methoxy-(2,2,2-trifluoro-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[methoxy-(2,2,2-trifluoro-ethyl)-amide].....
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2,2-difluoro-ethyl)-methoxy-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
20 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2,2-difluoro-ethyl)-methoxy-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-difluoromethoxy-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
25 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-difluoromethoxy-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-ethoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-difluoro-ethoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
30 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-3-hydroxy-propoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-difluoro-3-hydroxy-propoxy)-
 2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-3-methoxy-propoxy)-2H-
 pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 5 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-difluoro-3-methoxy-propoxy)-
 2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(3-difluoromethoxy-2,2-difluoro-propoxy)-
 2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide or
 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-difluoromethoxy-2,2-difluoro-
 10 propoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide.

In general, the meaning of any group, residue, heteroatom, number etc., which can occur
 more than once in the compounds of the formulae I, Ib and Ic, is independent of the meaning
 15 of this group, residue, heteroatom, number etc. in any other occurrence. All groups, residues,
 heteroatoms, numbers etc., which can occur more than once in the compounds of the
 formulae I, Ib and Ic can be identical or different.

As used herein, the term alkyl is to be understood in the broadest sense to mean hydrocarbon
 20 residues which can be linear, i. e. straight-chain, or branched and which can be acyclic or
 cyclic residues or comprise any combination of acyclic and cyclic subunits. Further, the term
 alkyl as used herein expressly includes saturated groups as well as unsaturated groups which
 latter groups contain one or more, for example one, two or three, double bonds and/or triple
 bonds, provided that the double bonds are not located within a cyclic alkyl group in such a
 25 manner that an aromatic system results. All these statements also apply if an alkyl group
 occurs as a substituent on another residue, for example in an alkyloxy residue, an
 alkyloxycarbonyl residue or an arylalkyl residue. Examples of „-(C₁-C₈)-alkyl" or „-(C₁-C₈)-
 alkylene" are alkyl residues containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms are methyl,
 methylene, ethyl, ethylene, propyl, propylene, butyl, butylene, pentyl, pentylene, hexyl, heptyl
 30 or octyl, the n-isomers of all these residues, isopropyl, isobutyl, 1-methylbutyl, isopentyl,
 neopentyl, 2,2-dimethylbutyl, 2-methylpentyl, 3-methylpentyl, isohexyl, sec-butyl, tBu, tert-
 pentyl, sec-butyl, tert-butyl or tert-pentyl. The term „-(C₀-C₆)-alkyl" or „-(C₀-C₈)-alkylene" is a

hydrocarbon residues containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. The term „C₀-alkyl" or „C₀-alkylene" is a covalent bond.

Unsaturated alkyl residues are, for example, alkenyl residues such as vinyl, 1-propenyl, 2-propenyl (= allyl), 2-butenyl, 3-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 5-hexenyl or 1,3-pentadienyl, or alkynyl residues such as ethynyl, 1-propynyl, 2-propynyl (= propargyl) or 2-butyne. Alkyl residues can also be unsaturated when they are substituted.

Examples of (C₃-C₈)-cycloalkyl cyclic alkyl residues are cycloalkyl residues containing 3, 4, 5, 6, 7 or 8 ring carbon atoms like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, which can also be substituted and/or unsaturated. Unsaturated cyclic alkyl groups and unsaturated cycloalkyl groups like, for example, cyclopentenyl or cyclohexenyl can be bonded via any carbon atom.

Of course, a cyclic alkyl group has to contain at least three carbon atoms, and an unsaturated alkyl group has to contain at least two carbon atoms. Thus, a group like (C₁-C₈)-alkyl is to be understood as comprising, among others, saturated acyclic (C₁-C₈)-alkyl, (C₃-C₆)-cycloalkyl, and unsaturated (C₂-C₈)-alkyl like (C₂-C₈)-alkenyl or (C₂-C₈)-alkynyl. Similarly, a group like (C₁-C₄)-alkyl is to be understood as comprising, among others, saturated acyclic (C₁-C₄)-alkyl, and unsaturated (C₂-C₄)-alkyl like (C₂-C₄)-alkenyl or (C₂-C₄)-alkynyl.

Unless stated otherwise, the term alkyl preferably comprises acyclic saturated hydrocarbon residues which have from one to six carbon atoms and which can be linear or branched. A particular group of saturated acyclic alkyl residues is formed by (C₁-C₄)-alkyl residues like methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl and *t*Bu.

Unless stated otherwise, and irrespective of any specific substituents bonded to alkyl groups which are indicated in the definition of the compounds of the formulae I, Ib and Ic, alkyl groups can in general be unsubstituted or substituted by one or more, for example one, two or three, identical or different substituents. Any kind of substituents present in substituted alkyl residues can be present in any desired position provided that the substitution does not lead to an unstable molecule. Examples of substituted alkyl residues are alkyl residues in which one or

more, for example 1, 2 or 3, hydrogen atoms are replaced with halogen atoms, in particular fluorine atoms.

The terms "a monocyclic or bicyclic 6- to 14-membered aryl" or " $-(C_6-C_{14})$ -aryl" are understood as meaning aromatic hydrocarbon radicals containing from 6 to 14 carbon atoms in the ring. Examples of $-(C_6-C_{14})$ -aryl radicals are phenyl, naphthyl, for example 1-naphthyl and 2-naphthyl, biphenyl, for example 2-biphenyl, 3-biphenyl and 4-biphenyl, anthryl or fluorenyl. Biphenyl radicals, naphthyl radicals and, in particular, phenyl radicals are preferred aryl radicals.

10

The terms "mono- or bicyclic 4- to 15-membered heterocycl" or " $-(C_4-C_{15})$ -heterocycl" refer to heterocycles in which one or more of the 4 to 15 ring carbon atoms are replaced by heteroatoms such as nitrogen, oxygen or sulfur.


Examples are acridinyl, azaindole (1H-pyrrolopyridinyl), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxazolyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolyl, oxetanyl, oxocanyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydrofuranyl, tetrahydropyranyl,

tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl.

Preferred are heterocyclis, such as benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnoliny, 2-furyl, 3-furyl; 10 imidazolyl, indolyl, indazolyl, isochromanyl, isoindolyl, isoquinoliny, isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pteridiny, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrrolyl; 2-pyrrolyl, 3-pyrrolyl, quinoliny, quinazolinyl, quinoxaliny, tetrazolyl, thiazolyl, 2-thienyl and 3-thienyl.

15

Also preferred are:



The terms "het" or "a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms" refer to structures of heterocycles which can be derived from compounds such as azepine, azetidine, aziridine, azirine, 1,4 diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-
20 diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline,

isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxetan, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, 5 pyrrolidinone, pyrroline, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole.

- 10 The term "R¹-N-R²-V can form a 4- to 8-membered cyclic group" or "R¹¹ and R¹² together with the nitrogen atom to which they are bonded can form a 4- to 8-membered monocyclic heterocyclic ring which in addition to the nitrogen atom can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen" refer to structures of heterocycles which can be derived from compounds such as
- 15 azepane, azepine, azetidine, dioxazole, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline,
- 20 tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole.

The term "R¹⁵ and R¹⁶ together with the carbon atom to which they are bonded can form a 3- to 6 membered carbocyclic ring" refer to structures, which can be derived from compounds 25 such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

The term "R¹ and R³ together with the atoms to which they are bonded can form a 6- to 8-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen" refers to structures of heterocycles which can be derived from compounds such as 30 azocane, azocane-2-one, cycloheptyl cyclohexyl, cyclooctane, cyclooctene, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine, 1,4-oxazepane,

1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine, 1,2-oxathiepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, [1,4]oxazocane, [1,3]oxazocan-2-one, oxocane, oxocan-2-one, phenyl, piperazine, piperidine, pyran, pyrazine, pyridazine, pyrimidine, 5,6,7,8-5 tetrahydro-1H-azocin-2-one or thiomorpholine.

The fact that many of the before-listed names of heterocycles are the chemical names of unsaturated or aromatic ring systems does not imply that the, the 4-15 membered mono- or polycyclic group could only be derived from the respective unsaturated ring system. The names
10 here only serve to describe the ring system with respect to ring size and the number of the heteroatoms and their relative positions. As explained above, the 4-15 membered mono- or polycyclic group can be saturated or partially unsaturated or aromatic, and can thus be derived not only from the before-listed heterocycles themselves but also from all their partially or completely hydrogenated analogues and also from their more highly unsaturated analogues
15 if applicable. As examples of completely or partially hydrogenated analogues of the before-listed heterocycles from which this group may be derived the following may be mentioned: pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane,
20 piperazine, perhydro-1,4-oxazine (= morpholine), perhydro-1,4-thiazine (= thiomorpholine), perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, etc.

The 4-15 membered mono- or polycyclic group may be bonded via any ring carbon atom, and
25 in the case of nitrogen heterocycles via any suitable ring nitrogen atom. Thus, for example, a pyrrolyl residue can be 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, a pyrrolidinyl residue can be pyrrolidin-1-yl (= pyrrolidino), pyrrolidin-2-yl or pyrrolidin-3-yl, a pyridinyl residue can be pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, a piperidinyl residue can be piperidin-1-yl (= piperidino), piperidin-2-yl, piperidin-3-yl or piperidin-4-yl. Furyl can be 2-furyl or 3-furyl,
30 thienyl can be 2-thienyl or 3-thienyl, imidazolyl can be imidazol-1-yl, imidazol-2-yl, imidazol-4-yl or imidazol-5-yl, 1,3-oxazolyl can be 1,3-oxazol-2-yl, 1,3-oxazol-4-yl or 1,3-oxazol-5-yl, 1,3-thiazolyl can be 1,3-thiazol-2-yl, 1,3-thiazol-4-yl or 1,3-thiazol-5-yl, pyrimidinyl can be

pyrimidin-2-yl, pyrimidin-4-yl (= 6-pyrimidinyl) or 5-pyrimidinyl, piperazinyl can be piperazin-1-yl (= piperazin-4-yl = piperazino) or piperazin-2-yl. Indolyl can be indol-1-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl or indol-7-yl. Similarly benzimidazolyl, benzoxazolyl and benzothiazol residues can be bonded via the 2-position and via any of the positions 4, 5, 6, 5 and 7. Quinolinyl can be quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl or quinolin-8-yl, isoquinolinyl can be isoquinol-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl or isoquinolin-8-yl. In addition to being bonded via any of the positions indicated for quinolinyl and isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl and 1,2,3,4-tetrahydroisoquinolinyl can also be bonded via the nitrogen
10 atoms in 1-position and 2-position, respectively.

Unless stated otherwise, and irrespective of any specific substituents bonded to the 4-15-membered mono- or polycyclic group or any other heterocyclic groups which are indicated in the definition of the compounds of the formulae I, Ib and Ic, the 4-15 membered mono- or polycyclic group can be unsubstituted or substituted on ring carbon atoms with one or more,
15 for example one, two, three, four or five, identical or different substituents like (C₁-C₈)-alkyl, in particular (C₁-C₄)-alkyl, (C₁-C₈)-alkyloxy, in particular (C₁-C₄)-alkyloxy, (C₁-C₄)-alkylthio, halogen, nitro, amino, ((C₁-C₄)-alkyl)carbonylamino like acetylamino, trifluoromethyl, trifluoromethoxy, hydroxy, oxo, hydroxy-(C₁-C₄)-alkyl such as, for example, hydroxymethyl or 1-hydroxyethyl or 2-hydroxyethyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, aminosulfonyl,
20 methylsulfonyl, hydroxycarbonyl, aminocarbonyl, (C₁-C₄)-alkyloxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, benzyl optionally substituted in the phenyl group, benzyloxy optionally substituted in the phenyl group, etc. The substituents can be present in any desired position provided that a stable molecule results. Of course an oxo group cannot be present in an aromatic ring. Each suitable ring nitrogen atom in the 4-15 membered
25 mono- or polycyclic group can independently of each other be unsubstituted, i. e. carry a hydrogen atom, or can be substituted; i. e. carry a substituent like (C₁-C₈)-alkyl, for example (C₁-C₄)-alkyl such as methyl or ethyl, optionally substituted phenyl, phenyl-(C₁-C₄)-alkyl, for example benzyl, optionally substituted in the phenyl group, hydroxy-(C₂-C₄)-alkyl such as, for example 2-hydroxyethyl, acetyl or another acyl group, methylsulfonyl or another sulfonyl
30 group, aminocarbonyl, (C₁-C₄)-alkyloxycarbonyl, etc. In general, in the compounds of the formulae I, Ib and Ic nitrogen heterocycles can also be present as N-oxides or as quaternary salts. Ring sulfur atoms can be oxidized to the sulfoxide or to the sulfone. Thus, for example a tetrahydrothienyl residue may be present as S,S-dioxotetrahydro-thienyl residue or a

thiomorpholinyl residue like thiomorpholin-4-yl may be present as 1-oxo-thiomorpholin-4-yl or 1,1-dioxo-thiomorpholin-4-yl. A substituted 4 to 15 membered mono- or polycyclic group that can be present in a specific position of the compounds of formulae I, Ib and Ic can independently of other groups be substituted by substituents selected from any desired
5 subgroup of the substituents listed before and/or in the definition of that group.

The 3-7 membered monocyclic group may be bonded via any ring carbon atom, and in the case of nitrogen heterocycles via any suitable ring nitrogen atom. Thus, for example, a pyrrolyl residue can be 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, a pyrrolidinyl residue can be pyrrolidin-1-yl
10 (= pyrrolidino), pyrrolidin-2-yl or pyrrolidin-3-yl, a pyridinyl residue can be pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, a piperidinyl residue can be piperidin-1-yl (= piperidino), piperidin-2-yl, piperidin-3-yl or piperidin-4-yl. Furyl can be 2-furyl or 3-furyl, thienyl can be 2-thienyl or 3-thienyl, imidazolyl can be imidazol-1-yl, imidazol-2-yl, imidazol-4-yl or imidazol-5-yl, 1,3-oxazolyl can be 1,3-oxazol-2-yl, 1,3-oxazol-4-yl or 1,3-oxazol-5-yl, 1,3-thiazolyl can be
15 1,3-thiazol-2-yl, 1,3-thiazol-4-yl or 1,3-thiazol-5-yl, pyrimidinyl can be pyrimidin-2-yl, pyrimidin-4-yl (= 6-pyrimidinyl) or 5-pyrimidinyl, piperazinyl can be piperazin-1-yl (= piperazin-4-yl = piperazino) or piperazin-2-yl. Unless stated otherwise, and irrespective of any specific substituents bonded to the 3-7 membered monocyclic group or any other heterocyclic groups which are indicated in the definition of the compounds of the formulae I, Ib and Ic, can
20 be unsubstituted or substituted on ring carbon atoms with one or more, for example one, two, three, four or five, identical or different substituents like (C₁-C₈)-alkyl, in particular (C₁-C₄)-alkyl, (C₁-C₈)-alkyloxy, in particular (C₁-C₄)-alkyloxy, (C₁-C₄)-alkylthio, halogen, nitro, amino, ((C₁-C₄)-alkyl)carbonylamino like acetylamino, trifluoromethyl, trifluoromethoxy, hydroxy, oxo, hydroxy-(C₁-C₄)-alkyl such as, for example, hydroxymethyl or 1-hydroxyethyl or 2-hydroxyethyl,
25 methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, aminosulfonyl, methylsulfonyl, hydroxycarbonyl, aminocarbonyl, (C₁-C₄)-alkyloxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, benzyl optionally substituted in the phenyl group, benzyloxy optionally substituted in the phenyl group, etc. The substituents can be present in any desired position provided that a stable molecule results. Of course an oxo group cannot be present in
30 an aromatic ring. Each suitable ring nitrogen atom in the 3-7 membered monocyclic group can independently of each other be unsubstituted, i. e. carry a hydrogen atom, or can be substituted, i. e. carry a substituent like (C₁-C₈)-alkyl, for example (C₁-C₄)-alkyl such as methyl or ethyl, optionally substituted phenyl, phenyl-(C₁-C₄)-alkyl, for example benzyl, optionally

substituted in the phenyl group, hydroxy-(C₂-C₄)-alkyl such as, for example 2-hydroxyethyl, acetyl or another acyl group, methylsulfonyl or another sulfonyl group, aminocarbonyl, (C₁-C₄)-alkyloxycarbonyl, etc. In general, in the compounds of the formulae I nitrogen heterocycles can also be present as N-oxides or as quaternary salts. Ring sulfur atoms can be oxidized to the
 5 sulfoxide or to the sulfone. Thus, for example a tetrahydrothienyl residue may be present as S,S-dioxotetrahydrothienyl residue or a thiomorpholinyl residue like thiomorpholin-4-yl may be present as 1-oxo-thiomorpholin-4-yl or 1,1-dioxo-thiomorpholin-4-yl. A substituted 3-7 membered monocyclic group that can be present in a specific position of the compounds of formulae I can independently of other groups be substituted by substituents selected from any
 10 desired subgroup of the substituents listed before and/or in the definition of that group.

The term “-(C₁-C₃)-perfluoroalkyl” is a partial or totally fluorinated alkyl-residue, which can be derived from residues such as -CF₃, -CHF₂, -CH₂F, -CHF-CF₃, -CHF-CHF₂, -CHF-CH₂F, -CH₂-CF₃,

-CH₂-CHF₂, -CH₂-CH₂F, -CF₂-CF₃, -CF₂-CHF₂, -CF₂-CH₂F, -CH₂-CHF-CF₃, -CH₂-CHF-CHF₂,
 15 -CH₂-CHF-CH₂F, -CH₂-CH₂-CF₃, -CH₂-CH₂-CHF₂, -CH₂-CH₂-CH₂F, -CH₂-CF₂-CF₃,
 -CH₂-CF₂-CHF₂, -CH₂-CF₂-CH₂F, -CHF-CHF-CF₃, -CHF-CHF-CHF₂, -CHF-CHF-CH₂F, -CHF-CH₂-CF₃,
 -CHF-CH₂-CHF₂, -CHF-CH₂-CH₂F, -CHF-CF₂-CF₃, -CHF-CF₂-CHF₂, -CHF-CF₂-CH₂F, -CF₂-CHF-CF₃,
 -CF₂-CHF-CHF₂, -CF₂-CHF-CH₂F, -CF₂-CH₂-CF₃, -CF₂-CH₂-CHF₂, -CF₂-CH₂-CH₂F, -CF₂-CF₂-CF₃,
 20 -CF₂-CF₂-CHF₂ or -CF₂-CF₂-CH₂F.

The term “-(C₁-C₃)-perfluoroalkylene” is a partial or totally fluorinated alkylene-residue, which can be derived from residues such as -CF₂-, -CHF-, -CHF-CHF₂-, -CHF-CHF-, -CH₂-CF₂-,
 -CH₂-CHF-, -CF₂-CF₂-, -CF₂-CHF-, -CH₂-CHF-CF₂-, -CH₂-CHF-CHF-, -CH₂-CH₂-CF₂-,
 -CH₂-CH₂-CHF-, -CH₂-CF₂-CF₂-, -CH₂-CF₂-CHF-, -CHF-CHF-CF₂-, -CHF-CHF-CHF-, -CHF-CH₂-CF₂-,
 25 -CHF-CH₂-CHF-, -CHF-CF₂-CF₂-, -CHF-CF₂-CHF-, -CF₂-CHF-CF₂-, -CF₂-CHF-CHF-, -CF₂-CH₂-CF₂-,
 -CF₂-CH₂-CHF-, -CF₂-CF₂-CF₂-, or -CF₂-CF₂-CHF.

Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or iodine, particularly preferably chlorine or iodine.

Optically active carbon atoms present in the compounds of the formulae I, Ib and Ic can independently of each other have R configuration or S configuration. The compounds of the formulae I, Ib and Ic can be present in the form of pure enantiomers or pure diastereomers or in the form of mixtures of enantiomers and/or diastereomers, for example in the form of
5 racemates. The present invention relates to pure enantiomers and mixtures of enantiomers as well as to pure diastereomers and mixtures of diastereomers. The invention comprises mixtures of two or of more than two stereoisomers of the formulae I, Ib and Ic, and it comprises all ratios of the stereoisomers in the mixtures. In case the compounds of the formulae I, Ib and Ic can be present as E isomers or Z isomers (or cis isomers or trans isomers)
10 the invention relates both to pure E isomers and pure Z isomers and to E/Z mixtures in all ratios. The invention also comprises all tautomeric forms of the compounds of the formulae I, Ib and Ic.

Diastereomers, including E/Z isomers, can be separated into the individual isomers, for
15 example, by chromatography. Racemates can be separated into the two enantiomers by customary methods, for example by chromatography on chiral phases or by resolution, for example by crystallization of diastereomeric salts obtained with optically active acids or bases. Stereochemically uniform compounds of the formulae I, Ib and Ic can also be obtained by employing stereochemically uniform starting materials or by using stereoselective reactions.

20

Physiologically tolerable salts of the compounds of formulae I, Ib and Ic are nontoxic salts that are physiologically acceptable, in particular pharmaceutically utilizable salts. Such salts of compounds of the formulae I, Ib and Ic containing acidic groups, for example a carboxyl group COOH, are for example alkali metal salts or alkaline earth metal salts such as sodium salts,
25 potassium salts, magnesium salts and calcium salts, and also salts with physiologically tolerable quaternary ammonium ions such as tetramethylammonium or tetraethylammonium, and acid addition salts with ammonia and physiologically tolerable organic amines, such as methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, ethanolamine or tris-(2-hydroxyethyl)amine. Basic groups contained in the compounds of the formulae I, Ib and
30 Ic, for example amino groups or guanidino groups, form acid addition salts, for example with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, or with organic carboxylic acids and sulfonic acids such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic acid, succinic acid, malonic acid, benzoic acid,

maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. Compounds of the formulae I, Ib and Ic, which simultaneously contain a basic group and an acidic group, for example a guanidino group and a carboxyl group, can also be present as zwitterions (betaines) which are likewise included in the present invention.

5

Salts of compounds of the formulae I, Ib and Ic can be obtained by customary methods known to those skilled in the art, for example by combining a compound of the formulae I, Ib and Ic with an inorganic or organic acid or base in a solvent or dispersant, or from other salts by cation exchange or anion exchange. The present invention also includes all salts of the

10 compounds of the formulae I, Ib and Ic which, because of low physiological tolerability, are not directly suitable for use in pharmaceuticals but are suitable, for example, as intermediates for carrying out further chemical modifications of the compounds of the formulae I, Ib and Ic or as starting materials for the preparation of physiologically tolerable salts.

The present invention furthermore includes all solvates of compounds of the formulae I, Ib
15 and Ic, for example hydrates or adducts with alcohols.

The invention also includes derivatives and modifications of the compounds of the formulae I, Ib and Ic, for example prodrugs, protected forms and other physiologically tolerable derivatives, as well as active metabolites of the compounds of the formulae I, Ib and Ic. The invention relates in particular to prodrugs and protected forms of the compounds of the
20 formulae I, Ib and Ic, which can be converted into compounds of the formulae I, Ib and Ic under physiological conditions. Suitable prodrugs for the compounds of the formulae I, Ib and Ic, i. e. chemically modified derivatives of the compounds of the formulae I, Ib and Ic having properties which are improved in a desired manner, for example with respect to solubility, bioavailability or duration of action, are known to those skilled in the art. More detailed
25 information relating to prodrugs is found in standard literature like, for example, Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Fleisher et al., Advanced Drug Delivery Reviews 19 (1996) 115-130; or H. Bundgaard, Drugs of the Future 16 (1991) 443 which are all incorporated herein by reference. Suitable prodrugs for the compounds of the formulae I, Ib and Ic are especially acyl prodrugs and carbamate prodrugs of acylatable nitrogen-containing groups
30 such as amino groups and the guanidino group and also ester prodrugs and amide prodrugs of carboxylic acid groups which may be present in compounds of the formulae I, Ib and Ic. In the acyl prodrugs and carbamate prodrugs one or more, for example one or two, hydrogen atoms on nitrogen atoms in such groups are replaced with an acyl group or a carbamate, preferably a

-(C₁-C₆)-alkyloxycarbonyl group. Suitable acyl groups and carbamate groups for acyl prodrugs and carbamate prodrugs are, for example, the groups R^{P1}-CO- and R^{P2}O-CO-, in which R^{P1} is hydrogen, (C₁-C₁₈)-alkyl, (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkyl-(C₁-C₄)-alkyl-, (C₆-C₁₄)-aryl, Het-, (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl- or Het-(C₁-C₄)-alkyl- and in which R^{P2} has the meanings indicated for R^{P1} 5 with the exception of hydrogen.

Especially preferred compounds of the formulae I, Ib and Ic are those wherein two or more residues are defined as indicated before for preferred compounds of the formulae I, Ib and Ic, or residues can have one or some of the specific denotations of the residues given in their 10 general definitions or in the definitions of preferred compounds before. All possible combinations of definitions given for preferred definitions and of specific denotations of residues explicitly are a subject of the present invention.


Also with respect to all preferred compounds of the formulae I, Ib and Ic all their 15 stereoisomeric forms and mixtures thereof in any ratio and their physiologically acceptable salts explicitly are a subject of the present invention, as well as are their prodrugs. Similarly, also in all preferred compounds of the formulae I, Ib and Ic, all residues that are present more than one time in the molecule are independent of each other and can be identical or different.

20 The compounds of the formulae I, Ib and Ic can be prepared by utilising procedures and techniques, which per se are well known and appreciated by one of ordinary skill in the art. Starting materials or building blocks for use in the general synthetic procedures that can be applied in the preparation of the compounds of formulae I, Ib and Ic are readily available to one of ordinary skill in the art. In many cases they are commercially available or have been 25 described in the literature. Otherwise they can be prepared from readily available precursor compounds analogously to procedures described in the literature, or by procedures or analogously to procedures described in this application.

In general, compounds of the formulae I, Ib and Ic can be prepared, for example in the course 30 of a convergent synthesis, by linking two or more fragments which can be derived retrosynthetically from the formulae I, Ib and Ic. More specifically, suitably substituted starting Pyrazole derivatives are employed as building blocks in the preparation of the compounds of


formulae I, Ib and Ic. If not commercially available, such Pyrazole derivatives can be prepared according to the well-known standard procedures for the formation of the Pyrazole ring system. By choosing suitable precursor molecules, these pyrazole syntheses allow the introduction of a variety of substituents into the various positions of the pyrazole system, which can be chemically modified in order to finally arrive at the molecule of the formulae I, Ib and Ic having the desired substituent pattern. As one of the comprehensive reviews in which numerous details and literature references on the chemistry of pyrazole and on synthetic procedures for their preparation can be found, J. Eiguero in "Comprehensive Heterocyclic Chemistry II"; Eds. A. Katritzky, Ch. Rees, E. Scriven; Elsevier 1996, Vol. 3; K. Kirschke in Houben-Weyl, "Methoden der Organischen Chemie" (Methods of Organic Chemistry), Georg Thieme Verlag, Stuttgart, Germany 1994, Vol. E8b Heterarene; T. Nagai et al. Org. Prep. Proced. Int. (1993), 25, 403; M. Elnagdi et al. Heterocycles (1985) 23, 3121; K. Makino et al. J. Heterocycl. Chem. (1998) 35, 489; K. Makino et al. J. Heterocycl. Chem. (1999) 36, 321. If starting pyrazole derivatives are not commercially available and have to be synthesized this can be done, for example, according to the well-known pyrazole syntheses mentioned above. In the following procedures of particular interest for the embodiment of this invention are listed and referenced briefly, however, they are standard procedures comprehensively discussed in the literature, and are well known to one skilled in the art. Although not always shown explicitly, in certain cases positional isomers will occur during the synthesis of the below mentioned reactions. Nevertheless such mixtures of positional isomers, can be separated by modern separation techniques like, for example, preparative HPLC.

- 1) a) N. Kudo et al. Chem. Pharm. Bull. (1999) 47, 857.
b) M. Dewar et al. J. Chem. Soc. (1945) 114.
- 25 c) L. J. Smith, J. Am. Chem. Soc. (1949) 71, 2671.
d) J. Zhang, et al., Bioorg. Med. Chem. Lett. (2000) 10, 2575.




- 2) a) A. Padwa, J. Heterocycl. Chem. (1987) 24, 1225.
- 30 b) A. W. Erian et al.; Synth Commun. (1999) 29, 1527.

81




5 3) N. K. Markova et al., Zh. Org. Khim. (1983) 19, 2281.




4) P. Bravo et al., Tetrahedron (1994) 50, 8827.

10



5) a) M. A. Martins et al., Synthesis (1995) 12, 1491.


b) M. A. Martins et al., J. Heterocycl. Chem. (1999) 36, 217.




15

6) R. G. Jones et al., J. Org. Chem. (1955) 20, 1342.


82




- 7) W. T. Ashton et al., J. Heterocycl. Chem. (1993) 30, 307.



- 8) a) K. I. Bookermilburn, Synlett, (1992) 327.
 b) G. Heinisch et al., J. Chem. Soc. Perkin. Trans 1 (1990) 1829.
 c) K. Turnbull et al., Org. Prep. Proced. Int. (2000) 32, 593




- 9) F. Farina et al., Heterocycles (1989) 29, 967.




- 10) T. Haque et al., J. Med. Chem. (2002) 4669.

83




11) H. V. Patel, *Synth. Commun.* (1991) 21, 1583.

5




12) F. Farina et al., *Heterocycles* (1989) 29, 967.

10




13) R. Huisgen et al., *J. Am. Chem. Soc.* (1979) 101, 3647.

15




14) W. Sucrow et al., *Angew. Chem., Int. Ed.* (1975) 14, 560.


84



15) C. Baldoli et al., J. Heterocycl. Chem. (1989) , 26, 241.




5 16) G. M. Pilling et al., Tetrahedron Lett. (1988) 29, 1341.




17) D. Sauer et al., J. Org. Chem. (1990) 55, 5535.

10




18) K. Washizuka et al., Tetrahedron Lett. (1999) 40, 8849.



15

19) F. Foti et al., Tetrahedron Lett. (1999) 40, 2605.

85



Further, in order to obtain the desired substituents at the pyrazole ring system in the formulae 5 I, Ib and Ic, the functional groups introduced into the ring system during the pyrazole synthesis can be chemically modified. Especially the groups present in the pyrazole ring system can be modified by a variety of reactions and thus the desired residues R^{1a} , R^{1b} be obtained. For example, an pyrazole carrying a hydrogen atom in the 3-position can also be obtained by saponification and subsequent decarboxylation of pyrazole carrying an ester group in the

10 respective position. Alkyl- or hydroxymethyl groups as well as formyl groups attached to the pyrazole core can be transformed to a variety of functional groups, for example, to the corresponding carboxylic acid or carboxylic ester by many oxidative reactions well known to those skilled in the art. Moreover a nitrile group attached to the pyrazole ring can, for example, easily be converted into the desired acid under acidic or basic conditions. In

15 addition, carboxylic acid groups and acetic acid groups in the 3-position, the 4-position and the 5-position can be converted into their homologues by usual reactions for chain elongation of carboxylic acids. Halogen atoms can be introduced into the 3-position, the 4-position and the 5-position, for example according to procedures like the following described in the literature. For the fluorination of pyrazoles N-fluoro-2,4,6-trimethylpyridinium triflate is the

20 reagent of choice (T. Umemoto, S. Fukami, G. Tomizawa, K. Harasawa, K. Kawada, K. Tomita, J. Am. Chem. Soc. (1990) 112, 8563 see also K. Manko et al., J. Fluorine Chem. (1988) 39, 435; R. Storer et al. Nucleosides Nucleotides (1999) 18; 203) however, other suitable fluorinating reagents may also be employed where appropriate. The chlorination, bromination, or iodination of pyrazoles can be accomplished by the reaction with elemental halogens or by the

25 use of NCS, NBS or NIS and many other reagents well known to those skilled in the art. In addition suitable procedures are for example reported by M. Rodriguez-Franco et al., Tetrahedron Lett. (2001) 42, 863; J. Pawlas et al., J. Org. Chem. (2000) 65, 9001; Y. Huang et al., Org Lett (2000) 2, 2833; W. Holzer et al., J. Heterocycl. Chem. (1995) 32, 1351; N. Kudo et al., Chem. Pharm. Bull. (1999) 47, 857; G. Auzzi et al., Farmaco, Ed Sci (1979) 34, 743; K. Morimoto

30 et al., J. Heterocycl. Chem. (1997) 34, 537; D. Jeon et al., Synth. Commun. (1998) 28, 2159.

Depending on the reaction conditions, reagent, stoichiometry and substitution pattern the halogen is introduced in the 3-position and/or 4-position and/or 5-position. By selective halogen/metal exchange or metalation by selective hydrogen/metal exchange and subsequent reaction with a wide range of electrophiles various substituents can be introduced at the heterocyclic nucleus. (M. R. Grimmett, *Heterocycles* (1994) 37, 2087; V. D. Gardner et al., *J. Heterocycl. Chem.* (1984) 21, 121; D. Butler et al., *J. Org. Chem.* (1971) 36, 2542). Halogens or hydroxy groups (via their triflates or nonaflates) – or primary amines (via their diazonium salts) present in the pyrazole structure – can be converted directly, or after interconversion to the corresponding stannane, or boronic acid, into a variety of other functional groups like for example –CN, –CF₃, –C₂F₅, ethers, acids, amides, amines, alkyl- or aryl- groups mediated by means of transition metals, namely palladium or nickel catalysts or copper salts and reagents for example referred to below (F. Diederich, P. Stang, *Metal-catalyzed Cross-coupling Reactions*, Wiley-VCH, 1998; or M. Beller, C. Bolm, *Transition Metals for Organic Synthesis*, Wiley-VCH, 1998; J. Tsuji, *Palladium Reagents and Catalysts*, Wiley, 1996; J. Hartwig, *Angew. Chem.* (1998) 110, 2154; B. Yang, S. Buchwald, *J. Organomet. Chem.* (1999) 576, 125; T. Sakamoto, K. Ohsawa, *J. Chem. Soc. Perkin Trans I* (1999) 2323; D. Nichols, S. Frescas, D. Marona-Lewicka, X. Huang, B. Roth, G. Gudelsky, J. Nash, *J. Med. Chem.* (1994) 37, 4347; P. Lam, C. Clark, S. Saubern, J. Adams, M. Winters, D. Chan, A. Combs, *Tetrahedron Lett.* (1998) 39, 2941; D. Chan, K. Monaco, R. Wang, M. Winters, *Tetrahedron Lett.* (1998) 39, 2933; V. Farina, V. Krishnamurthy, W. Scott, *The Stille Reaction*, Wiley, 1994; F. Qing et al. *J. Chem. Soc. Perkin Trans. I* (1997) 3053; S. Buchwald et al. *J. Am. Chem. Soc.* (2001) 123, 7727; S. Kang et al. *Synlett* (2002) 3, 427; S. Buchwald et al. *Organic Lett.* (2002) 4, 581; T. Fuchikami et al. *Tetrahedron Lett.* (1991) 32, 91; Q. Chen et al. *Tetrahedron Lett.* (1991) 32, 7689).

For example, nitro groups can be reduced to amino groups by means of various reducing agents, such as sulfides, dithionites, complex hydrides or by catalytic hydrogenation. A reduction of a nitro group may also be carried out at a later stage of the synthesis of a compound of the formulae I, Ib and Ic, and a reduction of a nitro group to an amino group may also occur simultaneously with a reaction performed on another functional group, for example when reacting a group like a cyano group with hydrogen sulfide or when hydrogenating a group. In order to introduce the residues R^{1a}, R^{1b}, amino groups can then be modified according to standard procedures for alkylation, for example by reaction with (substituted) alkyl halogenides or by reductive amination of carbonyl compounds, according to standard procedures for acylation, for example by reaction with activated carboxylic acid

derivatives such as acid chlorides, anhydrides, activated esters or others or by reaction with carboxylic acids in the presence of an activating agent, or according to standard procedures for sulfonylation, for example by reaction with sulfonyl chlorides.

- 5 Ester groups present in the pyrazole nucleus can be hydrolyzed to the corresponding carboxylic acids, which after activation can then be reacted with amines or alcohols under standard conditions to give amides or alcohols, respectively. Ester groups present in the pyrazole nucleus can be converted to other esters by transesterification. Carboxylic acids attached to a suitable pyrazole nucleus can also be alkylated to give esters. Ether groups present at the
- 10 pyrazole nucleus, for example benzyloxy groups or other easily cleavable ether groups, can be cleaved to give hydroxy groups which then can be reacted with a variety of agents, for example etherification agents or activating agents allowing replacement of the hydroxy group by other groups. Sulfur-containing groups can be reacted analogously.
- 15 During the course of the synthesis in order to modify the groups R^{87} or R^{88} attached to the pyrazole ring system by application of parallel synthesis methodology, a variety of reactions can be extremely useful, including, for example, palladium, nickel or copper catalysis. Such reactions are described for example in F. Diederich, P. Stang, *Metal-catalyzed Cross-coupling Reactions*, Wiley-VCH (1998) ; or M. Beller, C. Bolm, *Transition Metals for Organic Synthesis*,
- 20 Wiley-VCH (1998) ; J. Tsuji, *Palladium Reagents and Catalysts*, Wiley (1996) ; J. Hartwig, *Angew. Chem.* (1998) , 110, 2154; B. Yang, S. Buchwald, *J. Organomet. Chem.* (1999) , 576, 125; P. Lam, C. Clark, S. Saubern, J. Adams, M. Winters, D. Chan, A. Combs, *Tetrahedron Lett.* (1998) , 39, 2941; D. Chan, K. Monaco, R. Wang, M. Winters, *Tetrahedron Lett.* (1998) , 39, 2933; J. Wolfe, H. Tomori, J. Sadight, J. Yin, S. Buchwald, *J. Org. Chem.* (2000) , 65, 1158; V. Farina, V.
- 25 Krishnamurthy, W. Scott, *The Stille Reaction*, Wiley, (1994) ; S. Buchwald et al., *J. Am. Chem. Soc.* (2001) , 123, 7727; S. Kang et al., *Synlett* (2002) , 3, 427; S. Buchwald et al., *Org. Lett.* (2002) , 4, 581.

The previously-mentioned reactions for the conversion of functional groups are furthermore,


30 in general, extensively described in textbooks of organic chemistry like M. Smith, J. March, *March's Advanced Organic Chemistry*, Wiley-VCH, 2001 and in treatises like Houben-Weyl, *"Methoden der Organischen Chemie"* (Methods of Organic Chemistry), Georg Thieme Verlag, Stuttgart, Germany, or *"Organic Reactions"*, John Wiley & Sons, New York, or R. C. Larock, "

Comprehensive Organic Transformations", Wiley-VCH, 2nd ed (1999), B. Trost, I. Fleming (eds.) Comprehensive Organic Synthesis, Pergamon, 1991; A. Katritzky, C. Rees, E. Scriven Comprehensive Heterocyclic Chemistry II, Elsevier Science, 1996) in which details on the reactions and primary source literature can be found. Due to the fact that in the present case
5 the functional groups are attached to an pyrazole ring it may in certain cases become necessary to specifically adapt reaction conditions or to choose specific reagents from a variety of reagents that can in principle be employed in a conversion reaction, or otherwise to take specific measures for achieving a desired conversion, for example to use protection group techniques. However, finding out suitable reaction variants and reaction conditions in such
10 cases does not cause any problems for one skilled in the art.

The structural elements present in the residues attached at the 1-position of the pyrazole ring in the compounds of the formulae I, Ib and Ic and in the COR^{8'} group present in the 3-position and/or in the 5-position of the pyrazole ring can be introduced into the starting pyrazole derivative obtainable as outlined above by consecutive reaction steps using synthesis
15 methodologies like those outlined below using procedures which per se are well known to one skilled in the art.

The residues R^{8'} that can be introduced in formula 2, for example, by condensing a corresponding carboxylic acid of the formula 2 with a compound of the formula HR^{8'},
20 i. e. with an amine of the formula HN(R¹)R^{2'}-V-G-M to give a compound of the formula 3. The compound of the formula 3 thus obtained can already contain the desired final groups, i. e. the groups R^{8'} and R⁸⁷ can be the groups -N(R¹)-R²-V-G-M and R⁰-Q- as defined in the formulae I, Ib and Ic, or optionally in the compound of the formula 3 thus obtained subsequently the residue or the residues R^{8'} and the residue R⁸⁷ are converted into the residues -N(R¹)R²-V-G-M
25 and R⁰-Q-, respectively, to give the desired compound of the formulae I, Ib and Ic.

89



Thus, the residues R⁸ and the residues R¹ and R²-V-G-M contained therein can have the denotations of R¹ and R²-V-G-M, respectively, given above or in addition in the residues R¹ and R²-V-G-M functional groups can also be present in the form of groups that can subsequently be transformed into the final groups R¹ and R²-V-G-M, i.e. functional groups can be present in the form of precursor groups or of derivatives, for example in protected form. In the course of the preparation of the compounds of the formulae I, Ib and Ic, it can generally be advantageous or necessary to introduce functional groups which reduce or prevent undesired reactions or side reactions in the respective synthesis step, in the form of precursor groups which are later converted into the desired functional groups, or to temporarily block functional groups by a protective group strategy suited to the synthesis problem. Such strategies are well known to those skilled in the art (see, for example, Greene and Wuts, *Protective Groups in Organic Synthesis*, Wiley, 1991, or P. Kocienski, *Protecting Groups*, Thieme 1994). As examples of precursor groups cyano groups and nitro groups may be mentioned. The cyano group can in a later step be transformed into carboxylic acid derivatives or by reduction into aminomethyl groups, or the nitro groups may be transformed by reduction like catalytic hydrogenation into amino groups. Protective groups can also have the meaning of a solid phase, and cleavage from the solid phase stands for the removal of the protective group. The use of such techniques is known to those skilled in the art (Burgess K (Ed.) *Solid Phase Organic Synthesis*, New York, Wiley, 2000). For example, a phenolic hydroxy group can be attached to a trityl-polystyrene resin, which serves as a protecting group, and the molecule is cleaved from this resin by treatment with TFA at a later stage of the synthesis.

The residue R^{87} in the compounds of the formulae 2 and 3 can denote the group $-Q-R^0$ as defined above which finally is to be present in the desired target molecule of the formulae 1, 1b and 1c, or it can denote a group which can subsequently be transformed into the group $-Q-R^0$, for example a precursor group or a derivative of the group $-Q-R^0$ in which functional groups are present in protected form, or R^{87} can denote a hydrogen atom or a protective group for the nitrogen atom of the pyrazole ring. Similarly, the residues R^{1a} and R^{1b} in the formulae 2 and 3 have the corresponding definitions of R^4 and R^3 in formulae 1, 1b and 1c as defined above, however, for the synthesis of the compounds of the formulae 1, 1b and 1c these residues, too, can in principle be present at the stage of the condensation of a compound of the formula 2 with a compound of the formula HR^8 giving a compound of the formula 3 in the form of precursor groups or in protected form.

The residues R^{86} in the compounds of the formula 2 which can be identical or different, can be, for example, hydroxy or (C_1-C_4) -alkoxy, i. e., the groups COR^{86} present in the compounds of the formula 2 can be, for example, the free carboxylic acids or esters thereof like alkyl esters as can be the groups COR^8 in the compounds of the formulae 1, 1b and 1c. The groups COR^{86} can also be any other activated derivative of a carboxylic acid which allows amide formation, ester formation or thioester formation with a compound of the formula HR^8 . The group COR^{86} can be, for example, an acid chloride, an activated ester like a substituted phenyl ester or an N-hydroxysuccinimide or a hydroxybenzotriazole ester, an azolide like an imidazolide, an azide or a mixed anhydride, for example a mixed anhydride with a carbonic acid ester or with a sulfonic acid, which derivatives can all be prepared from the carboxylic acid by standard procedures and can be reacted with an amine, an alcohol or a mercaptan of the formula HR^8 under standard conditions. A carboxylic acid group $COOH$ representing COR^{86} in a compound of the formula 2 can be obtained, for example, from an ester group introduced into the pyrazole system during a pyrazole synthesis by standard hydrolysis procedures. It can also be obtained, for example, by hydrolysis of a nitrile group introduced into the pyrazole system during a pyrazole synthesis.

Compounds of the formulae 1, 1b and 1c in which a group COR^8 is an ester group can also be prepared from compounds of the formula 2 in which COR^{86} is a carboxylic acid group by common esterification reactions like, for example, reacting the acid with an alcohol under acid

catalysis, or alkylation of a salt of the carboxylic acid with an electrophile like an alkyl halogenide, or by transesterification from another ester. Compounds of the formulae I, Ib and Ic in which a group COR^{87} is an amide group can be prepared from amines and compounds of the formula 2 in which COR^{86} is a carboxylic acid group or an ester thereof by common
5 amination reactions. Especially for the preparation of amides the compounds of the formula 2 in which COR^{86} is a carboxylic acid group can be condensed under standard conditions with compounds of the formula HR^{87} which are amines by means of common coupling reagents used in peptide synthesis. Such coupling reagents are, for example, carbodiimides like dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide, carbonyldiazoles like
10 carbonyldiimidazole (CDI) and similar reagents, propylphosphonic anhydride, O-((cyano-(ethoxycarbonyl)-methylene)amino)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TOTU), diethylphosphoryl cyanide (DEPC) or bis-(2-oxo-3-oxazolidinyl)-phosphoryl chloride (BOP-Cl) and many others.

15 If the residue $-\text{Q}-\text{R}^0$ present in an pyrazole of the formulae I, Ib and Ic or the residue R^{87} present in an pyrazole of the formula 2, or a residue in which functional groups within the residue $-\text{Q}-\text{R}^0$ or R^{87} are present in protected form or in the form of a precursor group, have not already been introduced during a preceding step, for example during a synthesis of the pyrazole nucleus, these residues can, for example, be introduced into the 1-position of the
20 pyrazole system by conventional literature procedures well known to one skilled in the art for N-alkylation, reductive amination, N-arylation, N-acylation or N-sulfonylation of ring nitrogen atoms of heterocycles. The starting pyrazole derivative that is to be employed in such a reaction carries a hydrogen atom in the 1-position. N-Alkylation of a ring nitrogen atom can, for example, be performed under standard conditions, preferably in the presence of a base like
25 K_2CO_3 , Cs_2CO_3 , NaH or KO^tBu , using an alkylating compound of the formula $\text{LG}-\text{Q}-\text{R}^0$ or of the formula $\text{R}^{87}-\text{LG}$, wherein the atom in the group Q or in the group R^{87} bonded to the group LG in this case is an aliphatic carbon atom of an alkyl moiety and LG is a leaving group, for example halogen like chlorine, bromine or iodine, or a sulfonyloxy group like tosyloxy, mesyloxy or trifluormethylsulfonyloxy. LG may, for example, also be a hydroxy group which, in order to
30 achieve the alkylation reaction, is activated in a well-known Mitsunobu reaction by a conventional activating agent. The regioselectivity of the N-alkylation can be controlled by the choice of the base, solvent and reaction conditions. Nevertheless mixtures of positional

isomers, can be separated by modern separation techniques like, for example, flash chromatography, crystallisation or preparative HPLC.

For the preparation of compounds in which A is a direct linkage and an aromatic group is directly bonded to the 1-position of the pyrazole system, conventional arylation procedures can be used. For example aryl fluorides like alkyl fluorobenzoates or 4-fluorophenyl nitriles can be employed as arylating agents. Such processes are described, for example, by K. Cooper et al., *J. Med. Chem.* (1992), 35, 3115; M. Artico et al., *Eur. J. Med. Chem. Chim. Ther.* (1992) 27, 219; X.-J. Wang et al., *Tetrahedron Letters* (2000) 41, 5321; M. L. Cerrada et al., *Synth. Commun.* (1993) 23, 1947. Alternatively a wide variety of substituted aryl iodides, aryl bromides or aryl triflates can serve as arylating agents at the 1-position of the heterocyclic nitrogen in a copper salt or palladium mediated reaction according for example to P. Cozzi et al. *Farmaco* (1987) 42, 205; P. Unangst, D. Connor, R. Stabler, R. Weikert, *J. Heterocycl. Chem.* (1987) 24, 811; G. Tokmakov, I. Grandberg, *Tetrahedron* (1995) 51, 2091; D. Old, M. Harris, S. Buchwald, *Org. Lett.* (2000) 2, 1403; G. Mann, J. Hartwig, M. Driver, C. Fernandez-Rivas, *J. Am. Chem. Soc.* (1998) 120, 827; J. Hartwig, M. Kawatsura, S. Hauk, K. Shaughnessy, *L. J. Org. Chem.* (1999) 64, 5575; S. Buchwald et al., *J. Am. Chem. Soc.* (2001) 123, 7727. Moreover such arylations can also be accomplished by reaction of a wide range of substituted aryl boronic acids as demonstrated for example by P. Lam et al., *Tetrahedron Lett.* (1998) 39, 2941; V. Collot et al., *Tetrahedron Lett.* (2000) 41, 9053; P. Lam et al., *Tetrahedron Lett.* (2001) 42, 3415;

Preferred methods include, but are not limited to those described in the examples.

The compounds of the present invention are serine protease inhibitors, which inhibit the activity of the blood coagulation enzyme factors Xa and/or factor VIIa. In particular, they are highly active inhibitors of factor Xa. They are specific serine protease inhibitors inasmuch as they do not substantially inhibit the activity of other proteases whose inhibition is not desired. The activity of the compounds of the formulae I, Ib and Ic can be determined, for example, in the assays described below or in other assays known to those skilled in the art. With respect to factor Xa inhibition, a preferred embodiment of the invention comprises compounds which have a $K_i < 1$ mM for factor Xa inhibition as determined in the assay described below, with or without concomitant factor VIIa inhibition, and which preferably do not substantially inhibit the activity of other proteases involved in coagulation and fibrinolysis whose inhibition is not

desired (using the same concentration of the inhibitor). The compounds of the invention inhibit factor Xa catalytic activity either directly, within the prothrombinase complex or as a soluble subunit, or indirectly, by inhibiting the assembly of factor Xa into the prothrombinase complex.

5

As inhibitors of factor Xa and/or factor VIIa the compounds of the formulae I, Ib and Ic and their physiologically tolerable salts and their prodrugs are generally suitable for the therapy and prophylaxis of conditions in which the activity of factor Xa and/or factor VIIa plays a role or has an undesired extent, or which can favorably be influenced by inhibiting factor Xa and/or factor VIIa or decreasing their activities, or for the prevention, alleviation or cure of which an inhibition of factor Xa and/or factor VIIa or a decrease in their activity is desired by the physician. As inhibition of factor Xa and/or factor VIIa influences blood coagulation and fibrinolysis, the compounds of the formulae I, Ib and Ic and their physiologically tolerable salts and their prodrugs are generally suitable for reducing blood clotting, or for the therapy and prophylaxis of conditions in which the activity of the blood coagulation system plays a role or has an undesired extent, or which can favorably be influenced by reducing blood clotting, or for the prevention, alleviation or cure of which a decreased activity of the blood coagulation system is desired by the physician. A specific subject of the present invention thus are the reduction or inhibition of unwanted blood clotting, in particular in an individual, by:

10 administering an effective amount of a compound I or a physiologically tolerable salt or a prodrug thereof, as well as pharmaceutical preparations therefor.

15

The present invention also relates to the compounds of the formulae I, Ib and Ic and/or their physiologically tolerable salts and/or their prodrugs for use as pharmaceuticals (or medicaments), to the use of the compounds of the formulae I, Ib and Ic and/or their physiologically tolerable salts and/or their prodrugs for the production of pharmaceuticals for inhibition of factor Xa and/or factor VIIa or for influencing blood coagulation, inflammatory response or fibrinolysis or for the therapy or prophylaxis of the diseases mentioned above or below, for example for the production of pharmaceuticals for the therapy and prophylaxis of cardiovascular disorders, thromboembolic diseases or restenoses. The invention also relates to

25

30 the use of the compounds of the formulae I, Ib and Ic and/or their physiologically tolerable salts and/or their prodrugs for the inhibition of factor Xa and/or factor VIIa or for influencing blood coagulation or fibrinolysis or for the therapy or prophylaxis of the diseases mentioned

above or below, for example for use in the therapy and prophylaxis of cardiovascular disorders, thromboembolic diseases or restenoses, and to methods of treatment aiming at such purposes including methods for said therapies and prophylaxis. The present invention also relates to pharmaceutical preparations (or pharmaceutical compositions) which contain an
5 effective amount of at least one compound of the formulae I, Ib and Ic and/or its physiologically tolerable salts and/or its prodrugs in addition to a customary pharmaceutically acceptable carrier, i. e. one or more pharmaceutically acceptable carrier substances or excipients and/or auxiliary substances or additives.

- 10 The invention also relates to the treatment of disease states such as abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication or bypass
grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post
15 coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulopathy
20 occurring in vascular systems during septic shock, certain viral infections or cancer.

The compounds of the present invention can also be used to reduce an inflammatory response. Examples of specific disorders for the treatment or prophylaxis of which the compounds of the formulae I, Ib and Ic can be used are coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty
25 like PTCA, adult respiratory distress syndrome, multi-organ failure and disseminated intravascular clotting disorder. Examples of related complications associated with surgery are thromboses like deep vein and proximal vein thrombosis, which can occur following surgery.

The compounds of the formulae I, Ib and Ic and their physiologically tolerable salts and their
30 prodrugs can be administered to animals, preferably to mammals, and in particular to humans as pharmaceuticals for therapy or prophylaxis. They can be administered on their own, or in mixtures with one another or in the form of pharmaceutical preparations, which permit enteral or parenteral administration.

The pharmaceuticals can be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration, however, can also be carried out
5 rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injection solutions or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.

- 10 The pharmaceutical preparations according to the invention are prepared in a manner known per se and familiar to one skilled in the art, pharmaceutically acceptable inert inorganic and/or organic carriers being used in addition to the compound(s) of the formulae I, Ib and Ic and/or its (their) physiologically tolerable salts and/or its (their) prodrugs. For the production of pills, tablets, coated tablets and hard gelatin capsules it is possible to use, for example, lactose,
15 cornstarch or derivatives thereof, talc, stearic acid or its salts, etc. Carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc. Suitable carriers for the production of solutions, for example injection solutions, or of emulsions or syrups are, for example, water, saline, alcohols, glycerol, polyols, sucrose, invert sugar, glucose, vegetable oils, etc. Suitable carriers for microcapsules, implants
20 or rods are, for example, copolymers of glycolic acid and lactic acid. The pharmaceutical preparations normally contain about 0.5 % to 90 % by weight of the compounds of the formulae I, Ib and Ic and/or their physiologically tolerable salts and/or their prodrugs. The amount of the active ingredient of the formulae I, Ib and Ic and/or its physiologically tolerable salts and/or its prodrugs in the pharmaceutical preparations normally is from about 0.5 mg to
25 about 1000 mg, preferably from about 1 mg to about 500 mg.

In addition to the active ingredients of the formulae I, Ib and Ic and/or their physiologically acceptable salts and/or prodrugs and to carrier substances, the pharmaceutical preparations can contain additives such as, for example, fillers, disintegrants, binders, lubricants, wetting
30 agents, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the formulae I, Ib and Ic, and/or their physiologically

tolerable salts and/or their prodrugs. In case a pharmaceutical preparation contains two or more compounds of the formulae I, Ib and Ic, the selection of the individual compounds can aim at a specific overall pharmacological profile of the pharmaceutical preparation. For example, a highly potent compound with a shorter duration of action may be combined with a long-acting compound of lower potency. The flexibility permitted with respect to the choice of substituents in the compounds of the formulae I, Ib and Ic allows a great deal of control over the biological and physico-chemical properties of the compounds and thus allows the selection of such desired compounds. Furthermore, in addition to at least one compound of the formulae I, Ib and Ic and/or a physiologically tolerable salt and/or its prodrug, the pharmaceutical preparations can also contain one or more other therapeutically or prophylactically active ingredients.

When using the compounds of the formulae I, Ib and Ic the dose can vary within wide limits and, as is customary and is known to the physician, is to be suited to the individual conditions in each individual case. It depends, for example, on the specific compound employed, on the nature and severity of the disease to be treated, on the mode and the schedule of administration, or on whether an acute or chronic condition is treated or whether prophylaxis is carried out. An appropriate dosage can be established using clinical approaches well known in the medical art. In general, the daily dose for achieving the desired results in an adult weighing about 75 kg is from 0.01 mg/kg to 100 mg/kg, preferably from 0.1 mg/kg to 50 mg/kg, in particular from 0.1 mg/kg to 10 mg/kg, (in each case in mg per kg of body weight). The daily dose can be divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. As usual, depending on individual behavior it may be necessary to deviate upwards or downwards from the daily dose indicated.

25

A compound of the formulae I, Ib and Ic can also advantageously be used as an anticoagulant outside an individual. For example, an effective amount of a compound of the invention can be contacted with a freshly drawn blood sample to prevent coagulation of the blood sample. Further, a compound of the formulae I, Ib and Ic or its salts can be used for diagnostic purposes, for example in in vitro diagnoses, and as an auxiliary in biochemical investigations. For example, a compound of the formulae I, Ib and Ic can be used in an assay to identify the presence of factor Xa and/or factor VIIa or to isolate factor Xa and/or factor VIIa in a substantially purified form. A compound of the invention can be labeled with, for example, a

30

radioisotope, and the labeled compound bound to factor Xa and/or factor VIIa is then detected using a routine method useful for detecting the particular label. Thus, a compound of the formulae I, Ib and Ic or a salt thereof can be used as a probe to detect the location or amount of factor Xa and/or factor VIIa activity in vivo, in vitro or ex vivo.

5

Furthermore, the compounds of the formulae I, Ib and Ic can be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formulae I, Ib and Ic, for example by introduction of substituents or modification of functional groups.

10

The general synthetic sequences for preparing the compounds useful in the present invention are outlined in the examples given below. Both an explanation of, and the actual procedure for, the various aspects of the present invention are described where appropriate. The following examples are intended to be merely illustrative of the present invention, and not limiting thereof in either scope or spirit. Those with skill in the art will readily understand that known variations of the conditions and processes described in the examples can be used to synthesize the compounds of the present invention.

It is understood that changes that do not substantially affect the activity of the various embodiments of this invention are included within the invention disclosed herein. Thus, the following examples are intended to illustrate but not limit the present invention.

20

Examples

25 When in the final step of the synthesis of a compound an acid such as trifluoroacetic acid or acetic acid was used, for example when trifluoroacetic acid was employed to remove a tBu group or when a compound was purified by chromatography using an eluent which contained such an acid, in some cases, depending on the work-up procedure, for example the details of a freeze-drying process, the compound was obtained partially or completely in the form of a salt
30 of the acid used, for example in the form of the acetic acid salt or trifluoroacetic acid salt or hydrochloric acid salt.

Abbreviations used:

tert-Butyl	tBu
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl	Binap
Bis-(oxo-3-oxazolidinyl)-phosphoryl chloride	BOP-Cl
dibenzylidenacetone	dba
5 Dichloromethane	DCM
Dicyclohexyl-carbodiimide	DCC
Diethylphosphoryl cyanide	DEPC
Diisopropylethyl amine	DIPEA
4-Dimethylaminopyridine	DMAP
10 N,N-Dimethylformamide	DMF
Dimethylsulfoxide	DMSO
1,1'-Bis(diphenylphosphino)ferrocene	DPPF
O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium-hexafluorophosphate	HATU
15 N-Bromosuccinimide	NBS
N-Chlorosuccinimide	NCS
N-Iodosuccinimide	NIS
N-Ethylmorpholine	NEM
Methanol	MeOH
20 Room temperature 20 °C to 25 °C	RT
Saturated	sat.
Tetrahydrofuran	THF
Trifluoroacetic acid	TFA
O-((Ethoxycarbonyl)cyanomethyleneamino)-	
25 N,N,N',N'-tetramethyluronium tetrafluoroborate	TOTU

Example 1: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,

30 (i) (1-Isopropyl-piperidin-4-yl)-carbamic acid tert-butyl ester

To a solution of 5.0 g Piperidin-4-yl-carbamic acid tert-butyl ester in 15 ml methanol 7.34 ml acetone, 3.14 g Na(CN)BH₃ and 0.3 ml acetic acid were added. After stirring for 16 h at RT the solvent was removed under reduced pressure and the residue was partitioned between 30 ml

of water and 30 ml of ethyl acetate. The organic layer was washed with saturated Na_2CO_3 solution, water and then dried over Na_2SO_4 . Following filtration, the solvent was removed under reduced pressure to yields a white solid. Yield: 4.8g MS (ES^+): $m/e = 243$.

5 (ii) 1-Isopropyl-piperidin-4-ylamine

To 4.8 g (1-Isopropyl-piperidin-4-yl)-carbamic acid tert-butyl ester in 15 ml methanol, 20 ml methanolic hydrochloric acid (8M) were added and the mixture was stirred for 16 h. Removal of the solvent under reduced pressure yielded a white solid, which was coevaporated twice with 20 ml toluene. The product was obtained as its hydrochloride.

10 Yield: 5.42 g MS (ES^+): $m/e = 143$.

(iv) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3- carboxylic acid ethyl ester

To a solution of 2.0 g 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester in 5 ml DMF, 15 360 mg NaH (60% in mineral oil) and subsequently 2.8 g 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole [prepared by adopting a procedure described by Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls, Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen; Myers, Michael R.; Lau, Wan F.; Poli, Gregory B; PCT Int. Appl. (2001) 460 pp. WO 20 0107436 A2] were added and the mixture was stirred at 80 °C for 1h. After the addition of 5 ml water the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. The residue was directly subjected to the subsequent saponification reaction without further purification. Yield: 4 g.

25 (v) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3- carboxylic acid

To a solution of 4 g 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3- carboxylic acid ethyl ester in 20 ml THF, 10 ml water and 500 mg lithium hydroxide monohydrate were added. After stirring for 2 h at 60°C the reaction was cooled to RT. The 30 mixture was acidified with half concentrated hydrochloric acid to pH 3 and the precipitate collected by filtration and washed with 10 ml water The product was obtained as a white solid which was dried under reduced pressure. Yield: 3.8 g.

(vi) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To a solution of 200 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid, 0.3 ml N-NEM in 2 ml DCM, 168 mg TOTU were added and the mixture was stirred for 30 min at RT. Then 136 mg 1-Isopropyl-piperidin-4-ylamine hydrochloride were added and the reaction was further stirred for 2 h. After the addition of 2 ml sat. NaHCO_3 the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a $\text{H}_2\text{O}/\text{MeCN}$ gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt. Yield: 120 mg MS (ES⁺): m/e = 516, chloro pattern.

Example 2: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

This compound was isolated as a by-product in example 1.

MS (ES⁺): m/e = 516, chloro pattern.

Example 3: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 5-Methyl-2H-pyrazole-3-carboxylic acid methyl ester was used instead of 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester. MS (ESI⁺): m/e = 448, chloro pattern.

25

Example 4: 2-(6-Chloro-benzothiazol-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 2-(6-Chloro-benzothiazol-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid was used instead of 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester. MS (ESI⁺): m/e = 418, chloro pattern.

30

Example 5: 5-(5-Chloro-thiophen-2-yl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 5-(5-Chloro-thiophen-2-yl)-2H-pyrazole-3-carboxylic acid methyl ester was used instead of 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester. MS (ESI+): m/e = 550, chloro pattern.

Example 6: 5-(5-Chloro-thiophen-2-yl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

10 This compound was isolated as a by-product in example 5.

MS (ESI+): m/e = 550, chloro pattern.

Example 7: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-(2,4-dichloro-phenyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

15 The title compound was prepared analogously to example 1 with the difference that 4-(2,4-Dichloro-phenyl)-2H-pyrazole-3-carboxylic acid methyl ester was used instead of 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester. MS (ESI+): m/e = 578, chloro pattern.

Example 8: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-propyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 5-Propyl-2H-pyrazole-3-carboxylic acid methyl ester was used instead of 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester. MS (ESI+): m/e = 476, chloro pattern.

25 Example 9: 5-tert-Butyl-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 5-tert-Butyl-2H-pyrazole-3-carboxylic acid methyl ester was used instead of 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester. MS (ESI+): m/e = 490, chloro pattern.

30

Example 10: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

(i) 4-Iodo-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester

1.0 g (5.5 mmol) of 5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester was dissolved in 15 ml of dichloromethane and 1.23 g (5.5 mmol) of N-iodosuccinimide was added. The resulting solution was stirred at room temperature for 16 h. The solution was washed with aqueous sodium thiosulfate solution. The organic phase was dried with sodium sulfate and filtered. The resulting solution was passed through a short silica gel column, washing with dichloromethane. The solvent was removed under reduced pressure.
Yield: 1.5 g MS (LCMS-ES⁺): m/e = 309.

(ii) 4-Cyano-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester

1.5 g (4.9 mmol) of 4-iodo-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester, 0.87 g (9.7 mmol) of copper cyanide and 404 mg (2.4 mmol) of tetraethylammonium cyanide were dissolved in 10 ml of DMF and 20 ml of tetrahydrofuran and the solution was degassed with argon. 223 mg (0.2 mmol) of Tris(dibenzylideneacetone)dipalladium (0) and 404 mg (0.7 mmol) of 1,1'-bis-(diphenylphosphino) ferrocene were added at RT. The reaction was stirred at 120°C for 5 h. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate and this solution was washed with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulfate, filtered and the solvent was removed under reduced pressure. The product was purified by silica gel chromatography eluting with n-heptane:ethyl acetate/1:1.
Yield: 110 mg MS (LCMS-ES⁺): m/e = 208.

(iii) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-2H-pyrazole-3-carboxylic acid

112 mg (0.5 mmol) of 4-cyano-5-propyl-2H-pyrazole-3-carboxylic acid ethyl ester was dissolved in 2 ml of DMF and 23.8 mg (0.6 mmol) of sodium hydride (60% in mineral oil) were added at RT. After stirring for 20 min at room temperature the solution was cooled to -70°C and 166 mg (0.6 mmol) of 3-bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole were added. The reaction was stirred at room temperature for 3 h. The reaction solution was treated with 1 ml of 2N aqueous NaOH for 16 h at room temperature. The product was purified by preparative RP-HPLC eluting with a gradient of 0-100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as a white solid.
Yield 55.3 mg. MS (LCMS-ES⁺): m/e = 377, chloro pattern.

(iv) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To a solution of 55 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-2H-pyrazole-3-carboxylic acid, 0.1 ml N-NEM in 2 ml DMF, 48 mg TOTU were added and the mixture was stirred for 30 min at RT. Then 31 mg of 1-Isopropyl-piperidin-4-ylamine hydrochloride were added and the reaction was further stirred for 2 h. After addition of 2 ml sat. NaHCO₃ the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. After removal of the solvent under reduced pressure the residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt.

Yield: 18 mg MS (ES⁺): m/e = 501, chloro pattern.

Example 11: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

This compound was isolated as a by-product in example 10.

MS (ES⁺): m/e = 501, chloro pattern.

Example 12: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

(i) 4-Iodo-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester

1.0 g (4.5 mmol) of 5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester was dissolved in 15 ml of dichloromethane and 1.01 g (4.5 mmol) of N-iodosuccinimide was added. The

resulting solution was stirred at room temperature for 16 h. The solution was washed with aqueous sodium thiosulfate solution. The organic phase was dried with sodium sulfate and filtered. The resulting solution was passed through a short silica gel column, washing with dichloromethane. The solvent was removed under reduced pressure.

Yield: 1.57 g MS (LCMS-ES⁺): m/e = 349.

(ii) 4-Cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester

1.57 g (4.5 mmol) of 4-Iodo-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester, 0.81 g (9.0 mmol) of copper cyanide and 352 mg (2.3 mmol) of tetraethylammonium cyanide were dissolved in 10 ml of DMF and 20 ml of tetrahydrofuran and the solution was degassed with argon. 223 mg (0.2 mmol) of Tris(dibenzylideneacetone)dipalladium (0) and 374 mg (0.7 mmol) of 1,1'-bis-(diphenylphosphino) ferrocene were added at RT. The reaction was stirred at 120°C for 5 h. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate and this solution was washed with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulfate, filtered and the solvent was removed under reduced pressure. The product was purified by silica gel chromatography eluting with n-heptane:ethyl acetate/1:1.

Yield: 287 mg

MS (LCMS-ES⁺): m/e = 248.

(iii) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid

287 mg (1.2 mmol) of 4-Cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester was dissolved in 2 ml of DMF and 51.1 mg (1.3 mmol) of sodium hydride (60% in mineral oil) were added at RT. After stirring for 20 min at room temperature the solution was cooled to -70°C and 355 mg (1.3 mmol) of 3-bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole were added. The reaction was stirred at room temperature for 3 h. The reaction solution was treated with 1 ml of 2N aqueous NaOH for 16h at room temperature. The product was purified by preparative RP-HPLC eluting with a gradient of 0-100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as a white solid.
Yield 122 mg. MS (LCMS-ES⁺): m/e = 417.

(iv) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To a solution of 31 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid, 0.1 ml N-NEM in 1 ml DMF, 24 mg TOTU were added and the mixture was stirred for 30 min at RT. Then 16 mg 1-Isopropyl-piperidin-4-ylamine hydrochloride were added and the reaction was further stirred for 2 h. After addition of 2 ml sat. NaHCO₃ the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. After removal of the solvent under

reduced pressure the residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt.

5 Yield: 18 mg MS (ES⁺): m/e = 541, chloro pattern.

Example 13: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

This compound was isolated as a by-product in example 12.

10 MS (ES⁺): m/e = 541, chloro pattern.

Example 14: 2-[2-(5-Chloro-thiophen-2-yl)-thiazol-4-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 5-

15 Bromomethyl-2-(5-chloro-thiophen-2-yl)-thiazole [prepared by adopting a procedure described by Ewing, William R. et al.; PCT Int. Appl. (2001) 460 pp. WO 0107436 A2] was used instead of 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole. MS (ES⁺): m/e = 532, chloro pattern.

Example 15: 2-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-thiophen-2-yl-2H-pyrazole-3-
20 carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 2-

Bromomethyl-6-chloro-benzo[b]thiophene [prepared by adopting a procedure described by Ewing, William R. et al.; PCT Int. Appl. (1999) 300 pp. WO 9937304 A1; and Ewing, William R. et al. PCT Int. Appl. (2001) 460 pp. WO 0107436 A2] was used instead of 3-Bromomethyl-5-(5-
25 chloro-thiophen-2-yl)-isoxazole. MS (ES⁺): m/e = 499, chloro pattern.

Example 16: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-amide

(i) (3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamic acid tBu ester

30 A suspension of 5 g (23.3 mmol) Piperidin-4-ylmethyl-carbamic acid tBu ester, 3.85 g (25.7 mmol) 4-Chloropyridine hydrochloride in 15 ml n-BuOH/H₂O/NEt₃ 1:1:1 was boiled under reflux for 3 days. After removal of the solvent under reduced pressure the residue was purified

by chromatography on silica with DCM/MeOH 100:1 -> 50:1 -> 10:1 -> 5:1 to yield a white solid.

Yield: 4.3 g.

5 (ii) C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine

To a solution of 4.58 g (3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamic acid tBu ester in 12 ml DCM, 12 ml of TFA were added at RT. After stirring for 30 min the solution was diluted with 20 ml of toluene and then evaporated under reduced pressure. The residue was codistilled twice with toluene and was used in the subsequent reactions without further

10 purification. The product was obtained as its trifluoroacetate salt. Yield: 3.3 g.

(iii) -[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-amide

To a solution of 50 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid, 0.3 ml N-NEM in 1 ml DCM, 59 mg TOTU were added and the
15 mixture was stirred for 30 min at RT. Then 36 mg of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate were added and the reaction was further stirred for 2 h.

After the addition of 2 ml sat. NaHCO₃ the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient
20 with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt.

Yield: 23 mg MS (ES⁺): m/e = 565, chloro pattern.

Example 17: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-
25 carboxylic acid (1-isopropyl-piperidin-4-ylmethyl)-amide

(i) (1-Isopropyl-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester

To a solution of 1.0 g Piperidin-4-ylmethyl-carbamic acid tert-butyl ester in 20 ml acetonitrile 2.6 ml acetone and 586 mg Na(CN)BH₃ were added. After stirring for 16 h at RT the solvent was removed under reduced pressure and the residue was partitioned between 30 ml of water and
30 30 ml of ethylacetate. The organic layer was washed with saturated Na₂CO₃ solution, water and then was dried over Na₂SO₄. Removal of the solvent under reduced pressure yielded a white solid. Yield: 802 mg.

(ii) C-(1-Isopropyl-piperidin-4-yl)-methylamine

To a solution of 802 mg (1-Isopropyl-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester in 5 ml DCM 4 ml of TFA were added at RT. After stirring for 20 h the solution was diluted with 20 ml of toluene and the solvents were evaporated under reduced pressure. The residue was codestillled twice with toluene and used in the subsequent reaction without further purification. The product was obtained as its trifluoroacetate salt. Yield: 1.7 g

(iii) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-ylmethyl)-amide

To a solution of 50 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid, 0.3 ml N-NEM in 1 ml DCM, 59 mg TOTU were added and the mixture was stirred for 30 min at RT. Then 30 mg C-(1-Isopropyl-piperidin-4-yl)-methylamine trifluoroacetate were added and the reaction was stirred for a further 2 h. After the addition of 2 ml sat. NaHCO_3 the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. After removal of the solvent under reduced pressure the residue was purified by preparative HPLC (C18 reverse phase column, elution with a $\text{H}_2\text{O}/\text{MeCN}$ gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt. Yield: 14 mg MS (ES^+): $m/e = 530$, chloro pattern.

Example 18: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-amide

(i) (3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-carbamic acid tert-butyl ester

A solution of 3 g Piperidin-4-yl-carbamic acid tert-butyl ester and 2.5 g 4-Chloropyridine in 9 ml n-butanol/water/ NEt_3 1:1:1 was heated at 100 °C for 48 h. Then the solution was cooled to RT diluted with DCM and washed with NaHCO_3 solution and water. The organic layer was dried over Na_2SO_4 , filtered, and the solvent was removed under reduced pressure. Chromatographic purification of the residue on silica with DCM as eluent gave after evaporation of the fractions containing the product a white foam. Yield 1.7 g.

(ii) 3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-ylamine

To a solution of 4 g (3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-carbamic acid tert-butyl ester in 4 ml DCM, 12 ml TFA were added at RT. After stirring for 20 h the solution was diluted with 20 ml of toluene and the solvents were evaporated under reduced pressure. The residue was codestilled twice with toluene and then used in the subsequent reaction without further purification. The product was obtained as its trifluoroacetate salt. Yield: 2.7 g.

(iii) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-amide

To a solution of 50 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid, 0.3 ml N-NEM in 1 ml DCM, 59 mg TOTU were added and the mixture was stirred for 30 min at RT. Then 33 mg 3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-ylamine trifluoroacetate were added and the reaction was further stirred for 2 h. After the addition of 2 ml sat. NaHCO_3 the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a $\text{H}_2\text{O}/\text{MeCN}$ gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt. Yield: 25 mg

MS (ES^+): $m/e = 551$, chloro pattern.

20 Example 19: 2-(4-Chloro-benzyl)-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 12 with the difference that 1-Bromomethyl-4-chloro-benzene was used instead of 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole in the alkylation step. MS (ESI^+): $m/e = 468$, chloro pattern.

25

Example 20: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester

(i) 1H-Pyrazole-3,5-dicarboxylic acid dimethyl ester

To 12 g of 1H-Pyrazole-3,5-dicarboxylic acid 100 ml HCl in methanol (8M) were added at RT and stirred for 48h. Then the solvents were removed under reduced pressure and the residue codestilled with toluene (2X50 ml). Yield: 14g.

(ii) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid dimethyl ester

To a solution of 1 g 1H-Pyrazole-3,5-dicarboxylic acid diethyl ester in 20 ml of DMF and 188 mg of sodium hydride (60% in mineral oil) were added at RT. After stirring for 20 min at room temperature 1.32 g of 3-bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole were added. The reaction was stirred at room temperature for 3 h. Then 100 ml water were added and the precipitating product was collected by filtration. Yield: 1.7g.

10 (iii) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-methyl ester

To a solution of 1.7 g 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid dimethyl ester in 10 ml water/THF 1:1, 4 ml of a 1M aqueous NaOH were added at RT and the mixture was stirred for 3 h with LCMS reaction control. Then the reaction mixture was acidified to pH 3 with half concentrated HCl and extracted with DCM (3X50 ml). The organic phase was dried over MgSO₄, filtered and the solvent removed under reduced pressure. The residue was subjected to the next reaction step without further purification.

(iv) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester

20 To 1 g 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-methyl ester in 10 ml DCM and 1.4 ml NEt₃, 667 mg BOP-Cl were added at RT and the mixture was stirred for 30 min. After addition of 563 mg 1-Isopropyl-piperidin-4-ylamine hydrochloride the mixture was stirred for 16 h. After removal of the solvent under reduced pressure the residue was purified by silica gel chromatography eluting with DCM/MeOH/AcOH/H₂O 20:10:1:1 to yield a white solid. Yield: 800 mg MS (ES⁺): m/e= 492, chloro pattern:

Example 21: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid

30 To a solution of 800 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester in 5 ml water/THF 1:1, 3 ml of a 1M aqueous NaOH were added at RT and the mixture was heated for 10 h at 60 °C. Then the reaction mixture was acidified to pH 3 with half concentrated HCl and extracted with DCM (3X50 ml). The organic phase was dried over MgSO₄, filtered and the solvent removed

under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt.

5 Yield: 503 mg MS (ES⁺): m/e = 478, chloro pattern.

Example 22: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid

This compound was isolated as a by-product in example 21.

10 MS (ES⁺): m/e = 478, chloro pattern.

Example 23: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester

The title compound was prepared analogously to example 20 with the difference that 1H-

15 Pyrazole-3,5-dicarboxylic acid diethyl ester was used instead of 1H-Pyrazole-3,5-dicarboxylic acid diethyl ester. MS (ES⁺): m/e = 506, chloro pattern.

Example 24: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid ethyl ester

20 This compound was isolated as a by-product in example 23.

MS (ES⁺): m/e = 506, chloro pattern.

Example 25: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(morpholine-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

25 To a solution of 100 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid, 0.5 ml N-NEM in 2 ml DCM, 68 mg TOTU were added and the mixture was stirred for 30 min at RT. Then 49 mg morpholine were added and the reaction was further stirred for 16 h. After the addition of 2 ml sat. NaHCO₃ the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced
30 pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were

evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt.

Yield: 73 mg MS (ES⁺): m/e = 547, chloro pattern.

- 5 Example 26: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-methylamide

The title compound was prepared analogously to example 25 with the difference that methylamine hydrochloride was used instead of morpholine. MS (ES⁺): m/e = 491, chloro pattern.

- 10 Example 27: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(2-hydroxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]

The title compound was prepared analogously to example 25 with the difference that 2-amino-ethanol was used instead of morpholine. MS (ES⁺): m/e = 521, chloro pattern.

- 15 Example 28: {[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid

The title compound was prepared analogously to example 25 with the difference that amino-acetic acid hydrochloride was used instead of morpholine.

MS (ES⁺): m/e = 535, chloro pattern.

20

- Example 29: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To a solution of 50 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid, 0.1 ml N-NEM in 1 ml DCM, 34 mg

- 25 TOTU were added and the mixture was stirred for 10 min at RT. Then 10 µl hydrazine hydrate were added and the reaction was further stirred for 2 h. After removal of the solvent under reduced pressure the residue was codistilled with toluene (2X10 ml) and the dissolved in 1 ml THF. Then 91 mg Carbonic acid ditrichloromethyl ester were added at RT and the reaction mixture was stirred for 48 h. After the addition of 2 ml sat. NaHCO₃ the mixture was filtered
30 through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were

evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt.

Yield: 7 mg MS (ES⁺): m/e = 518, chloro pattern.

- 5 Example 30: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide
The title compound was prepared analogously to example 25 with the difference that 2-piperazin-1-yl-ethanol was used instead of morpholine. MS (ES⁺): m/e = 590, chloro pattern.

- 10 Example 31: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[bis-(2-methoxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]
The title compound was prepared analogously to example 25 with the difference that bis-(2-methoxy-ethyl)-amine was used instead of morpholine. MS (ES⁺): m/e = 593, chloro pattern.

- 15 Example 32: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-(2-oxo-imidazolidin-1-yl)-ethyl ester
The title compound was prepared analogously to example 25 with the difference that 1-(2-hydroxy-ethyl)-imidazolidin-2-one was used instead of morpholine.
MS (ES⁺): m/e = 590, chloro pattern.

20

- Example 33: {[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-methyl-amino}-acetic acid
The title compound was prepared analogously to example 25 with the difference that methylamino-acetic acid was used instead of morpholine. MS (ES⁺): m/e = 549, chloro pattern.

25

- Example 34: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(thiomorpholine-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide
The title compound was prepared analogously to example 25 with the difference that thiomorpholine was used instead of morpholine. MS (ES⁺): m/e = 563, chloro pattern.

30

- Example 35: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxy-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that piperidin-4-ol was used instead of morpholine. MS (ES⁺): m/e = 561, chloro pattern.

Example 36: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that pyrrolidin-3-ol was used instead of morpholine. MS (ES⁺): m/e = 547, chloro pattern.

Example 37: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxymethyl-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that piperidin-4-yl-methanol was used instead of morpholine. MS (ES⁺): m/e = 575, chloro pattern.

Example 38: 5-(8-Aza-spiro[4.5]decane-8-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that 8-aza-spiro[4.5]decane hydrochloride was used instead of morpholine.

MS (ES⁺): m/e = 599, chloro pattern.

Example 39: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-methanesulfonyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that 3-methanesulfonyl-pyrrolidine was used instead of morpholine.

MS (ES⁺): m/e = 609, chloro pattern.

Example 40: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[[1,1-dioxo-tetrahydro-1-thiophen-3-yl)-methyl-amide] 5-[[1-isopropyl-piperidin-4-yl)-amide]

The title compound was prepared analogously to example 25 with the difference that (1,1-Dioxo-tetrahydro-1-thiophen-3-yl)-methyl-aminewas used instead of morpholine.

MS (ES⁺): m/e = 609, chloro pattern.

Example 41: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-oxo-piperazine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that piperazin-2-one was used instead of morpholine. MS (ES⁺): m/e = 560, chloro pattern.

5

Example 42: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-([1,4]oxazepane-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that [1,4]oxazepane was used instead of morpholine. MS (ES⁺): m/e = 561, chloro pattern.

10

Example 43: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-trifluoromethyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that 2-trifluoromethyl-pyrrolidine was used instead of morpholine. MS (ES⁺): m/e = 599, chloro

15 pattern.

Example 44: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-sulfamoyl-ethyl)-amide]

20 The title compound was prepared analogously to example 25 with the difference that 2-aminoethanesulfonic acid amide was used instead of morpholine. MS (ES⁺): m/e = 584, chloro pattern.

Example 45: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-cyclopropylamide 5-[(1-isopropyl-piperidin-4-yl)-amide]

25 The title compound was prepared analogously to example 25 with the difference that cyclopropylamine was used instead of morpholine. MS (ES⁺): m/e = 517, chloro pattern.

Example 46: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-cyclobutylamide 5-[(1-isopropyl-piperidin-4-yl)-amide]

30 The title compound was prepared analogously to example 25 with the difference that cyclobutylamine was used instead of morpholine. MS (ES⁺): m/e = 531, chloro pattern.

Example 47: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-methoxy-ethyl)-amide]

The title compound was prepared analogously to example 25 with the difference that 2-methoxy-ethylamine was used instead of morpholine. MS (ES⁺): m/e = 535, chloro pattern.

5

Example 48: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that pyrrolidine was used instead of morpholine. MS (ES⁺): m/e = 531, chloro pattern.

10

Example 49: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that cyanamide was used instead of morpholine. MS (ES⁺): m/e = 502, chloro pattern.

15

Example 50: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester

(i) 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide

To a solution of 5 g 5-Chloro-pyridin-2-ylamine and 1.5 ml pyridine in 30 ml toluene, 8 g

20 bromo-acetyl bromide dissolved in 10 ml toluene was added dropwise under ice cooling. After 2 h the precipitate was isolated by filtration and recrystallized from toluene to yield a white solid.

Yield: 12 g.

25 (ii) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester

The title compound was prepared analogously to example 20 with the difference that 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide was used instead of 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole in the alkylation step. MS (ES⁺): m/e = 463, chloro pattern.

30

Example 51: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid

The title compound was prepared analogously to example 21 with the difference that 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide was used instead of 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole in the alkylation step. MS (ES⁺): m/e = 449, chloro pattern.

5 Alternatively 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid can be prepared by the following procedure:
To a solution of 1.5 g 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester in 100 ml CH₂Cl₂, 13.96 ml BBr₃ (1M in CH₂Cl₂) were added and the mixture stirred at RT for 2 days. The solvent was removed in vacuo
10 and the residue was purified by chromatography on silica gel using CH₂Cl₂/MeOH/HOAc/H₂O = 9/1/0.1/0.1. The fractions containing the product were evaporated and lyophilized. The product was obtained as its hydrobromide. Yield: 1.33 g MS (ES⁺): m/e = 449, chloro pattern.

15 Example 52: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3-cyclobutylamide 5-[(1-isopropyl-piperidin-4-yl)-amide].

The title compound was prepared analogously to example 46 with the difference that 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide was used instead of 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole in the alkylation step. MS (ES⁺): m/e = 502, chloro pattern.

20

Example 53: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 3-Trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl ester was used instead of 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester. MS (ES⁺): m/e = 502, chloro pattern.

25

Example 54: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid bis-[(1-isopropyl-piperidin-4-yl)-amide]

The title compound was prepared analogously to example 25 with the difference that 1-Isopropyl-piperidin-4-ylamine dihydrochloride was used instead of morpholine.

30

MS (ES⁺): m/e = 602, chloro pattern.

Example 55: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 4-Cyano-2H-pyrazole-3-carboxylic acid ethyl ester was used instead of 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester. MS (ES⁺): m/e = 459, chloro pattern.

Example 56: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

This compound was isolated as a by-product in example 55. MS (ES⁺): m/e = 459, chloro pattern.

Example 57: 2-[(4-Chloro-phenylcarbamoyl)-methyl]-4-cyano-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 1 with the difference that 2-Bromo-N-(4-chloro-phenyl)-acetamide and 4-Cyano-2H-pyrazole-3-carboxylic acid ethyl ester were used instead of 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide and 5-Thiophen-2-yl-2H-pyrazole-3-carboxylic acid ethyl ester in the alkylation step. MS (ESI⁺): m/e = 429, chloro pattern.

Example 58: 3-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-propionic acid

The title compound was prepared analogously to example 25 with the difference that 3-Amino-propionic acid was used instead of morpholine. MS (ES⁺): m/e = 549, chloro pattern.

Example 59: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-amide)

The title compound was prepared analogously to example 25 with the difference that O-Methyl-hydroxylamine hydrochloride was used instead of morpholine.

MS (ES⁺): m/e = 507, chloro pattern.

Example 60: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-carbamoylmethyl-amide 5-[(1-isopropyl-piperidin-4-yl)-amide]

The title compound was prepared analogously to example 25 with the difference that 2-Amino-acetamide hydrochloride was used instead of morpholine. MS (ES⁺): m/e = 534, chloro pattern.

Example 61: {[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid ethyl ester

The title compound was prepared analogously to example 25 with the difference that Amino-5 acetic acid ethyl ester hydrochloride was used instead of morpholine.

MS (ES⁺): m/e = 563, chloro pattern.

Example 62: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(3-hydroxy-propyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]

10 The title compound was prepared analogously to example 25 with the difference that 3-Amino-propan-1-ol was used instead of morpholine. MS (ES⁺): m/e = 535, chloro pattern.

Example 63: 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-(2S)-azetidine-2-carboxylic acid

15 The title compound was prepared analogously to example 25 with the difference that 2S-Azetidine-2-carboxylic acid was used instead of morpholine.

MS (ES⁺): m/e = 561, chloro pattern.

Example 64: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2S,2-hydroxymethyl-

20 pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that 2S-Pyrrolidin-2-yl-methanol was used instead of morpholine.

MS (ES⁺): m/e = 561, chloro pattern.

25 Example 65: 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-2S-pyrrolidine-2-carboxylic acid

The title compound was prepared analogously to example 25 with the difference that 2S-Pyrrolidine-2-carboxylic acid was used instead of morpholine.

MS (ES⁺): m/e = 575, chloro pattern.

30

Example 66: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2S,2-methoxymethyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that 2,2-Methoxymethyl-pyrrolidine was used instead of morpholine.

MS (ES⁺): m/e = 575, chloro pattern.

5 Example 67: 5-(2R,5R,2,5-Bis-methoxymethyl-pyrrolidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that 2R,5R,2,5-Bis-methoxymethyl-pyrrolidine was used instead of morpholine.

MS (ES⁺): m/e = 619, chloro pattern.

10

Example 68: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(4,5-dihydro-oxazol-2-yl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]

The title compound was prepared analogously to example 25 with the difference that 4,5-Dihydro-oxazol-2-ylamine hydrochloride was used instead of morpholine.

15 MS (ES⁺): m/e = 546, chloro pattern.

Example 69: 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-piperidine-4-carboxylic acid ethyl ester

The title compound was prepared analogously to example 25 with the difference that

20 Piperidine-4-carboxylic acid ethyl ester was used instead of morpholine.

MS (ES⁺): m/e = 617, chloro pattern.

Example 70: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-morpholin-4-yl-ethyl)-amide]

25 The title compound was prepared analogously to example 25 with the difference that 2-Morpholin-4-yl-ethylamine was used instead of morpholine.

MS (ES⁺): m/e = 590, chloro pattern.

Example 71: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4,4-difluoro-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

30 The title compound was prepared analogously to example 25 with the difference that 4,4-Difluoro-piperidine hydrochloride was used instead of morpholine.

MS (ES⁺): m/e = 581, chloro pattern.

Example 72: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-oxo-oxazolidine-3-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that

5 Oxazolidin-2-one was used instead of morpholine. MS (ES⁺): m/e = 547, chloro pattern.

Example 73: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-(2-oxo-imidazolidin-1-yl)-ethyl)-amide]

The title compound was prepared analogously to example 25 with the difference that 1-(2-

10 Amino-ethyl)-imidazolidin-2-one was used instead of morpholine.

MS (ES⁺): m/e = 589, chloro pattern.

Example 74: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[(2,2,2-trifluoro-ethyl)-amide]

15 The title compound was prepared analogously to example 25 with the difference that 2,2,2-Trifluoro-ethylamine was used instead of morpholine. MS (ES⁺): m/e = 559, chloro pattern.

Example 75: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(1,1-dioxo-tetrahydro-1-thiophen-3-yl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]

20 The title compound was prepared analogously to example 25 with the difference that 1,1-Dioxo-tetrahydro-1 -thiophen-3-ylamine was used instead of morpholine.

MS (ES⁺): m/e = 595, chloro pattern.

Example 76: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[(3-(2-oxo-pyrrolidin-1-yl)-propyl)-amide]

25 The title compound was prepared analogously to example 25 with the difference that 1-(3-Amino-propyl)-pyrrolidin-2-one was used instead of morpholine.

MS (ES⁺): m/e = 602, chloro pattern.

30 Example 77: 5-(Azetidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that Azetidine was used instead of morpholine. MS (ES⁺): m/e = 517, chloro pattern.

Example 78: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(thiazolidine-3-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that

5 Thiazolidine was used instead of morpholine. MS (ES⁺): m/e = 549, chloro pattern.

Example 79: 2-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-yl)carbamoyl]-1H-pyrazole-3-carbonyl]-amino-3,3,3-trifluoro-propionic acid

The title compound was prepared analogously to example 25 with the difference that 2-Amino-

10 3,3,3-trifluoro-propionic acid was used instead of morpholine.

MS (ES⁺): m/e = 603, chloro pattern.

Example 80: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-trimethylsilanylmethyl-amide

15 The title compound was prepared analogously to example 25 with the difference that C-Trimethylsilanyl-methylamine was used instead of morpholine.

MS (ES⁺): m/e = 563, chloro pattern.

Example 81: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[4-(2-oxo-pyrrolidin-1-yl)-piperidine-1-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)- amide

The title compound was prepared analogously to example 25 with the difference that 1-Piperidin-4-yl-pyrrolidin-2-one hydrochloride was used instead of morpholine.

MS (ES⁺): m/e = 628, chloro pattern.

25 Example 82: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methanesulfonylaminocarbonyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that

Methanesulfonamide was used instead of morpholine. MS (ES⁺): m/e = 555, chloro pattern.

30

Example 83: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-azetidine-1-carbonyl)- 2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 25 with the difference that Azetidin-3-ol hydrochloride was used instead of morpholine. MS (ES⁺): m/e = 533, chloro pattern.

As
57 1403
T 728

Example 84: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

(i) 4-Furan-2-yl-2,4-dioxo-butyric acid ethyl ester

To a solution of 16 g oxalic acid diethyl ester in 350 ml THF, 10.1 g KOt-Bu were added at 0°C. Then 10 g 1-furan-2-yl-ethanone in 50 ml THF were added dropwise. After 1 h the reaction mixture was diluted with 300 ml ethyl acetate and 200 ml water. This solution was acidified with diluted hydrochloric acid to pH 5. The organic layer was separated, washed with 150 ml water, dried over MgSO₄, filtered and concentrated under reduced pressure to yield a white solid.

Yield: 12 g.

15 (ii) N,N'-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-hydrazine dicarboxylic acid tert-butyl ester

To a solution of 1 g [5-(5-Chloro-thiophen-2-yl)-isoxazol-3-yl]-methanol [prepared by adopting a procedure described by Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls, Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen; Myers, Michael R.; Lau, Wan F.; Poli, Gregory B; PCT Int. Appl. (2001) 460 pp. WO 0107436 A2] and 3.01 g polymerbound triphenyl phosphine (Fluka, 3 mmol triphenylphosphine/g resin) added at 0°C. Then 2.1 g di-tert-butyl azodicarboxylate were added and the reaction mixture was stirred at RT for 2 h. The solids were filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a n-heptane/ethyl acetate gradient 100% >50%.

Yield: 1.6 g.

(iii) [5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-hydrazine

30 A solution of 1 g N,N'-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-hydrazine dicarboxylic acid tert-butyl ester was stirred in 15 ml methanolic hydrochloric acid (8M) for 16 h at RT.

Then 150 ml toluene were added and the solvents were removed under reduced pressure.

Yield: 780 mg.

(iv) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3- carboxylic acid ethyl ester

A solution of 550 mg 4-Furan-2-yl-2,4-dioxo-butyric acid ethyl ester and 601 mg [5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-hydrazine in 10 ml acetic acid was heated to 80°C for 2 h. Then the reaction mixture was diluted with 20 ml water and extracted with ethyl acetate (3X100 ml). The combined organic layers were dried over MgSO₄. The solvents were removed under reduced pressure and the residue was purified by silica gel chromatography eluting with a n-heptane:ethyl acetate gradient 100%→50%.

10

(v) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3- carboxylic acid

To a solution of 400 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3- carboxylic acid ethyl ester in 5 ml THF and 1 ml water, 1 ml aqueous NaOH (1M) were added and the mixture was stirred for 16 h at RT. Then the solution was acidified to pH 3 with half concentrated hydrochloric acid to precipitate the pure product, which was collected by filtration. Yield: 360 mg.

(vi) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To 240 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3- carboxylic acid in 4 ml DCM and 0.4 ml NEt₃, 173 mg 1-isopropyl-piperidin-4-ylamine dihydrochloride and 163 mg BOP-Cl were added at RT and the mixture was stirred for 16 h. After addition of 5 ml of water the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt.

Yield: 260 mg MS (ES⁺): m/e = 500, chloro pattern.

Example 85: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid

To a solution of 260 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide in 10 ml CCl₄/MeCN/water 2:2:3, 500 mg NaIO₄ and 2.1 mg Ru(III)Cl₃ were added at RT. The reaction mixture was vigorously stirred for 16 h and then filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a brown solid. The product was obtained as its trifluoroacetate salt. Yield: 130 mg MS (ES⁺): m/e = 478, chloro pattern.

10 Example 86: 5-(Azetidine-1-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To a solution of 50 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbonyl)-2H-pyrazole-3-carboxylic acid, 0.1 ml N-NEM in 2 ml DCM, 34 mg TOTU and 9 mg azetidine were added and the mixture was stirred for 16 h at RT. Then, the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt. Yield: 2.7 mg MS (ES⁺): m/e = 517, chloro pattern.

20

Example 87: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-sulfamoyl-ethyl)-amide]

The title compound was prepared analogously to example 86 with the difference that 2-Aminoethanesulfonic acid amide hydrochloride was used instead of azetidine.

25 MS (ES⁺): m/e = 584, chloro pattern.

Example 88: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[bis-(2-hydroxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]

To a solution of 650 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbonyl)-1H-pyrazole-3-carboxylic acid hydrochloride and 133 mg dietanolamine in 20 ml absolute DMF, 413 mg TOTU and 441 µl DIPEA were added and the mixture was stirred at RT for 3 h. The solvent was removed in vacuo and the residue purified

by chromatography on silica gel using $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc}/\text{H}_2\text{O} = 8/2/0.2/0.2$. The fractions containing the product were evaporated and lyophilized after addition of acetic acid to give a white solid. The product was obtained as its acetate. Yield: 280 mg MS (ES⁺): m/e = 565, chloro pattern.

5

Example 89: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(2-hydroxy-1,1-bis-hydroxymethyl-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide] To a solution of 600 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and 141 mg 2-Amino-2-hydroxymethyl-propane-1,3-diol in 20 ml absolute DMF, 381 mg TOTU and 407 μl DIPEA were added and the mixture was stirred at RT for 3 h. The solvent was removed in vacuo and the residue purified by chromatography on silica gel using $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc}/\text{H}_2\text{O} = 8/2/0.2/0.2$. The fractions containing the product were evaporated and lyophilized after addition of acetic acid to give a white solid. The product was obtained as its acetate.

10 Yield: 210 mg

MS (ES⁺): m/e = 581, chloro pattern.

Example 90: {1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid isopropyl ester.

To a solution of 800 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid hydrochloride and 239 mg L-glycine-isopropylester hydrochloride in 10 ml absolute DMF, 509 mg TOTU and 813 μl DIPEA were added and the mixture was stirred at RT for 3 h. The solvent was removed in vacuo and the residue purified by preparative HPLC (C18 reverse phase column, elution with a $\text{H}_2\text{O}/\text{MeCN}$ gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized after addition of hydrochloric acid to give a white solid. The product was obtained as its hydrochloride.

25 Yield: 585 mg

MS (ES⁺): m/e = 577, chloro pattern.

Example 91: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester

(i) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid diethyl ester

To a solution of 10 g 1H-Pyrazole-3,5-dicarboxylic acid diethyl ester in 200 ml absolute DMF 1.885g of a 60 % suspension of NaH in mineral oil were added in an argon atmosphere. The

30

mixture was stirred for 15 min at RT. 11.76 g 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide were added and the mixture stirred for 2 h at RT. After concentration in vacuo the residue was purified by chromatography on silica gel using $\text{CH}_2\text{Cl}_2/\text{ethylacetate} = 8/2$. The fractions containing the product were evaporated. Yield: 16.05 g.

5

(ii) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3-ethyl ester
To a solution of 8 g 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid diethyl ester in 200 ml THF and 50 ml H_2O 17.2 ml 1N NaOH is added. After standing for 16 h, the solution was acidified using 1 N HCl. THF was removed in vacuo and water was

10 removed by lyophilization. The residue was purified by chromatography on silica gel using ethyl acetate followed by $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc}/\text{H}_2\text{O} = 9/1/0.1/0.1$. The fractions containing the product were evaporated and lyophilized to give a white solid. Yield: 4.42 g.

(iii) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester
15

To a solution of 4.42 g 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3-ethyl ester and 2.69 g 1-Isopropyl-piperidin-4-ylamine dihydrochloride in 100 ml absolute DMF, 4.1 g TOTU and 6.54 ml DIPEA were added and the mixture was stirred at RT for 4 h. Then 1.345 g 1-Isopropyl-piperidin-4-ylamine dihydrochloride, 2.05 g TOTU and

20 3.27 ml DIPEA were added. After standing for 16 h the solvent was removed in vacuo, the residue was dissolved in CH_2Cl_2 and the CH_2Cl_2 solution washed two times with a saturated NaHCO_3 solution. The organic phase was dried over Na_2SO_4 . After filtration and removal of the solvent in vacuo the residue was purified by chromatography on silica gel using $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc}/\text{H}_2\text{O} = 9/1/0.1/0.1$. The fractions containing the product were evaporated and lyophilized to give a white solid. The product was obtained as its acetate. Yield: 2.96 g

MS (ES^+): $m/e = 477$, chloro pattern.

Example 92: {[1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid isopropyl ester

30 (i) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid

To a solution of 1.5 g 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester in 100 ml CH_2Cl_2 , 13.96 ml BBr_3 (1M in

CH₂Cl₂) were added and the mixture stirred at RT for 2 days. The solvent was removed in vacuo and the residue was purified by chromatography on silica gel using CH₂Cl₂/MeOH/HOAc/H₂O = 9/1/0.1/0.1. The fractions containing the product were evaporated and lyophilized. The product was obtained as its hydrobromide. Yield: 1.33 g.

5

(ii) {[1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid isopropyl ester

To a solution of 400 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid hydrobromide and 116 mg glycine-isopropyl ester-
10 hydrochloride in 15 ml absolute DMF, 247 mg TOTU and 401 µl DIPEA were added and the mixture was stirred at RT for 2 h. The solvent was removed in vacuo, the residue was dissolved in CH₂Cl₂ and the CH₂Cl₂ solution washed two times with a saturated NaHCO₃ solution. The organic phase was dried over Na₂SO₄. After filtration and removal of the solvent in vacuo the residue was purified by chromatography on silica gel using CH₂Cl₂/MeOH/HOAc/H₂O =
15 9/1/0.1/0.1. The fractions containing the product were evaporated and lyophilized. The residue was dissolved in CH₂Cl₂. Water was added and the pH of the mixture was adjusted to pH 13 by adding 1N NaOH. The phases were separated and the organic phase dried over Na₂SO₄. After filtration, the solvent was evaporated, the residue dissolved in water and lyophilized after addition of hydrochloric acid. The product was obtained as its hydrochloride.

20 Yield: 352 mg

MS (ES⁺): m/e = 548, chloro pattern.

Example 93: {[1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid ethyl ester

To a solution of 400 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid hydrobromide and 105 mg glycine-ethyl ester-
25 hydrochloride in 15 ml absolute DMF, 247 mg TOTU and 401 µl DIPEA were added and the mixture was stirred at RT for 2 h. The solvent was removed in vacuo, the residue was dissolved in CH₂Cl₂ and the CH₂Cl₂ solution washed two times with a saturated NaHCO₃ solution. The organic phase was dried over Na₂SO₄. After filtration and removal of the solvent in vacuo the
30 residue was purified by chromatography on silica gel using CH₂Cl₂/MeOH/HOAc/H₂O = 9/1/0.1/0.1. The fractions containing the product were evaporated and lyophilized. The residue was dissolved in CH₂Cl₂. Water was added and the pH of the mixture was adjusted to pH 13 by adding 1N NaOH. The phases were separated and the organic phase dried over

Na₂SO₄. After filtration, the solvent was evaporated, the residue dissolved in water and lyophilized after addition of hydrochloric acid. The product was obtained as its hydrochloride.
Yield: 352 mg MS (ES⁺): m/e = 534, chloro pattern.

5 Example 94: {1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl}-amino}-acetic acid

To a solution of 250 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid hydrobromide and 62 mg glycine-tert.butyl ester in 10 ml absolute DMF, 154 mg TOTU and 167 µl DIPEA were added and the mixture was
10 stirred at RT for 2 h. The solvent was removed in vacuo, the residue was dissolved in CH₂Cl₂ and the CH₂Cl₂ solution washed two times with a saturated NaHCO₃ solution. The organic phase was dried over Na₂SO₄. After filtration and removal of the solvent in vacuo the residue was purified by chromatography on silica gel using CH₂Cl₂/MeOH/HOAc/H₂O = 9/1/0.1/0.1. The fractions
15 containing the product were evaporated and lyophilized. The residue was dissolved in CH₂Cl₂. Water was added and the pH of the mixture was adjusted to pH 13 by adding 1N NaOH. The phases were separated and the organic phase dried over Na₂SO₄. After filtration, the solvent was evaporated and the residue dissolved in 10 ml of 90 % trifluoro acetic acid. After 1 h at RT trifluoro acetic acid was removed in vacuo, the residue dissolved in water by adding CH₃CN and lyophilized after addition of hydrochloric acid. The product was obtained as its hydrochloride.

20 Yield: 114 mg MS (ES⁺): m/e = 506, chloro pattern.

Example 95: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(3-hydroxy-azetidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To a solution of 500 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid hydrobromide and 103 mg Azetidin-3-ol in 20 ml
25 absolute DMF 309 mg TOTU and 501 µl DIPEA were added and the mixture was stirred at RT for 2 h. The solvent was removed in vacuo, the residue was dissolved in CH₂Cl₂ and the CH₂Cl₂ solution washed two times with a saturated NaHCO₃ solution. The organic phase was dried over Na₂SO₄. After filtration and removal of the solvent in vacuo the residue was purified by
30 chromatography on silica gel using CH₂Cl₂/MeOH/HOAc/H₂O = 9/1/0.1/0.1. The fractions containing the product were evaporated and lyophilized. The residue was dissolved in CH₂Cl₂. Water was added and the pH of the mixture was adjusted to pH 13 by adding 1N NaOH. The phases were separated and the organic phase dried over Na₂SO₄. After filtration, the solvent

was evaporated, the residue dissolved in water and lyophilized after addition of acetic acid. The product was obtained as its acetate. Yield: 249 mg MS (ES⁺): m/e = 504, chloro pattern.

5 Example 96: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid cyclopropylmethyl ester

To a solution of 400 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid hydrobromide and 327 mg Cyclopropyl-methanol in 15 ml absolute DMF 171 mg Dicyclohexylcarbodiimide and 83 mg DMAP were added and
10 the mixture was stirred at RT for 16 h. Then additional 171 mg Dicyclohexylcarbodiimide were added. After 1 day at RT the solvent was removed in vacuo and the residue was purified by chromatography on silica gel using CH₂Cl₂/MeOH/HOAc/H₂O = 9/1/0.1/0.1 and by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized. The residue was dissolved in
15 CH₂Cl₂. Water was added and the pH of the mixture was adjusted to pH 13 by adding 1N NaOH. The phases were separated and the organic phase dried over Na₂SO₄. After filtration, the solvent was evaporated, the residue dissolved in water and lyophilized after addition of acetic acid. The product was obtained as its acetate. Yield: 92 mg MS (ES⁺): m/e = 503, chloro pattern.

20

Example 97: 2-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-3-methyl-butyric acid ethyl ester

To a solution of 1.5 g 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid hydrochloride and 530 mg L-valine-
25 isopropylester hydrochloride in 20 ml absolute DMF 954 mg TOTU and 1.524 ml DIPEA were added and the mixture was stirred at RT for 3 h. After standing for 16 h at RT, the solvent was removed in vacuo. The residue was dissolved in ethyl acetate and the solution washed with a solution of KHSO₄/K₂SO₄ in water (2 times) and a saturated NaHCO₃ solution. The phases were separated and the organic phase dried over Na₂SO₄. After filtration, the solvent was removed in
30 vacuo and the residue purified by chromatography on silica gel using CH₂Cl₂/MeOH = 100/0 -> 40/60 and preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized after

addition of hydrochloric acid to give a white solid. The product was obtained as its hydrochloride.

Yield: 1.36 g

MS (ES⁺): m/e = 605, chloro pattern.

5 Example 98: 2-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-3-methyl-butyric acid

To a solution of 760 mg 2-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-3-methyl-butyric acid ethyl ester in 12.5 ml THF and 3.1 ml water 1.256 ml of 1N NaOH were added and the mixture stirred for 10 8h at RT. The solution was diluted with water, acidified by adding HCl and lyophilized. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized after addition of hydrochloric acid to give a white solid. The product was obtained as its hydrochloride.

Yield: 608 mg

MS (ES⁺): m/e = 577, chloro pattern:

15

Example 99: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide

(i) 4-(4-Nitro-phenyl)-morpholine

A mixture of 24.5 g morpholine and 13.3 g 1-Fluoro-4-nitro-benzene in 30 ml DMSO was 20 heated to 100°C for 4 h. This solution was poured on to 300 ml of water and the resulting precipitate was collected by filtration to yield a bright yellow crystalline product, which was dried in vacuo.

Yield: 19.7g.

25 (ii) 4-(4-Nitro-phenyl)-morpholin-3-one

To a solution of 10 g 4-(4-Nitro-phenyl)-morpholine in 200 ml DCM, 32 g Benzyl-triethyl-ammonium chloride and 22.7 g potassium permanganate (325 mesh) were cautiously added at RT. After stirring for 1 h at RT the reaction mixture was heated to reflux for 10 h. Then a solution of 95 g Na₂SO₃ in 450 ml water were added under ice cooling and vigorous stirring. 30 The mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The yellow solid was stirred with 250 ml water and the precipitated product was collected by filtration. This crude product was purified by chromatography on silica gel

eluting with a gradient of DCM/MeOH 100%→50%. The fractions containing the product were combined and the solvent evaporated under reduced pressure. Yield: 2.6 g.

(iii) 4-(4-Amino-phenyl)-morpholin-3-one

- 5 To a solution of 2.6 g 4-(4-Nitro-phenyl)-morpholin-3-one in 350 ml ethyl acetate and 17 ml ethanol, 13.2 g SnCl_2 dihydrate were added and the reaction mixture was heated to reflux for 2 h. Then after cooling to RT the mixture was stirred for 16 h. The precipitated product was collected by filtration and was pure enough for the next reaction step. Yield: 2.07 g.

- 10 (iv) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide

To 100 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid in 2 ml DCM and 0.1 ml NEt_3 , 62 mg 4-(4-Amino-phenyl)-morpholin-3-one and 67 mg BOP-Cl were added at RT and the mixture was stirred for 16 h. The mixture was

- 15 concentrated under reduced pressure and the residue was purified by preparative HPLC (C18 reverse phase column, elution with a $\text{H}_2\text{O}/\text{MeCN}$ gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid.

Yield: 63 mg MS (ES^+): $m/e = 550$, chloro pattern.

- 20 Example 100: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide

(i) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid ethyl ester

To a solution of 4 g 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-

- 25 dicarboxylic acid 3-ethyl ester in 50 ml THF 26 ml $\text{BH}_3 \cdot \text{THF}$ (1M in THF) were added slowly at RT. Then the mixture was warmed to 40°C for 6h. After cooling to 0°C 20 ml MeOH were added cautiously and the mixture was concentrated to dryness. The residue was again codistilled with 20 ml of MeOH and then purified by chromatography on silica gel eluting with n-heptane/ethyl acetate. The fractions containing the product were combined and the solvent evaporated

- 30 under reduced pressure. Yield: 1.9 g.

(ii) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid

To a solution of 380 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid ethyl ester in 5 ml THF and 5 ml of water 3 ml of a 1M NaOH were added and the reaction mixture was stirred for 3 h at RT. Then the mixture was acidified with half concentrated hydrochloric acid to pH 3 and the precipitate collected by filtration and washed with 10 ml water. The product was obtained as a white solid which was dried under reduced pressure. Yield: 320 mg.

(iii) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide

10 To 100 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid in 2 ml DCM and 0.1 ml NEt₃, 67 mg 4-(4-Amino-phenyl)-morpholin-3-one and 74 mg BOP-Cl were added at RT and the mixture was stirred for 16 h. The mixture was concentrated under reduced pressure and triturated in a mixture of water/DMF. The precipitate was collected by filtration and washed with water containing 0.5% TFA. The product was obtained as a white solid which was dried under reduced pressure. Yield: 108 mg MS (ES⁺): m/e = 514, chloro. pattern.

Example 101: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

20 (i) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid ethyl ester

To a solution of 100 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid ethyl ester in 2 ml DMF 11 mg NaH (60% in mineral oil) were added at RT and stirred for 10 min. Then 100 mg 1-Bromo-2-(2-methoxy-ethoxy)-ethane were added and the mixture was stirred for 16h. After addition of 5 ml of water the mixture was filtered through a chem elut® cartridge by elution with ethyl acetate and then concentrated under reduced pressure. The crude residue was directly subjected to the next reaction step. Yield: 130 mg.

30 (ii) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid

To a solution of 130 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid ethyl ester in 5 ml THF and 5 ml of water 3 ml of a 1M NaOH were added and the reaction mixture was stirred for 3 h at RT. Then the mixture was acidified with half concentrated hydrochloric acid to pH 3 and the precipitate 5 collected by filtration and washed with 10 ml water. The product was obtained as a white solid which was dried under reduced pressure. Yield: 60 mg.

(iii) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

10 To 60 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid in 2 ml DCM and 0.1 ml NEt_3 , 30 mg 1-Isopropyl-piperidin-4-ylamine hydrochloride and 34 mg BOP-Cl were added at RT and the mixture was stirred for 16 h. The mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC (C18 reverse phase column, elution with a $\text{H}_2\text{O}/\text{MeCN}$ gradient 15 with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. Yield: 19 mg MS (ES^+): $m/e = 566$, chloro pattern.

Example 102: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxy-ethoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

20 (i) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-2H-pyrazole-3-carboxylic acid

To a solution of 1 g 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-ethyl ester in 15 ml THF 314 mg LiBH_4 were added cautiously. Then the reaction mixture was stirred for 16 h, quenched with diluted HCl and filtered through a chem 25 elut® cartridge by elution with ethyl acetate and DCM. After concentration under reduced pressure the crude residue was directly subjected to the next reaction step. Yield: 800 mg.

(ii) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxy-ethoxymethyl)-2H-pyrazole-3-carboxylic acid

30 To a solution of 500 mg of 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-2H-pyrazole-3-carboxylic acid in 5 ml DMF 480 mg Cs_2CO_3 and 204 mg 1-Bromo-2-methoxyethane were added and the mixture was heated to 80°C for 5 h. Then the mixture was acidified

to pH 4 with aqueous HCl and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration the crude product was directly subjected to the next reaction step.

(iii) 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxy-ethoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To a solution of 200 mg 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxy-ethoxymethyl)-2H-pyrazole-3-carboxylic acid, 0.25 ml N-NEM in 5 ml DCM, 165 mg TOTU were added and the mixture was stirred for 30 min at RT. Then 165 mg 1-Isopropyl-piperidin-4-ylamine hydrochloride were added and the reaction was further stirred for 16 h. The reaction mixture was concentrated under reduced pressure and then purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt. Yield: 200 mg MS (ES⁺): m/e = 523, chloro pattern.

15

Example 103: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

(i) 3-[2-(2-Methoxy-ethoxy)-ethoxy]-propyne

To a solution of 2 g 2-(2-Methoxy-ethoxy)-ethanol in 20 ml THF 1.8 g KOt-Bu were added at 0°C. After stirring for 10 min 8.1 ml 3-Bromo-propyne (75% in toluene) were added and the mixture was warmed to RT and stirred for 4h. Then 10 ml of water were added and the mixture was filtered through a chem elut® cartridge by elution with CHCl₃. This solution containing the desired product was subjected to the next reaction step.

25 (ii) 5-[2-(2-Methoxy-ethoxy)-ethoxymethyl]-2H-pyrazole-3-carboxylic acid tert-butyl ester

To a solution containing approx. 2.5 g 3-[2-(2-Methoxy-ethoxy)-ethoxy]-propyne, 2.8 g Diazoacetic acid tert-butyl ester were added and the mixture was heated to 70°C for 5 days. Then the solution was concentrated under reduced pressure and directly purified by chromatography on silica eluting with a n-heptane/ethyl acetate gradient. Yield: 1.7 g.

30

(iii) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid tert-butyl ester

To a solution of 350 mg 5-[2-(2-Methoxy-ethoxy)-ethoxymethyl]-2H-pyrazole-3-carboxylic acid tert-butyl ester in 5 ml of DMF and 46 mg of sodium hydride (60% in mineral oil) were added at RT. After stirring for 20 min at room temperature 290 mg of 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide were added. The reaction was stirred at room temperature for 3 h. Then 10 ml of water were added and the mixture was filtered through a chem elut® cartridge by elution with DCM. After concentration under reduced pressure the crude was subjected to the next reaction without further purification. Yield: 400 mg.

(iv) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid

To a solution of 400 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid tert-butyl ester in 5 ml DCM, 15 ml TFA were added at RT. After 3 h 30 ml toluene were added and the solvents were removed under reduced pressure. The residue was then three times codistilled with toluene and subjected to the next reaction step without further purification.

(v) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To 400 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid in 5 ml DCM and 0.3 ml NEt₃, 217 mg 1-Isopropyl-piperidin-4-ylamine hydrochloride and 250 mg BOP-Cl were added at RT and the mixture was stirred for 16 h. The mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid.

Yield: 87 mg MS (ES⁺): m/e = 537, chloro pattern.

Example 104: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxy]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

(i) 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester

To a solution of 5 g Diethyl Oxalacetate sodium salt in 100 ml ethanol, 1.5 g hydrazine monohydrochloride were added and the reaction mixture was heated to 80°C for 3h. Then the

solution was diluted with 100 ml of water containing 3 ml of halfconcentrated HCl and extracted with DCM (3x100 ml). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was subjected to the next reaction step without further purification. Yield: 3.4 g

5

(ii) 5-[2-(2-Methoxy-ethoxy)-ethoxy]-2H-pyrazole-3-carboxylic acid ethyl ester

To a mixture of 3.4 g 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester and 3 g K₂CO₃ in 50 ml acetonitrile, 4 g 1-(2-Bromo-ethoxy)-2-methoxy-ethane were added. After stirring for 1h at RT the reaction was heated to 50°C for 4h. Then 50 ml of water were added and the mixture
10 was extracted with DCM (3x100 ml). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica eluting with a DCM/MeOH gradient. Yield: 1 g.

(iii) 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxy]-2H-pyrazole-
15 3-carboxylic acid ethyl ester

To a solution of 1 g 5-[2-(2-Methoxy-ethoxy)-ethoxy]-2H-pyrazole-3-carboxylic acid ethyl ester in 10 ml of DMF and 154 mg of sodium hydride (60% in mineral oil) were added at RT. After stirring for 5 min at room temperature, 966 mg of 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide were added. The reaction was stirred at room temperature for 2 h. Then 50 ml of water were
20 added and the mixture was extracted with DCM (3x100 ml). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. The product was used in the next reaction step without further purification. Yield: 1.2 g.

(iv) 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxy]-2H-pyrazole- 3-
25 carboxylic acid

To a solution of 1.2 g 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxy]-2H-pyrazole- 3-carboxylic acid ethyl ester in 5 ml THF 10 ml of a aqueous KOH solution (10%) were added and the reaction mixture was stirred for 4 h at RT. Then the mixture was acidified with half concentrated hydrochloric acid to pH 3 and the precipitate collected by
30 filtration and washed with 10 ml of water The product was obtained as a white solid which was dried under reduced pressure. Yield: 310 mg.

(v) 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxy]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To 310 mg 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxy]-2H-pyrazole-3-carboxylic acid in 5 ml DCM and 0.3 ml NEt₃, 110 mg 1-Isopropyl-piperidin-4-ylamine hydrochloride and 197 mg BOP-Cl were added at RT and the mixture was stirred for 16 h. The mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid.

10 Yield: 108 mg MS (ES⁺): m/e = 523, chloro pattern.

Example 105: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2,2-trifluoro-ethoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 104 with the difference that 15 Trifluoro-methanesulfonic acid 2,2,2-trifluoro-ethyl ester was used instead of 1-(2-Bromoethoxy)-2-methoxy-ethane in step (ii). MS (ES⁺): m/e = 503, chloro pattern.

Example 106: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-methoxy-ethyl ester

20 To a solution of 600 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid in 10 ml DMF, 0.9 ml 2-Methoxyethanol, 934 mg DCC and 552 mg DMAP were added. After stirring for 8 h at 40°C the reaction mixture was directly purified by chromatography on silica gel using CH₂Cl₂/MeOH/HOAc/H₂O = 9/1/0.1/0.1 and by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized. The residue was dissolved in CH₂Cl₂. Water was added and the pH of the mixture was adjusted to pH 13 by adding 1N NaOH. The phases were separated and the organic phase dried over Na₂SO₄. After filtration, the solvent was evaporated, the residue was dissolved in water and lyophilized after addition of hydrochloric acid. The product was obtained as its hydrochloride.

30 Yield: 345 mg MS (ES⁺): m/e = 507, chloro pattern.

Example 107: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-hydroxy-ethyl ester

The title compound was prepared analogously to example 106 with the difference that 10 equivalents of Ethane-1,2-diol were used instead of 2-Methoxyethanol.

MS (ES⁺): m/e = 493, chloro pattern.

5 Example 108: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[[1,4]oxazepane-4-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

The title compound was prepared analogously to example 92 with the difference that [1,4]Oxazepane hydrochloride was used instead of glycine-isopropyl ester-hydrochloride.

MS (ES⁺): m/e = 532, chloro pattern.

10

Example 109: 5-(1-Isopropyl-piperidin-4-ylcarbamoyl)-1-(3-methoxy-benzyl)-1H-pyrazole-3-carboxylic acid

The title compound was prepared analogously to example 21 with the difference that 1-Bromomethyl-3-methoxy-benzene was used instead of 3-bromomethyl-5-(5-chloro-thiophen-2-

15 yl)-isoxazole. MS (ES⁺): m/e = 401.

Example 110: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-hydroxy-ethyl ester

The title compound was prepared analogously to example 107 with the difference that 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid was used instead of 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid. MS (ES⁺): m/e = 522, chloro pattern.

25 Example 111: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid carboxymethyl ester

(i) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid tert-butoxycarbonylmethyl ester

The title compound was prepared analogously to example 110 with the difference that

30 Hydroxy-acetic acid tert-butyl ester was used instead of 1 Ethane-1,2-diol.

(ii) 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid carboxymethyl ester

A solution of 180 mg 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid tert-butoxycarbonylmethyl ester in 20 ml TFA were allowed to stand for 20 min at RT. Then the solvent was removed under reduced pressure and the residue was dissolved in water and lyophilized after addition of hydrochloric acid. The product was obtained as its hydrochloride. Yield: 145 mg MS (ES⁺): m/e = 536, chloro pattern.

Example 112: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3-carboxylic acid ethyl ester

10 (i) 4-Iodo-1H-pyrazole-3,5-dicarboxylic acid diethyl ester

To a solution of 10 g 1H-Pyrazole-3,5-dicarboxylic acid diethyl ester in 400 ml acetonitrile 13 g ammonium cerium(iv) nitrate (CAN) and 7.17 g iodine were added and the mixture was heated to reflux for 5 h. Then, after cooling to RT, 30 ml sat. sodium thiosulfate solution were added. The mixture was extracted with ethyl acetate (3x100 ml), the combined organic layers were washed with water and then dried over MgSO₄, filtered and the solvents were removed under reduced pressure. The residue was filtered through a pad of silica gel eluting with heptane/ethyl acetate 1:1. Yield: 13 g.

(ii) 4-(2,2,2-Trifluoro-ethoxy)-1H-pyrazole-3,5-dicarboxylic acid diethyl ester

20 To a solution of 1 g 4-Iodo-1H-pyrazole-3,5-dicarboxylic acid diethyl ester in 5 ml 2,2,2-trifluoro-ethanol 1.4 g Cs₂CO₃, 56 mg CuI and 106 mg 1,10-Phenanthroline were added. The reaction mixture heated for 4 h to 100 °C under microwave irradiation (100 W, CEM Discover™ apparatus). Then 10 HCl in ethanol (8M) was added and the solution was stirred at RT. After 16 h the solvents were removed under reduced pressure and the residue taken up in DCM and water. The organic phase was separated and the aqueous layer was extracted with DCM (2x50 ml). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. Yield: 359 mg.

30

(iii) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3,5-dicarboxylic acid diethyl ester

To a solution of 260 mg 4-(2,2,2-Trifluoro-ethoxy)-1H-pyrazole-3,5-dicarboxylic acid diethyl ester in 4 ml absolute DMF 33.5 mg of a 60 % suspension of NaH in mineral oil were added under an argon atmosphere. The mixture was stirred for 15 min at RT. Then 209 mg 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide were added and the mixture stirred for 2 h at RT. After concentration in vacuo the residue was directly subjected to the next reaction step without further purification.

Yield: 400 mg.

(iv) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3,5-dicarboxylic acid 3-ethyl ester

To a solution of 400 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3,5-dicarboxylic acid diethyl ester in 5 ml THF and 0.9 ml 1N NaOH were added. After standing for 16 h, the solution was acidified using 1 N HCl to pH 1. The precipitating product was collected by filtration and dried under reduced pressure. Yield: 142 mg.

(v) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3-carboxylic acid ethyl ester

To 100 mg 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3,5-dicarboxylic acid 3-ethyl ester in 2 ml DCM and 0.2 ml NEt₃, 128 mg 1-Isopropyl-piperidin-4-ylamine dihydrochloride and 87 mg BOP-Cl were added at RT and the mixture was stirred for 16 h. The mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt.

Yield: 10 mg MS (ES⁺): m/e = 575, chloro pattern.

Example 113: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

(i) 5-Hydroxymethyl-2H-pyrazole-3-carboxylic acid ethyl ester

A solution of 2 g Prop-2-yn-1-ol and 3 g Ethyl diazoacetate in 16 ml trichloromethane was stirred at 70°C for 24 h. Then the solvent was removed under reduced pressure and the residue was purified on silica gel eluting with a gradient n-heptane/ethyl acetate 1:1->1:2. The

fractions containing the product were collected and evaporated under reduced pressure.

Yield: 1.9 g.

(ii) 5-(tert-Butyl-diphenyl-silanyloxymethyl)-2H-pyrazole-3-carboxylic acid ethyl ester

5 To a solution of 768 mg 5-Hydroxymethyl-2H-pyrazole-3-carboxylic acid ethyl ester in 5 ml DMF, 1.9 g Imidazole and 3.2 g tert-Butyl-chloro-diphenyl-silane were added at RT and stirred for 3 h. Then 10 ml of water were added and the mixture was extracted with ethyl acetate (2x30 ml). The combined organic layers were washed with brine, dried over MgSO_4 and filtered. The solids were removed under reduced pressure to yield the product as a yellow oil. Yield: 5
10 g.

(iii) 5-(tert-Butyl-diphenyl-silanyloxymethyl)-1-[(5-chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3-carboxylic acid ethyl ester

To a solution of 5 g 5-(tert-Butyl-diphenyl-silanyloxymethyl)-2H-pyrazole-3-carboxylic acid ethyl
15 ester in 10 ml DMF 4 g Cs_2CO_3 and 3 g 2-Bromo-N-(5-chloro-pyridin-2-yl)-acetamide were added and the mixture was stirred for 3 h. Then 10 ml of water were added and the mixture was extracted with ethyl acetate (2x50 ml). The combined organic layers were dried over MgSO_4 , filtered and concentrated under reduced pressure. Inspection of the TLC and HPLC/MS indicated that a 1:1 mixture of the desired product together with the regioisomeric 5-(tert-
20 Butyl-diphenyl-silanyloxymethyl)-2-[(5-chloro-pyridin-2-ylcarbamoyl)-methyl]-2H-pyrazole-3-carboxylic acid ethyl ester was present. Purification of this mixture on silica gel eluting with a gradient on n-heptane/ethylacetate yielded the desired product as the faster eluting, less polar isomer.

Yield: 2 g.

25

(iv) 5-(tert-Butyl-diphenyl-silanyloxymethyl)-1-[(5-chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3-carboxylic acid

To a solution of 2 g 5-(tert-Butyl-diphenyl-silanyloxymethyl)-1-[(5-chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3-carboxylic acid ethyl ester in 10 ml THF, 7 ml aqueous
30 KOH solution (10%) were added at RT and the mixture was stirred for 16 h. Then the solution was acidified by addition of 10 ml half concentrated acetic acid and extracted with ethyl acetate (3x50 ml). The combined organic layers were dried over MgSO_4 , filtered and concentrated under reduced pressure. Yield: 1.8 g.

(v) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

To 500 mg 5-(tert-Butyl-diphenyl-silanyloxymethyl)-1-[(5-chloro-pyridin-2-ylcarbamoyl)-methyl]-5-1H-pyrazole-3-carboxylic acid in 10 ml DCM and 0.8 ml NEt_3 , 370 mg 1-Isopropyl-piperidin-4-ylamine dihydrochloride and 208 mg BOP-Cl were added at RT and the mixture was stirred for 16 h. Then 3 ml half concentrated HCl were added and the mixture was stirred for 2 h. After neutralization with of saturated aqueous NaHCO_3 the mixture was extracted with ethyl acetate (2x50 ml) and DCM (1x50 ml). The combined organic layers were dried over MgSO_4 , filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a $\text{H}_2\text{O}/\text{MeCN}$ gradient with 0.1% TFA). The fractions containing the product were evaporated and lyophilized to yield a white solid. The product was obtained as its trifluoroacetate salt. Yield: 16 mg MS (ES^+): $m/e = 435$, chloro pattern.

15.

Example 114: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3-carboxylic acid

can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3-carboxylic acid ethyl ester by a procedure analogous to example 21 or example 51.

Example 115: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2-difluoro-ethoxy)-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester

25 can be prepared from 2,2-Difluoro-ethanol using a procedure analogous to example 112.

Example 116: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2-difluoro-ethoxy)-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid

can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2,2-difluoro-ethoxy)-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester using a procedure analogous to example 21 or example 51.

30

Example 117: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-hydroxymethyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from 5-(tert-Butyl-diphenyl-silanyloxymethyl)-2-[(5-chloro-pyridin-2-ylcarbamoyl)-methyl]-2H-pyrazole-3-carboxylic acid ethyl ester using a procedure analogous to example 113.

Example 118: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-difluoromethoxymethyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-hydroxymethyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide using a procedure described by Q. Y. Chen et al. J. Fluorine Chem. (1989) 44, 433.

Example 119: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2,2-trifluoro-ethoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from Trifluoro-methanesulfonic acid 2,2,2-trifluoro-ethyl ester using a procedure analogous to example 103.

Example 120: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-ethoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from Trifluoro-methanesulfonic acid 2,2-difluoro-ethyl ester using a procedure analogous to example 103.

Example 121: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-3-hydroxy-propoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from Trifluoro-methanesulfonic acid 2,2-difluoro-3-hydroxy-propyl ester using a procedure analogous to example 103.

Example 122: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-3-methoxy-propoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from Trifluoro-methanesulfonic acid 2,2-difluoro-3-methoxy-propyl ester using a procedure analogous to example 103.

Example 123: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(3-difluoromethoxy-2,2-difluoro-propoxymethyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)- amide
can be prepared from Trifluoro-methanesulfonic acid 3-difluoromethoxy-2,2-difluoro-propyl ester using a procedure analogous to example 103.

5

Example 124: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1- isopropyl-piperidin-4-yl)-amide] 3-(cyanamide)
can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H- pyrazole-3-carboxylic acid using a procedure analogous to example 49.

10

Example 125: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1- isopropyl-piperidin-4-yl)-amide] 3-(N-cyano-methyl-amide)
can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H- pyrazole-3-carboxylic acid and Methyl-cyanamide [can be prepared adapting
a procedure described by R. Niwa et al. Chem. Pharm. Bull. (1996) 44, 2314] using a procedure
analogous to example 49.

Example 126: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-(N-cyano-methyl-amide)

can be prepared from 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and Methyl-cyanamide [can be prepared adapting a procedure described by R. Niwa et al. Chem. Pharm. Bull. (1996) 44, 2314] using a procedure analogous to example 49.

Example 127: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1- isopropyl-piperidin-4-yl)-amide] 3-[N-cyano-(2,2,2-trifluoro-ethyl)-amide]
can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H- pyrazole-3-carboxylic acid and 2,2,2-Trifluoro-ethyl-cyanamide [can be prepared adapting a procedure described by R. Niwa et al. Chem. Pharm. Bull. (1996) 44, 2314] using a procedure analogous to example 49.

Example 128: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[N-cyano-(2,2,2-trifluoro-ethyl)-amide]

can be prepared from 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and 2,2,2-Trifluoro-ethyl-cyanamide [can be prepared adapting a procedure described by R. Niwa et al. Chem. Pharm. Bull. (1996) 44, 2314] using a procedure analogous to example 49.

5

Example 129: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2,2-difluoro-ethyl)-N-cyano-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]

can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and 2,2-difluoro-ethyl-cyanamide [can be prepared
10 adapting a procedure described by R. Niwa et al. Chem. Pharm. Bull. (1996) 44, 2314] using a procedure analogous to example 49.

Example 130: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2,2-difluoro-ethyl)-N-cyano-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]

15 can be prepared from 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and 2,2-difluoro-ethyl-cyanamide [can be prepared adapting a procedure described by R. Niwa et al. Chem. Pharm. Bull. (1996) 44, 2314] using a procedure analogous to example 49.

20 Example 131: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-amide)

can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid using a procedure analogous to example 59.

25 Example 132: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-methyl-amide)

can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and O,N-dimethyl-hydroxylamine [can be prepared by adapting a procedure described by M. Strasser et al. Helv. Chim. Acta (1988) 71,
30 1156 or P. Beak et al. J. Org. Chem. (1989) 54, 5574] using a procedure analogous to example 59.

Example 133: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-methyl-amide) can be prepared from 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and O,N-dimethyl- hydroxylamine [can be prepared by adapting a procedure described by M. Strasser et al. *Helv. Chim. Acta* (1988) 71, 1156 or P. Beak et al. *J. Org. Chem.* (1989) 54, 5574] using a procedure analogous to example 59.

Example 134: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1- isopropyl-piperidin-4-yl)-amide] 3-[methoxy-(2,2,2-trifluoro-ethyl)-amide] can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H- pyrazole-3-carboxylic acid and O-methyl-N-(2,2,2-trifluoro- ethyl)-hydroxylamine [can be prepared by adapting a procedure described by M. Strasser et al. *Helv. Chim. Acta* (1988) 71, 1156 or P. Beak et al. *J. Org. Chem.* (1989) 54, 5574] using a procedure analogous to example 59.

Example 135: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5- [(1-isopropyl-piperidin-4-yl)-amide] 3-[methoxy-(2,2,2-trifluoro-ethyl)-amide] can be prepared from 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and O-methyl-N-(2,2,2-trifluoro- ethyl)-hydroxylamine [can be prepared by adapting a procedure described by M. Strasser et al. *Helv. Chim. Acta* (1988) 71, 1156 or P. Beak et al. *J. Org. Chem.* (1989) 54, 5574] using a procedure analogous to example 59.

Example 136: 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(2,2- difluoro-ethyl)-methoxy-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide] can be prepared from 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H- pyrazole-3-carboxylic acid and N-(2,2-difluoro-ethyl)-O- methyl- hydroxylamine [can be prepared by adapting a procedure described by M. Strasser et al. *Helv. Chim. Acta* (1988) 71, 1156 or P. Beak et al. *J. Org. Chem.* (1989) 54, 5574] using a procedure analogous to example 59.

Example 137: 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3- [(2,2-difluoro-ethyl)-methoxy-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide]

can be prepared from 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid and N-(2,2-difluoro-ethyl)-O-methyl-5-hydroxylamine [can be prepared by adapting a procedure described by M. Strasser et al. *Helv. Chim. Acta* (1988) 71, 1156 or P. Beak et al. *J. Org. Chem.* (1989) 54, 5574] using a procedure analogous to example 59.

Example 138: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-difluoromethoxy-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester using a procedure described by Q. Y. Chen et al. *J. Fluorine Chem.* (1989) 44, 433 and example 105.

Example 139: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-difluoromethoxy-2H-

pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester and 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole using a procedure described by Q. Y. Chen et al. *J. Fluorine Chem.* (1989) 44, 433 and example 105.

Example 140: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-ethoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester and Trifluoromethanesulfonic acid 2,2-difluoro-ethyl ester using a procedure analogous to example 105.

Example 141: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-difluoro-ethoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester, 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole and Trifluoromethanesulfonic acid 2,2-difluoro-ethyl ester using a procedure analogous to example 105.

Example 142: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-3-hydroxy-propoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester and Trifluoro-methanesulfonic acid 2,2-difluoro-3-hydroxy-propyl ester using a procedure analogous to example 105.

- 5 Example 143: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-difluoro-3-hydroxy-propoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide
can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester, 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole and Trifluoro-methanesulfonic acid 2,2-difluoro-3-hydroxy-propyl ester using a procedure analogous to example 105.

10

Example 144: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2-difluoro-3-methoxy-propoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide
can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester and Trifluoro-methanesulfonic acid 2,2-difluoro-3-methoxy-propyl ester using a procedure analogous to

15 example 105.

Example 145: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-difluoro-3-methoxy-propoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

- 20 can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester, 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole and Trifluoro-methanesulfonic acid 2,2-difluoro-3-methoxy-propyl ester using a procedure analogous to example 105.

Example 146: 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(3-difluoromethoxy-2,2-difluoro-propoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

- 25 can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester and Trifluoro-methanesulfonic acid 3-difluoromethoxy-2,2-difluoro-propyl ester using a procedure analogous to example 105.

Example 147: 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-difluoromethoxy-2,2-

- 30 difluoro-propoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide

can be prepared from 5-Hydroxy-2H-pyrazole-3-carboxylic acid ethyl ester, 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole and Trifluoro-methanesulfonic acid 3-difluoromethoxy-2,2-difluoro-propyl ester using a procedure analogous to example 105.

Pharmacological testing

The ability of the compounds of the formulae I, Ib and Ic to inhibit factor Xa or factor VIIa or other enzymes like thrombin, plasmin, or trypsin can be assessed by determining the concentration of the compound of the formulae I, Ib and Ic that inhibits enzyme activity by 50 %, i. e. the IC₅₀ value, which was related to the inhibition constant K_i. Purified enzymes were used in chromogenic assays. The concentration of inhibitor that causes a 50 % decrease in the rate of substrate hydrolysis was determined by linear regression after plotting the relative rates of hydrolysis (compared to the uninhibited control) versus the log of the concentration of the compound of formulae I, Ib and Ic. For calculating the inhibition constant K_i, the IC₅₀ value was corrected for competition with substrate using the formula

$$K_i = IC_{50} / \{1 + (\text{substrate concentration} / K_m)\}$$

wherein K_m is the Michaelis-Menten constant (Chen and Prusoff, *Biochem. Pharmacol.* 22 (1973) 3099-3108; I. H. Segal, *Enzyme Kinetics*, 1975, John Wiley & Sons, New York, 100-125;

which were incorporated herein by reference).

a) Factor Xa Assay

In the assay for determining the inhibition of factor Xa activity TBS-PEG buffer (50 mM Tris-HCl, pH 7.8, 200 mM NaCl, 0.05 % (w/v) PEG-8000, 0.02 % (w/v) NaN₃) was used. The IC₅₀ was determined by combining in appropriate wells of a Costar half-area microtiter plate 25 µl human factor Xa (Enzyme Research Laboratories, Inc.; South Bend, Indiana) in TBS-PEG; 40 µl 10 % (v/v) DMSO in TBS-PEG (uninhibited control) or various concentrations of the compound to be tested diluted in 10 % (v/v) DMSO in TBS-PEG; and substrate S-2765 (N(α)-benzyloxycarbonyl-D-Arg-Gly-L-Arg-p-nitroanilide; Kabi Pharmacia, Inc.; Franklin, Ohio) in TBS-PEG.

The assay was performed by pre-incubating the compound of formulae I, Ib and Ic plus enzyme for 10 min. Then the assay was initiated by adding substrate to obtain a final volume of 100 µl. The initial velocity of chromogenic substrate hydrolysis was measured by the change in absorbance at 405 nm using a Bio-tek Instruments kinetic plate reader (Ceres UV900HDi) at 25 °C during the linear portion of the time course (usually 1.5 min after addition of substrate). The enzyme concentration was 0.5 nM and substrate concentration was 140 µM.

30

b) Factor VIIa Assay

The inhibitory activity towards factor VIIa/tissue factor activity was determined using a chromogenic assay essentially as described previously (J. A. Ostrem et al., Biochemistry 37 (1998) 1053-1059 which was incorporated herein by reference). Kinetic assays were conducted at 25 °C in half-area microtiter plates (Costar Corp., Cambridge, Massachusetts) using a kinetic plate reader (Molecular Devices Spectramax 250). A typical assay consisted of 25 µl human factor VIIa and TF (5 nM and 10 nM, respective final concentration) combined with 40 µl of inhibitor dilutions in 10% DMSO/TBS-PEG buffer (50 mM Tris, 15 mM NaCl, 5 mM CaCl₂, 0.05 % PEG 8000, pH 8.15). Following a 15 minute preincubation period, the assay was initiated by the addition of 35 µl of the chromogenic substrate S-2288 (D-Ile-Pro-Arg-p-nitroanilide, Pharmacia Hepar Inc., 500 µM final concentration). The results (inhibition constants K_i (FXa) for inhibition of factor Xa) are shown in Table 1.


Table1:

Example	K _i (FXa) [µM]	Example	K _i (FXa) [µM]		K _i (FXa) [µM]	Example	K _i (FXa) [µM]
1	0,030	35	0,163	69	0,177	104	0,025
2	0,032	36	0,122	70	0,182	105	0,021
3	0,112	37	0,195	71	0,184	106	0,016
5	0,300	38	0,932	72	0,092	107	0,020
6	0,491	39	0,145	73	0,083	108	0,039
7	0,293	40	0,123	74	0,086	110	0,081
8	0,054	41	0,081	75	0,076	111	0,049
9	0,332	42	0,084	76	0,083		
10	0,041	43	0,072	77	0,063		
11	0,083	44	0,046	78	0,144		
12	0,014	45	0,061	79	0,080		
13	0,039	46	0,106	80	0,149		
14	0,046	47	0,086	81	0,142		
15	0,013	48	0,183	82	0,184		
16	0,165	49	0,040	83	0,104		
17	0,155	50	0,010	84	0,042		
18	0,205	52	0,016	85	0,185		

19	0,274	55	0,099	86	0,142		
20	0,073	56	0,144	87	0,181		
21	0,214	57	0,410	88	0,106		
23	0,144	58	0,063	89	0,192		
25	0,095	59	0,094	90	0,240		
26	0,068	60	0,056	92	0,041		
27	0,088	61	0,101	93	0,036		
28	0,082	62	0,080	94	0,023		
29	0,155	63	0,134	95	0,039		
30	0,262	64	0,090	96	0,018		
31	0,180	65	0,142	97	0,228		
32	0,045	66	0,152	98	0,140		
33	0,082	67	0,420	99	0,011		
34	0,108	68	0,099	100	0,004		

Patent Claims

1. A compound of the formula I,



wherein

- R^0 is
- 1) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R_8 , and which is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R_8 ,
 - 2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R_8 , or
 - 3) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R_8 ,

- R_8 is
- 1) halogen,
 - 2) $-NO_2$,
 - 3) $-CN$,
 - 4) $-C(O)-NH_2$,
 - 5) $-OH$,

- 6) $-\text{NH}_2$,
 7) $-\text{O}-\text{CF}_3$
 8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by halogen or $-\text{O}-(\text{C}_1-\text{C}_8)$ -alkyl,
 9) $-(\text{C}_1-\text{C}_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 , $-\text{OH}$ or a methoxy residue,
 10) $-\text{O}-(\text{C}_1-\text{C}_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 , $-\text{OH}$ or a methoxy residue,
 11) $-\text{SO}_2-\text{CH}_3$ or
 12) $-\text{SO}_2-\text{CF}_3$,

provided that R_8 is at least one halogen, if R^0 is a monocyclic or bicyclic 6- to 14-membered aryl,

Q is a direct bond, $-(\text{C}_0-\text{C}_2)$ -alkylene- $\text{C}(\text{O})-\text{NR}^{10}$ -, $-\text{NR}^{10}-\text{C}(\text{O})-\text{NR}^{10}$ -, $-\text{NR}^{10}-\text{C}(\text{O})$ -, $-\text{SO}_2$ -, $-(\text{C}_1-\text{C}_6)$ -alkylene, $-(\text{CH}_2)_m-\text{NR}^{10}-\text{C}(\text{O})-\text{NR}^{10}-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{NR}^{10}-\text{C}(\text{O})-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{S}-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{C}(\text{O})-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{SO}_2-\text{NR}^{10}-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{NR}^{10}-\text{SO}_2-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{NR}^{10}-\text{SO}_2-\text{NR}^{10}-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{CH}(\text{OH})-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{O}-\text{C}(\text{O})-\text{NR}^{10}-(\text{CH}_2)_n$ -, $-(\text{C}_2-\text{C}_3)$ -alkylene- $\text{O}-(\text{C}_0-\text{C}_3)$ -alkylene-, $-(\text{C}_2-\text{C}_3)$ -alkylene- $\text{S}(\text{O})$ -, $-(\text{C}_2-\text{C}_3)$ -alkylene- $\text{S}(\text{O})_2$ -, $-(\text{CH}_2)_m-\text{NR}^{10}-\text{C}(\text{O})-\text{O}-(\text{CH}_2)_n$ -, $-(\text{C}_2-\text{C}_3)$ -alkylene- $\text{S}(\text{O})_2-\text{NH}-(\text{R}^{10})$ -, $-(\text{C}_2-\text{C}_3)$ -alkylene- $\text{N}(\text{R}^{10})$ - or $-(\text{C}_0-\text{C}_3)$ -alkylene- $\text{C}(\text{O})-\text{O}$ -,

wherein R^{10} is as defined below, and wherein n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by $-(\text{CH}_2)_m$ - or $-(\text{CH}_2)_n$ - are unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-\text{NH}_2$ or $-\text{OH}$; or

-(C₃-C₆)-cycloalkylen, wherein cycloalkylen is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH;

R¹ is a hydrogen atom, -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R¹³; -(C₁-C₃)-alkylene-C(O)-NH-R⁰, -(C₁-C₃)-alkylene-C(O)-O-R¹⁰, a
 5 monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R⁸, wherein R⁸ is as defined above; a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen; -(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-S(O)-(C₁-C₄)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl,

10 -(C₁-C₃)-alkylene-S(O)₂-N(R^{4'})-R^{5'}, -(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl, -(C₀-C₃)-alkylene-(C₃-C₈)-cycloalkyl, or -(C₀-C₃)-alkylene-het, wherein het is a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

15 R^{4'} and R^{5'} are independent of one another are identical or different and are hydrogen atom or -(C₁-C₄)-alkyl;

R² is a direct bond or -(C₁-C₄)-alkylene, or

R¹ and R³ together with the atoms to which they are bonded can form a 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from
 20 nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

R¹-N-R²-V can form a 4- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

25 R¹⁴ is halogen, -OH, =O, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -NO₂, -(C₀-C₄)-alkyl-C(O)-O-R¹⁸, -CN, -(C₀-C₄)-alkyl-N(R¹⁸)-R²¹, -(C₀-C₄)-alkyl-O-R¹⁸, -(C₀-C₄)-alkyl-het, -(C₀-C₈)-alkyl-SO₂, -SO₂-(C₁-C₄)-alkyl, -SO₂-N(R¹⁸)-R²¹, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -NR¹⁸-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C₁-C₈)-alkyl]₂,

wherein R^{18} and R^{21} are independently from each other hydrogen atom,

$-(C_1-C_3)$ -perfluoroalkyl or $-(C_1-C_6)$ -alkyl,

V is 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

2) a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , or

3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

G is a direct bond, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-CH(OH)-(CH_2)_n$,

$-(CH_2)_m$, $-(CH_2)_m-O-(CH_2)_n$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-SO_2-(CH_2)_n$,

$-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$,

$-(CH_2)_m-S-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,

$-(CH_2)_m-NR^{10}$, $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n$ or $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n$,

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6,

M is 1) a hydrogen atom,

2) $-(C_1-C_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

3) $-C(O)-N(R^{11})-R^{12}$,

4) $-(CH_2)_m-NR^{10}$,

5) a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

6) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

7) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , or

8) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, wherein R14 is defined above,

5 R³ and R⁴ are independent of one another are identical or different and are

- 1) hydrogen atom,
- 2) halogen,
- 3) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 10 4) -(C₁-C₃)-perfluoroalkyl,
- 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6) -(C₀-C₄)-alkylene-O-R19, wherein R19 is
 - a) hydrogen atom,
 - 15 b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
 - c) phenyl; wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - d) -CF₃, or
 - 20 e) -CHF₂,

7) -NO₂,

8) -CN,

9) -SO_s-R¹¹, wherein s is 1 or 2,

10) -SO_t-N(R¹¹)-R¹³, wherein t is 1 or 2,

11) -(C₀-C₄)-alkylene-C(O)-R¹¹,


12) -(C₀-C₄)-alkylene-C(O)-O-R¹¹,

13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹³,

14) -(C₀-C₄)-alkylene-N(R¹¹)-R¹³,

15) -NR¹⁰-SO₂-R¹⁰,

- 16) -S-R¹⁰,
 17) -(C₀-C₂)alkylene-C(O)-O-(C₂-C₄)alkylene-O-C(O)-(C₁-C₄)alkyl,
 18) -C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷,
 19) -(C₀-C₂)alkylene-C(O)-O-(C₂-C₄)alkylene-O-C(O)-O-(C₁-C₆)alkyl,
 5 20) -C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷,
 21) -(C₀-C₄)alkylene-(C₆-C₁₄)aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R¹³,
 22) -(C₀-C₄)alkylene-(C₄-C₁₅)heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³
 10 23) -(C₀-C₄)alkylene-(C₃-C₈)cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 24) -(C₀-C₄)alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 25) -(C₀-C₄)alkylene-O-CH₂-(C₁-C₃)-perfluoroalkylene-CH₂-O-(C₀-C₄)alkyl, or
 15 26) a residue from the following list




if two -OR19 residues are attached to adjacent atoms they can form together with the atoms which they are attached to a 5- or 6- membered ring, which is unsubstituted or substituted one, two, three or four times by R13, R11 and R12 are independently of one another identical or different and are

- 1) hydrogen atom,
- 2) -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) -(C₀-C₆)-alkyl-(C₃-C₈)-cycloalkyl,
- 4) -SO_t-R¹⁰, wherein t is 1 or 2,
- 5) -(C₀-C₆)-alkyl-(C₆-C₁₄)-aryl, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13,
- 6) -(C₁-C₃)-perfluoroalkyl,
- 7) -O-R¹⁷, or
- 8) -(C₀-C₆)-alkyl-(C₄-C₁₅)-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded can form a 4- to 8-membered monocyclic heterocyclic ring which in addition to the nitrogen atom can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

R13 is hydrogen atom, halogen, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₃-C₈)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)_u-R¹⁰, wherein u is 1 or 2, -S-R¹⁰, -SO_r-R¹⁰, wherein r is 1 or 2, -S(O)_v-N(R¹⁰)-R²⁰, wherein v is 1 or 2, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy-, -O-CF₃, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷, -(C₁-C₃)-perfluoroalkyl, -O-R¹⁵, -NH-C(O)-NH-R¹⁰, -NH-C(O)-O-R¹⁰, or a residue from the following list



5 R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₆)-alkyl,
-(C₀-C₄)-alkyl-OH, -(C₀-C₄)-alkyl-O-(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl,
R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together with the
carbon atom to which they are bonded they can form a 3- to 6 membered
carbocyclic ring which is unsubstituted or substituted one to three times by R¹⁰,
10 and
R¹⁷ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl,
-(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl,
wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by
-OH,
15 -O-(C₁-C₄)-alkyl or R¹⁰,
in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically
tolerable salts.

2. A compound of formula I as claimed in claim 1, wherein

20 R⁰ is 1) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R₈,

2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl out of the group benzothiophen, indazolyl, indolyl, isoindolyl, isoquinolyl, phenylpyridyl, phthalazinyl, pyridyl, pyridinyl, pyrimidinyl, quinazolinyl and quinolyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and which is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,

R8 is 1) halogen,

2) -NO₂,

3) -CN,

4) -C(O)-NH₂,

5) -OH,

6) -NH₂, _____

7) -O-CF₃

8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by halogen or -O-(C₁-C₈)-alkyl,

9) -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue, or

10) -O-(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue,

11) -SO₂-CH₃ or

12) -SO₂-CF₃,

provided that R⁸ is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue, if R⁰ is a monocyclic or bicyclic 6- to 14-membered aryl,

Q is a direct bond, -(C₀-C₂)-alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -(C₁-C₆)-alkylene, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-,
 5 -(CH₂)_m-S-(CH₂)_n-, -(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n-,
 -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-CH(OH)-(CH₂)_n-,
 -(CH₂)_m-O-C(O)-NR¹⁰-(CH₂)_n-, -(C₂-C₃)-alkylene-O-(C₀-C₃)-alkylene-, -(C₂-C₃)-alkylene-S(O)-, -(C₂-C₃)-alkylene-S(O)₂-, -(CH₂)_m-NR¹⁰-C(O)-O-(CH₂)_n-, -(C₂-C₃)-alkylene-S(O)₂-NH-(R¹⁰)-,

10 -(C₂-C₃)-alkylene-N(R¹⁰)- or -(C₀-C₃)-alkylene-C(O)-O-,

wherein R¹⁰ is as defined below, and wherein n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by -(CH₂)_m- or -(CH₂)_n- are unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH; or -(C₃-C₆)-cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH;

R¹ is a hydrogen atom, -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R¹³; -(C₁-C₃)-alkylene-C(O)-NH-R⁰, -(C₁-C₃)-alkylene-C(O)-O-R¹⁵, a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or
 20 trisubstituted independently of one another by R⁸, wherein R⁸ is as defined above; a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen; -(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-S(O)-(C₁-C₄)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-N(R^{4'})-R^{5'}, -(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl,
 25 -(C₀-C₃)-alkylene-(C₃-C₈)-cycloalkyl, or -(C₀-C₃)-alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R^{4'} and R^{5'} are independent of one another are identical or different and are hydrogen atom or -(C₁-C₄)-alkyl,

R² is a direct bond or $-(C_1-C_4)\text{-alkylene}$, or

R¹ and R³ together with the atoms to which they are bonded can form a 6- to 8-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

R¹-N-R²-V can form a 4- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, =O, $-(C_1-C_8)\text{-alkyl}$, $-(C_1-C_4)\text{-alkoxy}$, -NO₂, $-(C_0-C_4)\text{-alkyl-C(O)-O-R}^{18}$, -CN, $-(C_0-C_4)\text{-alkyl-N(R}^{18})\text{-R}^{21}$, $-(C_0-C_4)\text{-alkyl-O-R}^{18}$, $-(C_0-C_4)\text{-alkyl-het}$, $-(C_0-C_8)\text{-alkyl-SO}_2$, $-\text{SO}_2\text{-(C}_1\text{-C}_4\text{)-alkyl}$, $-\text{SO}_2\text{-N(R}^{18})\text{-R}^{21}$, $-\text{C(O)-NH-(C}_1\text{-C}_8\text{)-alkyl}$, $-\text{C(O)-N-}[(C_1-C_8)\text{-alkyl}]_2$, $-\text{NR}^{18}\text{-C(O)-NH-(C}_1\text{-C}_8\text{)-alkyl}$, $-\text{C(O)-NH}_2$, $-\text{S-R}^{18}$, or $-\text{NR}^{18}\text{-C(O)-NH-}[(C_1-C_8)\text{-alkyl}]_2$,

wherein R¹⁸ and R²¹ are independently from each other hydrogen atom, $-(C_1-C_3)\text{-perfluoroalkyl}$ or $-(C_1-C_6)\text{-alkyl}$,

V is 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

2) a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

G is a direct bond, $-(CH_2)_m\text{-NR}^{10}\text{-SO}_2\text{-NR}^{10}\text{-(CH}_2\text{)}_n$, $-(CH_2)_m\text{-CH(OH)-(CH}_2\text{)}_n$,

$-(CH_2)_m$, $-(CH_2)_m\text{-O-(CH}_2\text{)}_n$, $-(CH_2)_m\text{-C(O)-NR}^{10}\text{-(CH}_2\text{)}_n$, $-(CH_2)\text{-SO}_2\text{-(CH}_2\text{)}_n$,

$-(CH_2)_m\text{-NR}^{10}\text{-C(O)-NR}^{10}\text{-(CH}_2\text{)}_n$, $-(CH_2)_m\text{-NR}^{10}\text{-C(O)-(CH}_2\text{)}_n$, $-(CH_2)_m\text{-C(O)-(CH}_2\text{)}_n$, -

$(CH_2)\text{-S-(CH}_2\text{)}_n$, $-(CH_2)_m\text{-SO}_2\text{-NR}^{10}\text{-(CH}_2\text{)}_n$, $-(CH_2)_m\text{-NR}^{10}\text{-SO}_2\text{-(CH}_2\text{)}_n$,

$-(CH_2)_m\text{-NR}^{10}$, $-(CH_2)_m\text{-O-C(O)-NR}^{10}\text{-(CH}_2\text{)}_n$ or $-(CH_2)_m\text{-NR}^{10}\text{-C(O)-O-(CH}_2\text{)}_n$,

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6,

M is 1) a hydrogen atom,

2) $-(C_1-C_8)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3) $-C(O)\text{-N(R11)\text{-R12}}$,

4) $-(CH_2)_m\text{-NR}^{10}$,

5) $-(C_6-C_{14})\text{-aryl}$, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

6) $-(C_4-C_{15})\text{-heterocyclyl}$, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

7) $-(C_3-C_8)\text{-cycloalkyl}$, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

8) a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, wherein R14 is defined above,

R³ and R⁴ are independent of one another are identical or different and are

1) hydrogen atom,

2) halogen,

3) $-(C_1-C_4)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4) $-(C_1-C_3)\text{-perfluoroalkyl}$,

5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,


6) $-(C_0-C_4)\text{-alkylene-O-R19}$, wherein R19 is

a) hydrogen atom,

b) $-(C_1-C_4)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

- d) $-\text{CF}_3$,
- e) $-\text{CHF}_2$,
- 7) $-\text{NO}_2$,
- 8) $-\text{CN}$,
- 5 9) $-\text{SO}_s\text{R}^{11}$, wherein s is 1 or 2,
- 10) $-\text{SO}_t\text{N}(\text{R}^{11})\text{R}^{12}$, wherein t is 1 or 2,
- 11) $-(\text{C}_0\text{--C}_4)\text{-alkylene-C(O)-R}^{11}$,
- 12) $-(\text{C}_0\text{--C}_4)\text{-alkylene-C(O)-O-R}^{11}$,
- 13) $-(\text{C}_0\text{--C}_4)\text{-alkylene-C(O)-N(R}^{11})\text{R}^{12}$,
- 10 14) $-(\text{C}_0\text{--C}_4)\text{-alkylene-N(R}^{11})\text{R}^{12}$,
- 15) $-\text{NR}^{10}\text{-SO}_2\text{-R}^{10}$,
- 16) $-\text{S-R}^{10}$,
- 17) $-(\text{C}_0\text{--C}_2)\text{-alkylene-C(O)-O-(C}_2\text{--C}_4)\text{-alkylene-O-C(O)-(C}_1\text{--C}_4)\text{-alkyl}$,
- 18) $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-R}^{17}$,
- 15 19) $-(\text{C}_0\text{--C}_2)\text{-alkylene-C(O)-O-(C}_2\text{--C}_4)\text{-alkylene-O-C(O)-O-(C}_1\text{--C}_6)\text{-alkyl}$,
- 20) $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-O-R}^{17}$,
- 21) $-(\text{C}_0\text{--C}_4)\text{-alkylene-(C}_6\text{--C}_{14})\text{-aryl}$, wherein aryl is mono-, di- or trisubstituted independently of one another by R^{13} ,
- 22) $-(\text{C}_0\text{--C}_4)\text{-alkylene-(C}_4\text{--C}_{15})\text{-heterocyclyl}$, wherein heterocyclyl is unsubstituted or
- 20 mono-, di- or trisubstituted independently of one another by R^{13}
- 23) $-(\text{C}_0\text{--C}_4)\text{-alkylene-(C}_3\text{--C}_8)\text{-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 24) $-(\text{C}_0\text{--C}_4)\text{-alkylene-het}$, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 25 25) $-(\text{C}_0\text{--C}_3)\text{-alkylene-O-CH}_2\text{-(C}_1\text{--C}_3)\text{-perfluoroalkylene-CH}_2\text{-O-(C}_0\text{--C}_3)\text{-alkyl}$, or
- 26) a residue from the following list



and

5 wherein Me is methyl, or

if two -OR₁₉ residues are attached to adjacent atoms they can form together with the atoms which they are attached to a 5- or 6- membered ring, which is unsubstituted or substituted one, two, three or four times by R₁₃,

R₁₁ and R₁₂ are independently of one another identical or different and are

10

- 1) hydrogen atom,
- 2) -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₃,
- 3) -(C₀-C₆)-alkyl-(C₃-C₈)-cycloalkyl,


15

- 4) -SO_t-R¹⁰, wherein t is 1 or 2,
- 5) -(C₀-C₆)-alkyl-(C₆-C₁₄)-aryl, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R₁₃,
- 6) -(C₁-C₃)-perfluoroalkyl,
- 7) -O-R¹⁷, or
- 8) -(C₀-C₆)-alkyl-(C₄-C₁₅)-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R₁₃, or

20

R11 and R12 together with the nitrogen atom to which they are bonded can form a 4- to 8-membered monocyclic heterocyclic ring which in addition to the nitrogen atom can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13.

R¹³ is halogen, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₃-C₈)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)_u-R¹⁰, wherein u is 1 or 2, -S-R¹⁰, -SO_r-R¹⁰, wherein r is 1 or 2, -S(O)_v-N(R¹⁰)-R²⁰, wherein v is 1 or 2, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy, -O-CF₃, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷, -(C₁-C₃)-perfluoroalkyl, -O-R¹⁵, -NH-C(O)-NH-R¹⁰, -NH-C(O)-O-R¹⁰, or a residue from the following list



R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₆)-alkyl or -(C₁-C₃)-perfluoroalkyl,

R15 and R16 are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together with the carbon atom to which they are bonded they can form a 3- to 6

membered carbocyclic ring which is unsubstituted or substituted one to three times by R^{10} , and

R^{17} is $-(C_1-C_6)$ -alkyl, $-(C_1-C_6)$ -alkyl-OH, $-(C_1-C_6)$ -alkyl-O- $-(C_1-C_6)$ -alkyl, $-(C_3-C_8)$ -cycloalkyl, $-(C_1-C_6)$ -alkyl-O- $-(C_1-C_8)$ -alkyl- $-(C_3-C_8)$ -cycloalkyl, $-(C_1-C_6)$ -alkyl- $-(C_3-C_8)$ -cycloalkyl,

wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH,

-O- $-(C_1-C_4)$ -alkyl or R^{10} ,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts

3. A compound of formula I as claimed in claims 1 or 2, wherein

R^0 is 1) a monocyclic or bicyclic 6- to 14-membered aryl out of the group phenyl, naphthyl, biphenyl, anthryl or fluorenyl, wherein aryl is mono-, di- or trisubstituted independently of one another by R_8 ,

2) a heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl; wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R_8 , or

3) a heterocyclyl, wherein heterocyclyl is selected out of the group acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl,

isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-
 isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl,
 octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-
 oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-
 5 oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl,
 oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl,
 phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl,
 piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl,
 pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl,
 10 pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-
 pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxalinyl,
 quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl,
 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl,
 tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl,
 15 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl,
 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl,
 thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl,
 thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-
 triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and
 20 xanthenyl,

wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted
 independently of one another by R₈, and

which is additionally substituted by a heterocyclyl selected out of the group
 acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidiny, aziridinyl,
 25 benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl,
 benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl,
 benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl,
 cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl,
 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-
 30 tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl,
 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl,
 isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl,
 isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-

isoxazoliny, ketopiperaziny, morpholiny, naphthyridiny,
octahydroisoquinoliny, oxadiazoly, 1,2,3-oxadiazoly, 1,2,4-oxadiazoly, 1,2,5-
oxadiazoly, 1,3,4-oxadiazoly, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-
oxazepanyl, 1,4-oxazepiny, 1,2-oxaziny, 1,3-oxaziny, 1,4-oxaziny, oxazolidiny,
5 oxazoliny, oxazoly, phenanthridiny, phenanthroliny, phenaziny,
phenothiaziny, phenoxathiiny, phenoxaziny, phthalaziny, piperaziny,
piperidiny, pteridiny, puriny, pyranly, pyraziny, pyrazolidiny, pyrazoliny,
pyrazoly, pyridaziny, pyridooxazoly, pyridoimidazoly, pyridothiazoly,
pyridiny, pyrimidiny, pyrrolidiny, pyrrolidinony, pyrroliny, 2H-pyrroly,
10 pyrroly, quinazoliny, quinoliny, 4H-quinoliziny, quinoxaliny, quinuclidiny,
tetrahydrofurany, tetrahydroisoquinoliny, tetrahydroquinoliny, 1,4,5,6-
tetrahydro-pyridaziny, tetrahydropyridiny, tetrahydrothiopheny, tetraziny,
tetrazoly, 6H-1,2,5-thiadiaziny, 1,2,3-thiadiazoly, 1,2,4-thiadiazoly, 1,2,5-
thiadiazoly, 1,3,4-thiadiazoly, thianthreny, 1,2-thiaziny, 1,3-thiaziny, 1,4-
15 thiaziny, 1,3-thiazoly, thiazoly, thiazolidiny, thiazoliny, thieny, thietany,
thienothiazoly, thienooxazoly, thienoimidazoly, thietany, thiomorpholiny,
thiophenoly, thiopheny, thiopyranly, 1,2,3-triaziny, 1,2,4-triaziny, 1,3,5-
triaziny, 1,2,3-triazoly, 1,2,4-triazoly, 1,2,5-triazoly, 1,3,4-triazoly and
xantheny,

20 wherein heterocycl is unsubstituted or mono-, di- or trisubstituted
independently of one another by R8,

R8 is 1) halogen,

2) -NO₂,

3) -CN,

25 4) -C(O)-NH₂,

5) -OH,

6) -NH₂,

7) -O-CF₃

8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is as
30 defined above and wherein aryl is mono-, di- or trisubstituted independently of
one another by halogen or -O-(C₁-C₈)-alkyl,

9) $-(C_1-C_8)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 , $-\text{OH}$ or a methoxy residue, or

10) $-\text{O}-(C_1-C_8)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 , $-\text{OH}$ or a methoxy residue,

11) $-\text{SO}_2\text{-CH}_3$ or

12) $-\text{SO}_2\text{-CF}_3$,

provided that R_8 is at least one halogen, $-\text{C}(\text{O})\text{-NH}_2$ or $-\text{O}-(C_1-C_8)\text{-alkyl}$ residue, if R^0 is a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is as defined above,

Q is a direct bond, $-(C_0-C_2)\text{-alkylene-C}(\text{O})\text{-NR}^{10}\text{-}$, $-\text{NR}^{10}\text{-C}(\text{O})\text{-NR}^{10}\text{-}$, $-\text{NR}^{10}\text{-C}(\text{O})\text{-SO}_2\text{-}$, $-(C_1-C_6)\text{-alkylene}$, $-(\text{CH}_2)_m\text{-NR}^{10}\text{-C}(\text{O})\text{-NR}^{10}\text{-(CH}_2)_n\text{-}$, $-(\text{CH}_2)_m\text{-NR}^{10}\text{-C}(\text{O})\text{-(CH}_2)_n\text{-}$, $-(\text{CH}_2)_m\text{-S-(CH}_2)_n\text{-}$, $-(\text{CH}_2)_m\text{-C}(\text{O})\text{-(CH}_2)_n\text{-}$, $-(\text{CH}_2)_m\text{-SO}_2\text{-NR}^{10}\text{-(CH}_2)_n\text{-}$, $-(\text{CH}_2)_m\text{-NR}^{10}\text{-SO}_2\text{-(CH}_2)_n\text{-}$, $-(\text{CH}_2)_m\text{-NR}^{10}\text{-SO}_2\text{-NR}^{10}\text{-(CH}_2)_n\text{-}$, $-(\text{CH}_2)_m\text{-CH}(\text{OH})\text{-(CH}_2)_n\text{-}$, $-(\text{CH}_2)_m\text{-O-C}(\text{O})\text{-NR}^{10}\text{-(CH}_2)_n\text{-}$, $-(C_2-C_3)\text{-alkylene-O-(C}_0\text{-C}_3\text{)-alkylene-}$, $-(C_2-C_3)\text{-alkylene-S}(\text{O})\text{-}$, $-(C_2-C_3)\text{-alkylene-S}(\text{O})_2\text{-}$, $-(\text{CH}_2)_m\text{-NR}^{10}\text{-C}(\text{O})\text{-O-(CH}_2)_n\text{-}$, $-(C_2-C_3)\text{-alkylene-S}(\text{O})_2\text{-NH-(R}^{10}\text{)-}$,

$-(C_2-C_3)\text{-alkylene-N(R}^{10}\text{)-}$ or $-(C_0-C_3)\text{-alkylene-C}(\text{O})\text{-O-}$,

wherein R^{10} is as defined below, and wherein n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by $-(\text{CH}_2)_m\text{-}$ or $-(\text{CH}_2)_n\text{-}$ are unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-\text{NH}_2$ or $-\text{OH}$; or $-(C_3-C_6)\text{-cycloalkylene}$, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-\text{NH}_2$ or $-\text{OH}$;

R^1 is a hydrogen atom, $-(C_1-C_4)\text{-alkyl}$, wherein alkyl is unsubstituted or substituted one to three times by R^{13} ; $-(C_1-C_3)\text{-alkylene-C}(\text{O})\text{-NH-R}^0$; $-(C_1-C_3)\text{-alkylene-C}(\text{O})\text{-O-R}^{15}$,

an aryl out of the group phenyl, naphthyl, biphenyl, anthryl or fluorenyl, wherein aryl is mono-, di- or trisubstituted independently of one another by R8, wherein R8 is as defined above;

a monocyclic or bicyclic 4- to 15-membered heterocycl, which is as defined above;

- 5 -(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-S(O)-(C₁-C₄)-alkyl,
 -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-N(R^{4'})-R^{5'},
 -(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl, -(C₀-C₃)-alkylene-(C₃-C₈)-cycloalkyl, or
 -(C₀-C₃)-alkylene-het, wherein het is a residue selected out of the group azepine,
 azetidine, aziridine, azirine, 1,4-diazapane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine,
 10 diaziridine, diazine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan,
 imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline,
 isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-
 oxazepane, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine,
 oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole,
 15 pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine,
 pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine
 thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine,
 thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine,
 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein het is unsubstituted or mono-, di-
 20 or trisubstituted independently of one another by R14,

R^{4'} and R^{5'} are independent of one another are identical or different and are hydrogen atom or -(C₁-C₄)-alkyl,

R² is a direct bond or -(C₁-C₄)-alkylene, or

R¹ and R³ together with the atoms to which they are bonded can form a 6- to 8-
 25 membered cyclic residue selected out of the group azocane, azocane-2-one, 1,2-
 diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one,
 [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine,
 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, [oxocane, oxocan-2-one, piperazine, piperidine,
 pyran, pyrazine, pyridazine, pyrimidine or 5,6,7,8-tetrahydro-1H-azocin-2-one, wherein
 30 said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one
 another by R14, or

R¹-N-R²-V can form a 4- to 8-membered cyclic group selected out of the group azepine, azetidine, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, =O, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -NO₂, -(C₀-C₄)-alkyl-C(O)-O-R¹⁸, -CN, -(C₀-C₄)-alkyl-N(R¹⁸)-R²¹, -(C₀-C₄)-alkyl-O-R¹⁸, -(C₀-C₄)-alkyl-het, wherein het is a residue selected from azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine;

-(C₀-C₈)-alkyl-SO₂, -SO₂-(C₁-C₄)-alkyl, -SO₂-N(R¹⁸)-R²¹, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -NR¹⁸-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C₁-C₈)-alkyl]₂,

wherein R¹⁸ and R²¹ are independently from each other hydrogen atom, -(C₁-C₃)-perfluoroalkyl or -(C₁-C₆)-alkyl,

V is 1) a monocyclic or bicyclic 6- to 14-membered aryl out of the group phenyl, naphthyl, biphenyl, anthryl or fluorenyl, wherein aryl is mono-, di- or trisubstituted independently of one another by R¹⁴,

2) a heterocyclyl out of the group acridinyl, azaindole (1H-pyrrolopyridine), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl,

cinnolinyl, decahydrochinolinyl, 1,4-diazepane, 4,5-dihydrooxa-zolinyl,
 dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl,
 dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl,
 imidazoliny, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl,
 5 isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl,
 isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl,
 isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl,
 naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-
 oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-
 10 oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-
 oxazinyl, oxazolidinyl, oxazoliny, oxazolyl, phenanthridinyl, phenanthrolinyl,
 phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl,
 piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl,
 pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl,
 15 pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl,
 pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny,
 quinoxaliny, quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinolinyl,
 tetrahydrochinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl,
 tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-
 20 thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,
 thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl,
 thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl,
 thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-
 triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-
 25 triazolyl and xanthenyl,

wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted
 independently of one another by R¹⁴,

G is a direct bond, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-CH(OH)-(CH_2)_n-$,

$-(CH_2)_m-$, $-(CH_2)_m-O-(CH_2)_n-$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)-SO_2-(CH_2)_n-$,

30 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n-$, $-(CH_2)_m-C(O)-(CH_2)_n-$, -

$(\text{CH}_2)\text{-S-(CH}_2)_n\text{, }-(\text{CH}_2)_m\text{-SO}_2\text{-NR}^{10}\text{-(CH}_2)_n\text{, }-(\text{CH}_2)_m\text{-NR}^{10}\text{-SO}_2\text{-(CH}_2)_n\text{,}$

$-(\text{CH}_2)_m\text{-NR}^{10}\text{, }-(\text{CH}_2)_m\text{-O-C(O)-NR}^{10}\text{-(CH}_2)_n\text{ or }-(\text{CH}_2)_m\text{-NR}^{10}\text{-C(O)-O-(CH}_2)_n\text{,}$

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6,

M is 1) a hydrogen atom,

2) $-(\text{C}_1\text{-C}_8)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3) $-\text{C(O)-N(R}^{11})\text{-R}^{12}$,

4) $-(\text{CH}_2)_m\text{-NR}^{10}$,

5) $-(\text{C}_6\text{-C}_{14})\text{-aryl}$, wherein aryl is as defined above and wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

6) $-(\text{C}_4\text{-C}_{15})\text{-heterocyclyl}$, wherein heterocyclyl is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

7) $-(\text{C}_3\text{-C}_8)\text{-cycloalkyl}$, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

R³ and R⁴ are independent of one another are identical or different and are:

1) hydrogen atom,

2) halogen,

3) $-(\text{C}_1\text{-C}_4)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4) $-(\text{C}_1\text{-C}_3)\text{-perfluoroalkyl}$,


5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

6) $-(\text{C}_0\text{-C}_4)\text{-alkylene-O-R}^{19}$, wherein R¹⁹ is

a) hydrogen atom,

b) $-(\text{C}_1\text{-C}_4)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

- c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- d) -CF₃,
- e) -CHF₂,
- 5 7) -NO₂,
- 8) -CN,
- 9) -SO_s-R¹¹, wherein s is 1 or 2,
- 10) -SO_t-N(R¹¹)-R¹², wherein t is 1 or 2,
- 11) -(C₀-C₄)-alkylene-C(O)-R¹¹,
- 10 12) -(C₀-C₄)-alkylene-C(O)-O-R¹¹,
- 13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹²,
- 14) -(C₀-C₄)-alkylene-N(R¹¹)-R¹²,
- 15) -NR¹⁰-SO₂-R¹⁰,
- 16) -S-R¹⁰,
- 15 17) -(C₀-C₂)-alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,
- 18) -C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷,
- 19) -(C₀-C₂)-alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl,
- 20) -C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷,
- 21) -(C₀-C₄)-alkylene-(C₆-C₁₄)-aryl, wherein aryl is mono-, di- or trisubstituted
- 20 independently of one another by R13,
- 22) -(C₀-C₄)-alkylene-(C₄-C₁₅)-heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13
- 23) -(C₀-C₄)-alkylene-(C₃-C₈)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 25 24) -(C₀-C₄)-alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
- 25) -(C₀-C₃)-alkylene-O-CH₂-(C₁-C₃)-perfluoroalkylene-CH₂-O-(C₀-C₃)-alkyl, or
- 26) a residue from the following list



and

5

wherein Me is methyl, or

if two -OR19-residues are attached to adjacent atoms they can form together with the atoms which they are attached to a 1,3-dioxole ring or a 2,3-dihydro-

[1,4]dioxine ring, which is substituted one, two, three or four times by R13,

R11 and R12 are independently of one another identical or different and are

10


- 1) hydrogen atom,
- 2) $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 3) $-(C_0-C_6)$ -alkyl- (C_3-C_8) -cycloalkyl,
- 4) $-SO_t-R^{10}$, wherein t is 1 or 2,
- 5) $-(C_0-C_6)$ -alkyl- (C_6-C_{14}) -aryl, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³,
- 6) $-(C_1-C_3)$ -perfluoroalkyl,
- 7) $-O-R^{17}$, or
- 8) $-(C_0-C_6)$ -alkyl- (C_4-C_{15}) -heterocyclyl, wherein alkyl and heterocyclyl are as defined above and are independently from one another unsubstituted or mono-, di- or trisubstituted by R¹³, or


15

20

R11 and R12 together with the nitrogen atom to which they are bonded form a heterocyclic ring out of the group azepine, azetidine, dioxazole, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, 1,4-oxazepine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

R13 is halogen, $-\text{NO}_2$, $-\text{CN}$, $=\text{O}$, $-\text{OH}$, $-\text{CF}_3$, $-\text{C}(\text{O})-\text{O}-\text{R}^{10}$, $-\text{C}(\text{O})-\text{N}(\text{R}^{10})-\text{R}^{20}$, $-\text{N}(\text{R}^{10})-\text{R}^{20}$, $-(\text{C}_3-\text{C}_8)\text{-cycloalkyl}$, $-(\text{C}_0-\text{C}_3)\text{-alkylene-O-R}^{10}$, $-\text{Si}-(\text{CH}_3)_3$, $-\text{N}(\text{R}^{10})-\text{S}(\text{O})_u-\text{R}^{10}$, wherein u is 1 or 2, $-\text{S}-\text{R}^{10}$, $-\text{SO}_r-\text{R}^{10}$, wherein r is 1 or 2, $-\text{S}(\text{O})_v-\text{N}(\text{R}^{10})-\text{R}^{20}$, wherein v is 1 or 2, $-\text{C}(\text{O})-\text{R}^{10}$, $-(\text{C}_1-\text{C}_8)\text{-alkyl}$, $-(\text{C}_1-\text{C}_8)\text{-alkoxy}$, phenyl, phenyloxy-, $-\text{O}-\text{CF}_3$, $-(\text{C}_0-\text{C}_4)\text{-alkyl-C}(\text{O})-\text{O}-\text{C}(\text{R}^{15}, \text{R}^{16})-\text{O}-\text{C}(\text{O})-\text{R}^{17}$, $-(\text{C}_1-\text{C}_4)\text{-alkoxy-phenyl}$, $-(\text{C}_0-\text{C}_4)\text{-alkyl-C}(\text{O})-\text{O}-\text{C}(\text{R}^{15}, \text{R}^{16})-\text{O}-\text{C}(\text{O})-\text{O}-\text{R}^{17}$, $-(\text{C}_1-\text{C}_3)\text{-perfluoroalkyl}$, $-\text{O}-\text{R}^{15}$, $-\text{NH}-\text{C}(\text{O})-\text{NH}-\text{R}^{10}$, $-\text{NH}-\text{C}(\text{O})-\text{O}-\text{R}^{10}$, or a residue from the following list





R^{10} and R^{20} are independently of one another hydrogen, $-(C_1-C_6)$ -alkyl,

$-(C_0-C_4)$ -alkyl-OH, $-(C_0-C_4)$ -alkyl-O- (C_1-C_4) -alkyl or $-(C_1-C_3)$ -perfluoroalkyl,

R^{15} and R^{16} are independently of one another hydrogen, $-(C_1-C_6)$ -alkyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10} , and

R^{17} is $-(C_1-C_6)$ -alkyl, $-(C_1-C_6)$ -alkyl-OH, $-(C_1-C_6)$ -alkyl-O- (C_1-C_6) -alkyl, $-(C_3-C_8)$ -cycloalkyl, $-(C_1-C_6)$ -alkyl-O- (C_1-C_8) -alkyl- (C_3-C_8) -cycloalkyl, $-(C_1-C_6)$ -alkyl- (C_3-C_8) -cycloalkyl, wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH,

-O- (C_1-C_4) -alkyl or R^{10} ,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

4. A compound of formula I as claimed in claims 1 to 3, wherein

R^0 is 1) a monocyclic or bicyclic 6- to 14-membered aryl out of the group phenyl, naphthyl, biphenyl, anthryl or fluorenyl, wherein aryl is mono-, di- or trisubstituted independently of one another by R^8 ,

2) a heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridiny, purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is

unsubstituted or mono-, di- or trisubstituted independently of one another by R⁸, or

3) a heterocyclyl out of the group azabenzimidazolyl, benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnoliny, 2-furyl, 3-furyl; imidazolyl, indolyl, indazolyl, isochromanyl, isoindolyl, isoquinoliny, isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pteridiny, puriny, pyraziny, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridiny, pyridopyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrroly; 2-pyrrolyl, 3-pyrrolyl, quinoliny, quinazoliny, quinoxaliny, tetrazolyl, thiazolyl, 2-thienyl or 3-thienyl,

which is additionally substituted by a heterocyclyl selected out of the group acridiny, azabenzimidazolyl, azaspirodecanyl, azepiny, azetidiny, aziridiny, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carboliny, chromanyl, chromenyl, cinnoliny, decahydrochinoliny, 4,5-dihydrooxa-zoliny, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiaziny, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidiny, imidazoliny, imidazolyl, 1H-indazolyl, indoliny, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindoliny, isoindolyl, isoquinoliny (benzimidazolyl), isothiazolyl, isothiazolidiny, isothiazoliny, isoxazolyl, isoxazoliny, isoxazolidiny, 2-isoxazoliny, ketopiperazinyl, morpholiny, naphthyridiny, octahydroisoquinoliny, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepiny, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidiny, oxazoliny, oxazolyl, phenanthridiny, phenanthroliny, phenazinyl, phenothiaziny, phenoxathiiny, phenoxazinyl, phthalazinyl, piperazinyl, piperidiny, pteridiny, puriny, pyranyl, pyraziny, pyrazolidiny, pyrazoliny, pyrazolyl, pyridazinyl, pyridoaxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridiny, pyridyl, pyrimidinyl, pyrrolidiny, pyrrolidinonyl, pyrroliny, 2H-pyrrolyl, pyrroly, quinazoliny, quinoliny, 4H-quinoliziny, quinoxaliny, quinuclidiny, tetrahydrofuranyl, tetrahydroisochinoliny, tetrahydrochinoliny, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridiny,

tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl,

wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈,

R₈ is

1. fluorine, chlorine or bromine,
2. -NO₂,
3. -CN,
4. -C(O)-NH₂,
5. -OH,
6. -NH₂,
7. -OCF₃,
8. a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is as defined above and is mono-, di- or trisubstituted independently of one another by halogen or -O-(C₁-C₈)-alkyl,
9. -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue, or
10. -O-(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue,
11. -SO₂CH₃ or
12. -SO₂CF₃,

provided that R₈ is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue, if R₀ is a aryl or a heterocyclyl, which are as defined above,

Q is a direct bond, $-(C_0-C_2)$ -alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂- or $-(C_1-C_6)$ -alkylene,

R¹ is a hydrogen atom, $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted one to three times by R¹³; $-(C_1-C_3)$ -alkylene-C(O)-NH-R⁰, $-(C_1-C_3)$ -alkylene-C(O)-O-R¹⁵,

5 $-(C_1-C_3)$ -perfluoroalkylene, $-(C_1-C_3)$ -alkylene-S(O)-(C₁-C₄)-alkyl,

$-(C_1-C_3)$ -alkylene-S(O)₂-(C₁-C₃)-alkyl, $-(C_1-C_3)$ -alkylene-S(O)₂-N(R^{4'})-R^{5'},

$-(C_1-C_3)$ -alkylene-O-(C₁-C₄)-alkyl, $-(C_0-C_3)$ -alkylene-(C₃-C₈)-cycloalkyl, or

$-(C_0-C_3)$ -alkylene-het, wherein het is a residue selected out of the group azepine,

azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazidine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline,

isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,4-oxazepine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine,

15 pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole,

pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole,

thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine,

1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein het is

20 unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R^{4'} and R^{5'} are independent of one another are identical or different and are hydrogen atom or $-(C_1-C_4)$ -alkyl,

R² is a direct bond or $-(C_1-C_4)$ -alkylene, or

R¹-N-R²-V form a 4- to 8-membered cyclic group selected out of the group azepine,

25 azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine,

isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole,

pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine,

30 pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole,

thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

R14 is fluorine, chlorine, bromine, iodine, -OH, =O, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -

NO₂, -C(O)-OH, -CN, -NH₂, -C(O)-O-(C₁-C₄)-alkyl, -(C₁-C₈)-alkylsulfonyl, -SO₂-(R¹⁸)-

R²¹,

-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -NR¹⁸-C(O)-NH-(C₁-C₈)-alkyl,

-C(O)-NH₂, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C₁-C₈)-alkyl]₂,

wherein R¹⁸ and R²¹ are independently from each other hydrogen atom,

-(C₁-C₃)-perfluoroalkyl or -(C₁-C₆)-alkyl,

V is 1) a het residue out of the group azaindole (1H-pyrrolopyridine), azepine, azetidene, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, which is as defined above and wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

2) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

G is a direct bond, -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n, -(CH₂)_m-CH(OH)-(CH₂)_n,

-(CH₂)_m, -(CH₂)_m-O-(CH₂)_n, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-SO₂-(CH₂)_n,

-(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n, -(CH₂)_m-C(O)-(CH₂)_n, -

$(\text{CH}_2)_5-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{SO}_2-\text{NR}^{10}-(\text{CH}_2)_n$ -, $-(\text{CH}_2)_m-\text{NR}^{10}-\text{SO}_2-(\text{CH}_2)_n$ -,
 $-(\text{CH}_2)_m-\text{NR}^{10}$ -, $-(\text{CH}_2)_m-\text{O}-\text{C}(\text{O})-\text{NR}^{10}-(\text{CH}_2)_n$ - or $-(\text{CH}_2)_m-\text{NR}^{10}-\text{C}(\text{O})-\text{O}-(\text{CH}_2)_n$ -,

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6,

M is 1) a hydrogen atom,

2) $-(\text{C}_1-\text{C}_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₄,

3) $-\text{C}(\text{O})-\text{N}(\text{R}_{11})-\text{R}_{12}$,

4) $-(\text{CH}_2)_m-\text{NR}^{10}$,

5) phenyl or naphthyl, wherein phenyl or naphthyl are unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₄,

6) heterocyclyl, wherein heterocyclyl is a residue out of the group which can be derived from azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole, thiophene, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₄, or

7) $-(\text{C}_3-\text{C}_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₄,

R³ and R⁴ are independent of one another are identical or different and are

1) hydrogen atom,


2) $-(\text{C}_0-\text{C}_3)$ -alkylene-O-CH₂-CHF₂,


3) $-(\text{C}_0-\text{C}_3)$ -alkylene-O-CH₂-CF₃,

4) $-(\text{C}_0-\text{C}_3)$ -alkylene-O-CH₂-CF₂-CH₂-O-(C₀-C₄)-alkyl,

5) $-(\text{C}_0-\text{C}_3)$ -alkylene-O-CH₂-CF₂-CF₂-CH₂-O-(C₀-C₄)-alkyl,

- 6) $-(C_0-C_3)\text{-alkylene-O-CHF}_2$,
 7) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CH}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_4\text{)-alkyl}$,
 8) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_4\text{)-alkyl}$,



- 9) $-(C_0-C_3)\text{-alkylene-C(O)-}$ 
 10) $-(C_0-C_3)\text{-alkylene-C(O)-N(R}^{10}\text{)-CN}$,
 11) $-(C_0-C_3)\text{-alkylene-C(O)-azetidiny}$,
 12) $-(C_0-C_3)\text{-alkylene-C(O)-azetidiny}$, wherein azetidiny is substituted by
 $-(C_0-C_3)\text{-alkylene-O-(C}_0\text{-C}_4\text{)-alkyl}$,
 13) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-N-pyrrolidin-1-yl}$,
 14) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-N-piperidin-1-yl}$,
 15) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-(C}_1\text{-C}_4\text{)-alkyl-cyclopropyl}$, wherein $-(C_1-C_4)\text{-alkyl}$ is
 substituted by R^{13} ,
 16) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-O-R}^{17}$,
 17) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-(C}_1\text{-C}_4\text{)-alkyl-heterocyclyl}$, wherein heterocyclyl is as
 defined above and wherein alkyl and heterocyclyl are independently from one
 another unsubstituted or mono-, di- or trisubstituted by R^{13} ,
 18) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-(C}_1\text{-C}_4\text{)-alkylene-C(O)-O-(C}_0\text{-C}_4\text{)-alkyl}$,
 19) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{21}\text{)-R}^{22}$, wherein R^{21} and R^{22} are both
 ethylene-C(O)-O-(C₀-C₄)-alkyl,
 20) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-CH}_2\text{-CH}_2\text{-SO}_2\text{-methyl}$,
 21) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-CH}_2\text{-CH}_2\text{-SO}_2\text{-CF}_3$,
 22) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-CH}_2\text{-CH}_2\text{-SO}_2\text{-NH}_2$,
 23) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-SO}_2\text{-CF}_3$,
 24) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-SO}_2\text{-N(R}^{10}\text{)-R}^{20}$,
 25) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-SO}_2\text{-methyl}$,

- 26) $-(C_0-C_4)\text{-alkylene-SO}_2\text{-N(R}^{11})\text{-CN}$,
- 27) $-(C_0-C_4)\text{-alkylene-S-CF}_3$,
- 28) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-(C}_1\text{-C}_4\text{)-alkylene-Si(CH}_3\text{)}_3$,
- 29) $-(C_0-C_4)\text{-alkylene-C(O)-O-(C}_1\text{-C}_4\text{)-alkylene-cyclopropyl}$,
- 5 30) $-(C_0-C_4)\text{-alkylene-C(O)-O-(C}_1\text{-C}_4\text{)-alkylene-C(O)-O-(C}_0\text{-C}_4\text{)-alkyl}$, or
- 31) $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-CN}$,

provided that one of R^3 or R^4 is not a hydrogen atom,

10 R11 and R12 are independently of one another identical or different and are

- 1) hydrogen atom,
- 2) $-(C_1-C_6)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)\text{-alkyl-(C}_6\text{-C}_{14}\text{)-aryl}$, wherein aryl is as defined above and wherein
- 15 alkyl and aryl are independently from one another unsubstituted or mono-, di- or trisubstituted by R13,
- 4) $-O-R^{17}$, or
- 5) $-(C_0-C_6)\text{-alkyl-(C}_4\text{-C}_{15}\text{)-heterocyclyl}$, wherein alkyl and heterocyclyl is as defined above and independently from one another are unsubstituted or
- 20 mono-, di- or trisubstituted by R13, or


R11 and R12 together with the nitrogen atom to which they are bonded can form a ring selected out of the group azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, 1,4-oxazepine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-

25

30

triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, which is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₃,

R13 is hydrogen atom, fluorine, chlorine, bromine, iodine, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)₂-R¹⁰, -S-R¹⁰, -SO₂-R¹⁰, -S(O)₂-N(R¹⁰)-R²⁰, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy-, -O-CF₃, -(C₁-C₃)-perfluoroalkyl, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷, -O-R¹⁵, -NH-C(O)-NH-R¹⁰, -NH-C(O)-O-R¹⁰, or a residue from the following list



R¹⁰ and R²⁰ are independently of one another

hydrogen atom, -(C₁-C₆)-alkyl, -(C₀-C₄)-alkyl-OH, -(C₀-C₄)-alkyl-O-(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl,

5 R¹⁵ and R¹⁶ are independently of one another

hydrogen, -(C₁-C₆)-alkyl, or together form a ring out of the group cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰, and

10 R¹⁷ is

-(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH, -O-(C₁-C₄)-alkyl or R¹⁰,

15

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

20 5. A compound of formula I as claimed in claims 1 to 4, wherein

R⁰ is 1) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈,

2) a heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, 25 chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by 30 R₈, or

3) a heterocyclyl out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈,

and in addition is substituted by a residue selected out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈

R₈ is 1. F, Cl, Br or I,

2. -C(O)-NH₂,

3. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or a methoxy residue, or

4. -O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or a methoxy residue, provided that R₈ is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue, if R₀ is an aryl or a heterocyclyl, which are as defined above,

Q is a direct bond, -C(O)-, -SO₂- or -(C₁-C₆)-alkylene, -(C₀-C₂)-alkylene-C(O)-NR¹⁰,

R¹ is hydrogen atom, -(C₁-C₂)-alkyl, -(C₁-C₃)-alkylene-C(O)-NH-R₀,

-(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-C(O)-O-R¹⁵,

-(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl or -(C₁-C₃)-alkylene-S(O)₂-N(R^{4'})-R^{5'},

wherein R^{4'} and R^{5'} are independent of one another are identical or different and are hydrogen atom or -(C₁-C₄)-alkyl,

R² is a direct bond or -(C₁-C₂)-alkylene,

R¹-N-R²-V can form a 4- to 7- membered cyclic group out of the group azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone,

1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is fluorine, chlorine, -OH, =O, -(C₁-C₈)-alkyl, -C(O)-OH, -CN, -NH₂, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -C(O)-NH₂ or -N(R¹⁸)-R²¹,

wherein R¹⁸ and R²¹ are independently from each other hydrogen atom, -(C₁-C₃)-perfluoroalkyl or -(C₁-C₄)-alkyl,

V is 1. a cyclic residue out of the group containing compounds which are derived from azaindole (1H-pyrrolopyridine), aziridine, azirine, azetidine, azetidinone, 1,4-diazepane, pyrrole, pyrrolidine, pyridonyl, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyrimidine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, tetrazine, tetrazole, azepine, diazirine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, pyridazine, piperidine, piperazine, pyrrolidinone, ketopiperazine, furan, pyran, dioxole, 1,4-oxazepane, 1,4-oxazepine, oxazole, isoxazole, 2-isoxazoline, isoxazolidine, morpholine, oxirane, oxaziridine, 1,3-dioxolene, 1,3-dioxolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxaziridine, thiophene, thiopyran, thietan, thiazole, isothiazole, isothiazoline, isothiazolidine, 1,2-oxathiolan, thiodiazole, thiopyran, 1,2-thiazine, 1,3-thiazole, 1,3-thiazine, 1,4-thiazine, thiadiazine or thiomorpholine, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

2. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

G is a direct bond, -(CH₂)_m-, or -(CH₂)_m-NR¹⁰-,

m is the integers zero, 1, 2, 3 or 4,

M is 1. a hydrogen atom,

2. heterocyclyl, wherein heterocyclyl is a residue out of the group which can be derived from azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, 1,4-oxazepine, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3. -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

4. (C₃-C₆)-cycloalkyl, or

5. -C(O)-N(R¹¹)-R¹²,

R³ and R⁴ are independent of one another are identical or different and are

1) hydrogen atom,

2) halogen,

3) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4) -(C₁-C₃)-perfluoroalkyl,

5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

6) -(C₀-C₄)-alkylene-O-R19, wherein R19 is

a) hydrogen atom,


b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

d) -CF₃, or

e) CHF₂,

- 7) -CN,
- 8) -NR¹⁰-SO₂-R¹⁰,
- 9) -SO_s-R¹¹, wherein s is 1 or 2,
- 10) -SO_t-N(R¹¹)-R¹², wherein t is 1 or 2,
- 11) -(C₀-C₄)-alkylene-C(O)-R¹¹,
- 12) -(C₀-C₄)-alkylene-C(O)-O-R¹¹,
- 13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹²,
- 14) -(C₀-C₄)-alkylene-N(R¹¹)-R¹²,
- 15) -(C₀-C₂)-alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,
- 16) -C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷,
- 17) -(C₀-C₂)-alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl,
- 18) -C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷, or
- 19) -(C₀-C₄)-alkylene-(C₃-C₆)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 20) -(C₀-C₃)-alkylene-O-CH₂-CF₂-CH₂-O-(C₀-C₃)-alkyl,
- 21) -(C₀-C₃)-alkylene-O-CH₂-CF₂-CF₂-CH₂-O-(C₀-C₃)-alkyl,
- 22) -(C₀-C₃)-alkylene-O-CH₂-(C₁-C₃)-perfluoroalkylene-CH₂-OH, or
- 23) a residue from the following list



wherein Me is methyl,

if two -OR19 residues are attached to adjacent atoms they can form together with the atoms which they are attached to a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, which is substituted one, two, three or four times by R13,

R11 and R12 are independently of one another identical or different and are

- 1) hydrogen atom,
- 2) $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)$ -alkyl- (C_6-C_{14}) -aryl, wherein aryl is as defined above and wherein alkyl and aryl are independently from one another unsubstituted or mono-, di- or trisubstituted by R13,
- 4) $-O-R^{17}$, or
- 5) $-(C_0-C_6)$ -alkyl- (C_4-C_{15}) -heterocyclyl, wherein alkyl and heterocyclyl is as defined above and independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded can form a ring selected out of the group azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]-oxazepane, 1,4-oxazepine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

R13 is fluorine, chlorine, $-NO_2$, $-CN$, $=O$, $-OH$, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$,


$-N(R^{10})-R^{20}$, $-(C_0-C_3)$ -alkylene- $O-R^{10}$, $-Si(CH_3)_3$, $-N(R^{10})-S(O)_2-R^{10}$, $-S-R^{10}$,

$-SO_2-R^{10}$, $-S(O)_2-N(R^{10})-R^{20}$, $-C(O)-R^{10}$, $-(C_1-C_8)$ -alkyl, $-(C_1-C_8)$ -alkoxy, phenyl, phenyloxy-, $-O-CF_3$, $-(C_1-C_3)$ -perfluoroalkyl, $-NH-C(O)-NH-R^{10}$,

$-(C_0-C_4)$ -alkyl- $C(O)-O-C(R^{15}, R^{16})-O-C(O)-R^{17}$, $-(C_1-C_4)$ -alkoxy-phenyl,

$-(C_0-C_4)$ -alkyl- $C(O)-O-C(R^{15}, R^{16})-O-C(O)-O-R^{17}$, $-O-R^{15}$, $-NH-C(O)-O-R^{10}$, or a residue from

the following list



wherein Me is methyl,

R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₆)-alkyl,

-(C₀-C₄)-alkyl-OH, -(C₀-C₄)-alkyl-O-(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl,

R15 and R16 are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together

form a ring out of the group cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰, and

R17 is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl,

-(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein

said cycloalkyl ring is unsubstituted or substituted one, two or three times by $-OH$,

-O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

6. A compound of formula I as claimed in claims 1 to 5, wherein

R0 is a heterocyclyl out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8.

and in addition is substituted by a residue selected out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein

said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R8

R8 is 1. is F, Cl, Br, I,

2. $-C(O)-NH_2$,

3. $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or a methoxy residue, or

4. $-O-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or a methoxy residue,

provided that R8 is at least one halogen, $-C(O)-NH_2$ or $-O-(C_1-C_6)$ -alkyl residue, if R0 is a aryl or a heterocyclyl, which are as defined above,

Q is a direct bond, $-C(O)-$, $-SO_2-$ or $-(C_1-C_6)$ -alkylen, $-(C_6-C_2)$ -alkylen- $C(O)-NR^{10}$,

R¹ is hydrogen atom or $-(C_1-C_2)$ -alkyl,

R² is a direct bond or $-(C_1-C_2)$ -alkylen, or

R¹-N-R²-V can form a 4- to 7- membered cyclic group out of the group piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-

isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

R14 is fluoro, chlorine, $-(C_1-C_4)$ -alkyl or $-NH_2$,

V is 1. a cyclic residue out of the group containing compounds, which are

derived from azaindolyl (1H-pyrrolopyridyl), azetidine, azepine, aziridine,

azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diazine,

1,3-dioxolane, dioxazole, furan, imidazole, isoquinoline, isothiazole,

isothiazolidine, isothiazoline, isoxazole, 2-isoxazoline, isoxazolidine,

ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, 1,2-

oxathiolan, piperidine, pyran, pyrazine, pyrazole, pyridazine, piperazine,

pyridine, pyridone, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, quinazoline,

quinoline, tetrazine, tetrazole, thiadiazine, 1,2-thiazine, 1,3-thiazine, 1,4-

thiazine, 1,3-thiazole, thietan, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

2. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

G is a direct bond, $-(CH_2)_m-$, or $-(CH_2)_m-NR^{10}-$,

m is the integers zero, 1, 2, 3 or 4,

M is 1. a hydrogen atom,

2. heterocyclyl, wherein heterocyclyl is a residue out of the group which can be derived from 1,4-diazepane, ketomorpholine, thiophene, pyridazone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, pyridonyl, imidazole, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, thiadiazole or thiomorpholine, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3. $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

4. (C_3-C_6) -cycloalkyl,

R³ and R⁴ are independent of one another are identical or different and are

1) hydrogen atom,

2) halogen,

3) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,


4) $-(C_1-C_3)$ -perfluoroalkyl,

5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

6) $-(C_0-C_4)$ -alkylene-O-R19, wherein R19 is

a) hydrogen atom,

- b) $-(C_1-C_4)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
- c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 5 d) $-\text{CF}_3$, or
- e) $-\text{CHF}_2$,
- 7) $-\text{CN}$,
- 8) $-\text{NR}^{10}\text{-SO}_2\text{-R}^{10}$,
- 9) $-\text{SO}_s\text{-R}^{11}$, wherein s is 1 or 2,
- 10 10) $-\text{SO}_t\text{-N(R}^{11})\text{-R}^{12}$, wherein t is 1 or 2,
- 11) $-(C_0-C_4)\text{-alkylene-C(O)-R}^{11}$,
- 12) $-(C_0-C_4)\text{-alkylene-C(O)-O-R}^{11}$,
- 13) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-R}^{12}$,
- 14) $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-R}^{12}$,
- 15 15) $-(C_0-C_2)\text{-alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-(C}_1\text{-C}_4\text{)-alkyl}$,
- 16) $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-R}^{17}$,
- 17) $-(C_0-C_2)\text{-alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-O-(C}_1\text{-C}_6\text{)-alkyl}$,
- 18) $-\text{C(O)-O-C(R}^{15}, \text{R}^{16})\text{-O-C(O)-O-R}^{17}$,
- 19) $-(C_0-C_3)\text{-alkylene-(C}_3\text{-C}_6\text{)-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-
- 20 , di- or trisubstituted independently of one another by R13,
- 20) $-(C_0-C_4)\text{-alkylene-(C}_3\text{-C}_6\text{)-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-
- , di- or trisubstituted independently of one another by R13,
- 21) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$,
- 22) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$,
- 25 23) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-(C}_1\text{-C}_3\text{)-perfluoroalkylene-CH}_2\text{-OH}$, or
- 24) a residue from the following list




wherein Me is methyl,

R11 and R12 are independently of one another identical or different and are

- 1) hydrogen atom,
- 2) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)$ -alkyl- (C_3-C_6) -cycloalkyl,
- 4) $-O-R^{17}$, or
- 5) $-(C_0-C_6)$ -alkyl- (C_4-C_{15}) -heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein heterocyclyl is selected out of the group azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine, or

R11 and R12 together with the nitrogen atom to which they are bonded form a heterocyclic ring, which is selected out of the group azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, 1,4-oxazepine, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine,

R13 is fluorine, $-CN$, $=O$, $-OH$, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_3-C_6)$ -cycloalkyl, $-(C_0-C_3)$ -alkylene- $O-R^{10}$, $-Si-(CH_3)_3$, $-S-R^{10}$, $-SO_2-R^{10}$, $-(C_1-C_3)$ -perfluoroalkyl, or a residue from the following list



wherein Me is methyl,

R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₄)-alkyl or

-(C₁-C₃)-perfluoroalkyl,

R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₄)-alkyl, or together form a ring out of the group cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl,

wherein each ring is unsubstituted or substituted one to three times by R¹⁰; and

R¹⁷ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₃-C₈)-cycloalkyl,

-(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein

said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH;

-O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

7. A compound of formula I as claimed in claims 1 to 5, wherein R⁰ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R⁸, and wherein R¹, R², R³, R⁴, R⁸, V, G, M and Q are as defined in claim 6.

8. A compound of formula I as claimed in claims 1 to 5, wherein R⁰ is a heterocycl selected out of the group indolyl, isoindolyl, benzofuranyl, benzothiophenyl, 1,3-benzodioxolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromanyl, isochromanyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridinyl, purinyl and pteridinyl,

wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,
and wherein R1, R2, R3, R4, R8, V, G, M and Q are as defined in claim 6.

5 9. A compound of formula I as claimed in claims 1 to 5, wherein

R0 is a heterocyclyl out of the group thienyl, thiadiazolyl, isoxazolyl and thiazolyl, wherein said heterocyclyl is substituted by a residue selected out of the group thienyl, 2-thienyl and 3-thienyl, wherein said residue is unsubstituted or mono- or disubstituted independently of one another by R8,

10 R8 is F, Cl, Br, -OCH₃, -C(O)-NH₂ or -O-CF₃,

Q is a direct bond, -C(O)-; -SO₂-, -CH₂-C(O)-NH-, methylene or ethylene,

R¹ is hydrogen atom,

R² is a direct bond or methylene,

15 R¹-N-R²-V can form a 4- to 8-membered cyclic group out of the group azetidine, pyrrolidine, piperidine and piperazine,

R14 is fluorine, chlorine, methyl, ethyl or -NH₂,

V is 1. a residue out of the group containing compounds which is derived from azaindolyl (1H-pyrrolopyridyl), azetidine, 1,4-diazepane, isoxazole, isoquinoline, piperazine, piperidine, pyrazine, pyridazine, pyrimidine, pyrrolidine, 20 quinazoline, quinoline or tetrahydropyran,

wherein said cyclic residue is unsubstituted or mono- or disubstituted independently of one another by R14, or

2. phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R14,

25 G is a direct bond, -(CH₂)_m-, or -(CH₂)_m-NR¹⁰-,

m is the integers zero, 1 or 2,

M is a hydrogen atom, (C₂-C₄)-alkyl, azepanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, ketomorpholinyl, morpholinyl, [1,4]oxazepanyl, piperidinyl, piperidonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidyl, pyrrolidinyl, 1,4,5,6- 30 tetrahydro-pyridazinyl, or tetrahydropyranyl, wherein the residues are unsubstituted or mono- or disubstituted independently of one another by R14

R³ and R⁴ are independent of one another are identical or different and are

- 1) hydrogen atom,
- 2) fluorine, chlorine,
- 3) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted
- 5 independently of one another by R¹³,
- 4) -(C₁-C₃)-perfluoroalkyl,
- 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted
- independently of one another by R¹³,
- 6) -(C₀-C₂)-alkylene-O-R¹⁹, wherein R¹⁹ is

- 10 a) hydrogen atom,
- b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or
- trisubstituted independently of one another by R¹³, or
- c) phenyl, wherein phenyl is unsubstituted or mono-, di- or
- trisubstituted independently of one another by R¹³,
- 15 d) -CF₃, or
- e) -CHF₂,

7) -CN,

8) -NR¹⁰-SO₂-R¹⁰,

9) -SO_s-R¹¹, wherein s is 1 or 2,

10) -SO_t-N(R¹¹)-R¹², wherein t is 1 or 2,

11) -(C₀-C₄)-alkylene-C(O)-R¹¹,

12) -(C₀-C₄)-alkylene-C(O)-O-R¹¹,

13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹²,

14) -(C₀-C₄)-alkylene-N(R¹¹)-R¹²,


15) -(C₀-C₂)-alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,

16) -C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-R¹⁷,

17) -(C₀-C₂)-alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl,

18) -C(O)-O-C(R¹⁵, R¹⁶)-O-C(O)-O-R¹⁷,

- 19) $-(C_0-C_3)\text{-alkylene-(C}_3\text{-C}_6\text{)-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 20) *pyridinyl*, wherein *pyridinyl* is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 21) *thiazolyl*, wherein *thiazolyl* is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
- 22) $-(C_0-C_4)\text{-alkylene-(C}_3\text{-C}_6\text{)-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 23) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$,
- 24) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$,
- 25) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-(C}_1\text{-C}_3\text{)-perfluoroalkylene-CH}_2\text{-OH}$; or
- 26) a residue from the following list



wherein Me is methyl,


R11 and R12 are independently of one another identical or different and are

- 1) hydrogen atom,
- 2) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₁₃,
- 3) -(C₀-C₆)-alkyl-(C₃-C₆)-cycloalkyl,
- 4) -O-R₁₇, or
- 5) -(C₀-C₆)-alkyl-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R₁₃ and wherein heterocyclyl is selected out of the group azetidine, imidazolidine, morpholine, (1,4)-oxazepane or pyrrolidine or

R11 and R12 together with the nitrogen atom to which they are bonded can form a ring, which is selected out of the group azetidine, imidazolidine, morpholine, (1,4)-oxazepane, 1,4-oxazepine, piperazine, piperidine, pyrrolidine or thiomorpholine,

R13 is fluorine, chlorine, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰,

-N(R¹⁰)-R²⁰, -(C₃-C₆)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -S-R¹⁰, -SO₂-R¹⁰,
-(C₁-C₄)-alkyl, -(C₁-C₃)-perfluoroalkyl, or a residue from the following list



wherein Me is methyl

R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₄)-alkyl or

-(C₁-C₃)-perfluoroalkyl;

R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₄)-alkyl, or

together form a ring out of the group cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl,

wherein each ring is unsubstituted or substituted one to three times by R¹⁰, and

R17 is $-(C_1-C_6)$ -alkyl, $-(C_1-C_6)$ -alkyl-OH, $-(C_1-C_6)$ -alkyl-O- (C_1-C_6) -alkyl, $-(C_3-C_8)$ -cycloalkyl,

-(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein

said cycloalkyl ring is unsubstituted or substituted one, two or three times by $-OH$,

-O-(C₁-C₄)-alkyl or R¹⁰,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

10. A compound of formula I as claimed in claims 1 to 5, wherein


R0 is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted

independently of one another by R8,

and wherein R1, R2, R3, R4, R8, V, G, M and Q are as defined in claim 9.


11. A compound of formula I as claimed in claims 1 to 5, wherein
 R0 is pyridyl, wherein pyridyl is unsubstituted or mono- or disubstituted
 independently of one another by R8,
 and wherein R1, R2, R3, R4, R8, V, G, M and Q are as defined in claim 9.

12. A compound of formula I as claimed in claim 1, wherein the compound of formula I is
 a compound of the formula Ib,



wherein R⁰ ; R¹ ; R² ; R³ ; R⁴ ; Q ; V, G and M have the meanings indicated in formula I.

13. A compound of formula I as claimed in claim 1, wherein the compound of formula I is
 a compound of the formula Ic,



wherein R⁰ ; R¹ ; R² ; R³ ; R⁴ ; Q ; V, G and M have the meanings indicated in formula I.

14. A compound of formula I as claimed in one or more of claims 1 to 13, wherein the
 compound of formula I is

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-
 carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-
 carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-2H-pyrazole-3-carboxylic
 acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-1H-pyrazole-3-carboxylic
 acid (1-isopropyl-piperidin-4-yl)-amide,

2-(6-Chloro-benzothiazol-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

5-(5-Chloro-thiophen-2-yl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

5 5-(5-Chloro-thiophen-2-yl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-(2,4-dichloro-phenyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

10 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-(2,4-dichloro-phenyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-propyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-propyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

15 5-tert-Butyl-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

5-tert-Butyl-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

20 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-propyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[2-(5-Chloro-thiophen-2-yl)-thiazol-4-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

30 1-[2-(5-Chloro-thiophen-2-yl)-thiazol-4-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-amide,

5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-ylmethyl)-amide,

10 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-ylmethyl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-amide,

15 2-(4-Chloro-benzyl)-4-cyano-5-thiophen-2-yl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-(4-Chloro-benzyl)-4-cyano-5-thiophen-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

20 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid methyl ester,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid,

25 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester,

30 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid ethyl ester,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(morpholine-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(morpholine-4-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-dimethylamide 5-[(1-isopropyl-piperidin-4-yl)-amide],

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-dimethylamide 3-[(1-isopropyl-piperidin-4-yl)-amide],

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2-hydroxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(2-hydroxy-ethyl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],

{[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid,

{[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-amino}-acetic acid,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

Sulfuric acid mono-(2-{[1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-ethyl) ester,

Sulfuric acid mono-(2-{[2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-amino}-ethyl) ester,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-oxo-oxazolidine-3-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-oxo-oxazolidine-3-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-morpholin-4-yl-ethyl)-amide],

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
[(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-morpholin-4-yl-ethyl)-amide],

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
[bis-(2-methoxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],

5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-
[bis-(2-methoxy-ethyl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
[[4,5-dihydro-oxazol-2-yl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],

10 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-
[[4,5-dihydro-oxazol-2-yl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[3-(2-hydroxy-ethyl)-2-oxo-
imidazolidine-1-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-
amide,

15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[3-(2-hydroxy-ethyl)-2-oxo-
imidazolidine-1-carbonyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-
amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxymethyl-pyrrolidine-1-
carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

20 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxymethyl-pyrrolidine-1-
carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

{[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-
ylcarbamoyl)-1H-pyrazole-3-carbonyl]-methyl-amino}-acetic acid,

{[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-
ylcarbamoyl)-2H-pyrazole-3-carbonyl]-methyl-amino}-acetic acid,

25 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-
ylcarbamoyl)-1H-pyrazole-3-carbonyl]-piperidine-4-carboxylic acid ethyl ester,

1-[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-
ylcarbamoyl)-2H-pyrazole-3-carbonyl]-piperidine-4-carboxylic acid ethyl ester,

30 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-
ylcarbamoyl)-1H-pyrazole-3-carbonyl]-azetidine-2-carboxylic acid,

1-[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-
ylcarbamoyl)-2H-pyrazole-3-carbonyl]-azetidine-2-carboxylic acid,

- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(thiomorpholine-4-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(thiomorpholine-4-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 5 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-pyrrolidine-2-carboxylic acid,
 1-[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-pyrrolidine-2-carboxylic acid,
 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxy-piperidine-1-carbonyl)-
 10 2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxy-piperidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-pyrrolidine-1-carbonyl)-
 20 1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 5-(2,5-Bis-methoxymethyl-pyrrolidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 5-(2,5-Bis-methoxymethyl-pyrrolidine-1-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 25 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxymethyl-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4-hydroxymethyl-piperidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 5-(8-Aza-spiro[4.5]decane-8-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-
 30 2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
 5-(8-Aza-spiro[4.5]decane-8-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-methanesulfonyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-methanesulfonyl-pyrrolidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[[1,1-dioxo-tetrahydro-1-thiophen-3-yl)-methyl-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],

10 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[[1,1-dioxo-tetrahydro-1-thiophen-3-yl)-methyl-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],

1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-azetidine-3-carboxylic acid,

1-[2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-azetidine-3-carboxylic acid,

15 5-(Azetidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

5-(Azetidine-1-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

20 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-oxo-piperazine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-oxo-piperazine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4,4-difluoro-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4,4-difluoro-piperidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[[1,4]oxazepane-4-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

30 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[[1,4]oxazepane-4-carbonyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-azetidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-azetidine-1-carbonyl)-
1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-trifluoromethyl-pyrrolidine-1-
carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-trifluoromethyl-pyrrolidine-1-
carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-dimethyl-pyrrolidine-1-
carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2,2-dimethyl-pyrrolidine-1-
10 carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-
[(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-sulfamoyl-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
[(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-sulfamoyl-ethyl)-amide],
15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
cyclopropylamide 5-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-
cyclopropylamide 3-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-
20 ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino)-methanesulfonic acid,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-
ylcarbamoyl)-2H-pyrazole-3-carbonyl]-amino)-methanesulfonic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
cyclobutylamide 5-[(1-isopropyl-piperidin-4-yl)-amide],
25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-
cyclobutylamide 3-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-
[(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-methoxy-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-
30 [(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-methoxy-ethyl)-amide],
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(pyrrolidine-1-carbonyl)-2H-
pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(pyrrolidine-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

5 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

Phosphoric acid mono-(2-[[1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-ethyl) ester,

10 Phosphoric acid mono-(2-[[2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carbonyl]-amino]-ethyl) ester,

1-[[5-Chloro-pyridin-2-ylcarbamoyl]-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid methyl ester,

1-[[5-Chloro-pyridin-2-ylcarbamoyl]-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid,

15 1-[[5-Chloro-pyridin-2-ylcarbamoyl]-methyl]-1H-pyrazole-3,5-dicarboxylic acid 3-cyclobutylamide 5-[[1-isopropyl-piperidin-4-yl)-amide],

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

20 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid bis-[[1-isopropyl-piperidin-4-yl)-amide],

2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

25 2-[[4-Chloro-phenylcarbamoyl]-methyl]-4-cyano-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

3-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-propionic acid,

30 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[[1-isopropyl-piperidin-4-yl)-amide] 3-(methoxy-amide),

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-carbamoylmethyl-amide 5-[[1-isopropyl-piperidin-4-yl)-amide],

- 1-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-acetic acid ethyl ester,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(3-hydroxy-propyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 5 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-(2S)-azetidine-2-carboxylic acid,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2S,2-hydroxymethyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-2S-pyrrolidine-2-carboxylic acid,
- 10 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2S,2-methoxymethyl-pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 5-(2R,5R,2,5-Bis-methoxymethyl-pyrrolidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(4,5-dihydro-oxazol-2-yl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-piperidine-4-carboxylic acid ethyl ester,
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[(2-morpholin-4-yl-ethyl)-amide],
- 20 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(4,4-difluoro-piperidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-oxo-oxazolidine-3-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
- 25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[[2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[(2,2,2-trifluoro-ethyl)-amide],
- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(1,1-dioxo-tetrahydro-1-thiophen-3-yl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
- 30 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[(1-isopropyl-piperidin-4-yl)-amide] 3-[[3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide],

- 5-(Azetidine-1-carbonyl)-2-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(thiazolidine-3-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
5 2-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-3,3,3-trifluoro-propionic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 5-[[1-isopropyl-piperidin-4-yl)-amide] 3-trimethylsilanylmethyl-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[4-(2-oxo-pyrrolidin-1-yl)-
10 piperidine-1-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methanesulfonylamino-carbonyl-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-azetidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-2H-pyrazole-3-carboxylic acid,
5-(Azetidine-1-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
20 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[[1-isopropyl-piperidin-4-yl)-amide] 5-[(2-sulfamoyl-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[bis-(2-hydroxy-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
25 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrazole-3,5-dicarboxylic acid 3-[(2-hydroxy-1,1-bis-hydroxymethyl-ethyl)-amide] 5-[(1-isopropyl-piperidin-4-yl)-amide],
[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid isopropyl ester,
1-[[5-Chloro-pyridin-2-ylcarbamoyl]-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid ethyl ester,
30 [[1-[[5-Chloro-pyridin-2-ylcarbamoyl]-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid isopropyl ester,

{1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid ethyl ester,

{1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino}-acetic acid,

5 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(3-hydroxy-azetidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid cyclopropylmethyl ester,

10 2-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-3-methyl-butyric acid ethyl ester,

2-[[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carbonyl]-amino]-3-methyl-butyric acid,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-furan-2-yl-1H-pyrazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide,

15 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

20 2-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-[2-methoxy-ethoxymethyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxymethyl]-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[2-(2-methoxy-ethoxy)-ethoxy]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

25 2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2,2,2-trifluoro-ethoxy)-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-methoxy-ethyl ester,

30 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-hydroxy-ethyl ester,

2-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-[[1,4]oxazepane-4-carbonyl]-2H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1-(3-methoxy-benzyl)-1H-pyrazole-3-carboxylic acid,


1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid 2-hydroxy-ethyl ester,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrazole-3-carboxylic acid carboxymethyl ester,


1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-4-(2,2,2-trifluoro-ethoxy)-1H-pyrazole-3-carboxylic acid ethyl ester or

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-hydroxymethyl-1H-pyrazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide.

15. A process for the preparation of a compound of the formula I as claimed in one or more of claims 1 to 14, which comprises condensing a corresponding carboxylic acid of the formula 2



with a compound of the formula $\text{HR}^{8'}$ or with an amine of the formula $\text{HN}(\text{R}^{1'})\text{R}^{2'}-\text{V}-\text{G}-\text{M}$ to give a compound of the formula 3



and optionally converting the compound of formula 3 into a compound of the formula I,

wherein the groups $\text{R}^{8'}$ and R^{87} are the groups $-\text{N}(\text{R}^1)-\text{R}^2-\text{V}-\text{G}-\text{M}$ and $\text{R}^0-\text{Q}-$ and are as defined in the formula I and R^{1a} and R^{1b} have the meaning of R^3 and R^4 in formula I.

16. A pharmaceutical preparation, comprising at least one compound of the formula I as claimed in one or more of claims 1 to 14 in all its stereoisomeric forms and mixtures

thereof in any ratio and/or its physiologically tolerable salts and a pharmaceutically acceptable carrier.

17. The use of a compound of the formula I as claimed in one or more of claims 1 to 14 in
5 all its stereoisomeric forms and mixtures thereof in any ratio and/or their
physiologically tolerable salts for the production of pharmaceuticals for inhibition of
factor Xa and/or factor VIIa or for influencing blood coagulation or fibrinolysis.
18. The use as claimed in claim 17 for abnormal thrombus formation, acute myocardial
10 infarction, cardiovascular disorders, unstable angina, thromboembolism, acute vessel closure
associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty
(PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the
coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary or venous
angioplasty, maintenance of vascular access patency in long-term hemodialysis patients,
15 pathologic thrombus formation occurring in the veins of the lower extremities following
abdominal, knee or hip surgery, pathologic thrombus formation occurring in the veins of the
lower extremities following abdominal, knee and hip surgery, a risk of pulmonary
thromboembolism, or disseminated systemic-intravascular coagulopathy occurring in
vascular systems during septic shock, viral infections or cancer, or reducing an inflammatory
20 response, fibrinolysis, or treatment of coronary heart disease, myocardial infarction, angina
pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult
respiratory distress syndrome, multi-organ failure and disseminated intravascular clotting
disorder, deep vein or proximal vein thrombosis, which can occur following surgery.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/13979

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D413/14 C07D417/14 C07D409/14 C07D401/14 C07D401/12
A61K31/4155 A61P7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 998 424 A (GALEMMO JR ROBERT A ET AL) 7 December 1999 (1999-12-07) tables 1,2,4 claims	1-14
X	WO 01/32628 A (DU PONT PHARM CO ; PINTO DONALD J P (US)) 10 May 2001 (2001-05-10) claims table 1	1-14
X	WO 99/32454 A (DU PONT PHARM CO) 1 July 1999 (1999-07-01) claims tables 1,2,4	1-14
X	WO 00/39131 A (DU PONT PHARM CO) 6 July 2000 (2000-07-06) examples	1-14

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

31 March 2004

Date of mailing of the international search report

08/04/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Kollmannsberger, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/13979

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/085356 A (SQUIBB BRISTOL MYERS CO) 31 October 2002 (2002-10-31) claim 1	1-14
X	WO 01/19798 A (COR THERAPEUTICS INC) 22 March 2001 (2001-03-22) examples 1-146	1-14
X	US 6 339 099 B1 (LAM PATRICK Y ET AL) 15 January 2002 (2002-01-15) tables 1,2,4	1-14
X	WO 01/05784 A (DU PONT PHARM CO) 25 January 2001 (2001-01-25) examples claim 1	1-14
X	WO 02/00647 A (DU PONT PHARM CO) 3 January 2002 (2002-01-03) examples; tables	1-14
X	US 2002/091116 A1 (JIA ZHAOZHONG JON ET AL) 11 July 2002 (2002-07-11) examples	1-14
X	WO 02/00651 A (DU PONT PHARM CO) 3 January 2002 (2002-01-03) examples claim 1	1-14
X	US 6 020 357 A (ORWAT MICHAEL JAMES ET AL) 1 February 2000 (2000-02-01) tables 1,2,4 claims	1-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/13979

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-13, 15-18 (all partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-13, 15-18 (all partially)

The claims are so broadly drafted that the initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search is only complete for the example compounds as defined in 14. Some illustrative documents have been cited for other parts of the claims.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

overcome.			
1944-1945	1944-1945	1944-1945	1944-1945
1946-1947	1946-1947	1946-1947	1946-1947
1948-1949	1948-1949	1948-1949	1948-1949
1950-1951	1950-1951	1950-1951	1950-1951
1952-1953	1952-1953	1952-1953	1952-1953
1954-1955	1954-1955	1954-1955	1954-1955
1956-1957	1956-1957	1956-1957	1956-1957
1958-1959	1958-1959	1958-1959	1958-1959
1960-1961	1960-1961	1960-1961	1960-1961
1962-1963	1962-1963	1962-1963	1962-1963
1964-1965	1964-1965	1964-1965	1964-1965
1966-1967	1966-1967	1966-1967	1966-1967
1968-1969	1968-1969	1968-1969	1968-1969
1970-1971	1970-1971	1970-1971	1970-1971
1972-1973	1972-1973	1972-1973	1972-1973
1974-1975	1974-1975	1974-1975	1974-1975
1976-1977	1976-1977	1976-1977	1976-1977
1978-1979	1978-1979	1978-1979	1978-1979
1980-1981	1980-1981	1980-1981	1980-1981
1982-1983	1982-1983	1982-1983	1982-1983
1984-1985	1984-1985	1984-1985	1984-1985
1986-1987	1986-1987	1986-1987	1986-1987
1988-1989	1988-1989	1988-1989	1988-1989
1990-1991	1990-1991	1990-1991	1990-1991
1992-1993	1992-1993	1992-1993	1992-1993
1994-1995	1994-1995	1994-1995	1994-1995
1996-1997	1996-1997	1996-1997	1996-1997
1998-1999	1998-1999	1998-1999	1998-1999
2000-2001	2000-2001	2000-2001	2000-2001
2002-2003	2002-2003	2002-2003	2002-2003
2004-2005	2004-2005	2004-2005	2004-2005
2006-2007	2006-2007	2006-2007	2006-2007
2008-2009	2008-2009	2008-2009	2008-2009
2010-2011	2010-2011	2010-2011	2010-2011
2012-2013	2012-2013	2012-2013	2012-2013
2014-2015	2014-2015	2014-2015	2014-2015
2016-2017	2016-2017	2016-2017	2016-2017
2018-2019	2018-2019	2018-2019	2018-2019
2020-2021	2020-2021	2020-2021	2020-2021
2022-2023	2022-2023	2022-2023	2022-2023
2024-2025	2024-2025	2024-2025	2024-2025
2026-2027	2026-2027	2026-2027	2026-2027
2028-2029	2028-2029	2028-2029	2028-2029
2030-2031	2030-2031	2030-2031	2030-2031
2032-2033	2032-2033	2032-2033	2032-2033
2034-2035	2034-2035	2034-2035	2034-2035
2036-2037	2036-2037	2036-2037	2036-2037
2038-2039	2038-2039	2038-2039	2038-2039
2040-2041	2040-2041	2040-2041	2040-2041
2042-2043	2042-2043	2042-2043	2042-2043
2044-2045	2044-2045	2044-2045	2044-2045
2046-2047	2046-2047	2046-2047	2046-2047
2048-2049	2048-2049	2048-2049	2048-2049
2050-2051	2050-2051	2050-2051	2050-2051
2052-2053	2052-2053	2052-2053	2052-2053
2054-2055	2054-2055	2054-2055	2054-2055
2056-2057	2056-2057	2056-2057	2056-2057
2058-2059	2058-2059	2058-2059	2058-2059
2060-2061	2060-2061	2060-2061	2060-2061
2062-2063	2062-2063	2062-2063	2062-2063
2064-2065	2064-2065</		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/13979

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5998424	A	07-12-1999	US 2003092740 A1	15-05-2003
			US 6403620 B1	11-06-2002
			AU 8150398 A	04-01-1999
			BR 9810151 A	08-08-2000
			CA 2290982 A1	23-12-1998
			EE 9900584 A	15-08-2000
			EP 0991625 A2	12-04-2000
			HR 980334 A1	30-04-1999
			HU 0003906 A2	28-05-2001
			JP 2002507968 T	12-03-2002
			LV 12516 A	20-07-2000
			LV 12516 B	20-03-2001
			NO 996316 A	17-12-1999
			PL 337831 A1	11-09-2000
			SI 20208 A	31-10-2000
			SK 174699 A3	14-08-2000
			WO 9857937 A2	23-12-1998
WO 0132628	A	10-05-2001	EP 1226123 A1	31-07-2002
			WO 0132628 A1	10-05-2001
			US 6407256 B1	18-06-2002
WO 9932454	A	01-07-1999	AU 1724499 A	12-07-1999
			BR 9813835 A	10-10-2000
			CA 2314401 A1	01-07-1999
			EP 1042299 A1	11-10-2000
			JP 2001526268 T	18-12-2001
			WO 9932454 A1	01-07-1999
			ZA 9811517 A	15-06-2000
			US 6271237 B1	07-08-2001
			US 2002016326 A1	07-02-2002
WO 0039131	A	06-07-2000	AU 759711 B2	17-04-2003
			AU 2371700 A	31-07-2000
			BR 9917080 A	12-03-2002
			CA 2349330 A1	06-07-2000
			CN 1391575 T	15-01-2003
			EP 1140941 A1	10-10-2001
			HR 990396 A1	31-08-2000
			JP 2002533465 T	08-10-2002
			NO 20013072 A	20-06-2001
			NZ 511674 A	28-11-2003
			WO 0039131 A1	06-07-2000
			US 2003069237 A1	10-04-2003
			US 6413980 B1	02-07-2002
			US 2004038980 A1	26-02-2004
			US 2003004167 A1	02-01-2003
			ZA 200103795 A	12-08-2002
WO 02085356	A	31-10-2002	CA 2444571 A1	31-10-2002
			EP 1379245 A1	14-01-2004
			WO 02085356 A1	31-10-2002
			US 2002177713 A1	28-11-2002
WO 0119798	A	22-03-2001	AU 7486600 A	17-04-2001
			AU 7486700 A	17-04-2001
			BR 0014076 A	15-10-2002
			BR 0014078 A	31-12-2002

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/13979

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0119798	A	CA 2385589 A1	22-03-2001
		CA 2385592 A1	22-03-2001
		CN 1390207 T	08-01-2003
		CN 1391555 T	15-01-2003
		CZ 20020959 A3	17-07-2002
		CZ 20020961 A3	14-08-2002
		EP 1216231 A2	26-06-2002
		EP 1216228 A2	26-06-2002
		HU 0203289 A2	28-01-2003
		HU 0203954 A2	28-03-2003
		JP 2003509406 T	11-03-2003
		JP 2003509412 T	11-03-2003
		NO 20021229 A	21-05-2002
		NO 20021230 A	21-05-2002
		NZ 517828 A	31-10-2003
		TR 200201413 T2	21-02-2003
		WO 0119798 A2	22-03-2001
		WO 0119788 A2	22-03-2001
		US 6686368 B1	03-02-2004
		US 2002091116 A1	11-07-2002
US 6339099	B1 15-01-2002	US 2003069258 A1	10-04-2003
		US 2002025963 A1	28-02-2002
WO 0105784	A 25-01-2001	AU 2481501 A	05-02-2001
		BR 0013200 A	07-05-2002
		CA 2380727 A1	25-01-2001
		CN 1454211 T	05-11-2003
		EP 1196412 A1	17-04-2002
		NO 20020217 A	15-03-2002
		WO 0105784 A1	25-01-2001
		US 2003096820 A1	22-05-2003
		US 6429205 B1	06-08-2002
		ZA 200200094 A	18-02-2003
WO 0200647	A 03-01-2002	AU 6871101 A	08-01-2002
		CA 2409762 A1	03-01-2002
		EP 1296977 A1	02-04-2003
		JP 2004501913 T	22-01-2004
		WO 0200647 A1	03-01-2002
		US 2002103202 A1	01-08-2002
US 2002091116	A1 11-07-2002	US 6686368 B1	03-02-2004
		AU 7486600 A	17-04-2001
		AU 7486700 A	17-04-2001
		BR 0014076 A	15-10-2002
		BR 0014078 A	31-12-2002
		CA 2385589 A1	22-03-2001
		CA 2385592 A1	22-03-2001
		CN 1390207 T	08-01-2003
		CN 1391555 T	15-01-2003
		CZ 20020959 A3	17-07-2002
		CZ 20020961 A3	14-08-2002
		EP 1216231 A2	26-06-2002
		EP 1216228 A2	26-06-2002
		HU 0203289 A2	28-01-2003
		HU 0203954 A2	28-03-2003
		JP 2003509406 T	11-03-2003

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/13979

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002091116	A1	JP 2003509412 T	11-03-2003
		NO 20021229 A	21-05-2002
		NO 20021230 A	21-05-2002
		NZ 517828 A	31-10-2003
		TR 200201413 T2	21-02-2003
		WO 0119798 A2	22-03-2001
		WO 0119788 A2	22-03-2001
WO 0200651	A	AU 7304001 A	08-01-2002
	03-01-2002	WO 0200651 A2	03-01-2002
US 6020357	A	US 6548512 B1	15-04-2003
	01-02-2000	AU 730224 B2	01-03-2001
		AU 5602098 A	17-07-1998
		CA 2275796 A1	02-07-1998
		CN 1246847 A	08-03-2000
		EA 3056 B1	26-12-2002
		EE 9900316 A	15-02-2000
		EP 0946508 A1	06-10-1999
		HR 970698 A1	31-10-1998
		HU 0000735 A2	28-04-2001
		JP 2001509145 T	10-07-2001
		LT 99076 A ,B	25-02-2000
		LV 12430 A	20-02-2000
		LV 12430 B	20-07-2000
		NO 992633 A	20-08-1999
		NZ 336162 A	29-09-2000
		PL 334250 A1	14-02-2000
		SI 20017 A	29-02-2000
		SK 86699 A3	07-11-2000
		TW 492971 B	01-07-2002
		WO 9828269 A1	02-07-1998
		ZA 9711586 A	01-07-1999
		BR 9714073 A	09-05-2000